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DOSCATs: Double Standards in Quantitative Proteomics   
Richard J. W. Bennett 
Abstract 
Since its inception, the field of proteomics has shifted from being a qualitative discipline, 
generating long lists of proteins within a sample, to a quantitative one, where how much of 
a protein is reported. With the advent of systems biology, the routine analysis of biomarker 
levels, and the requirement for robust, reliable data comparable between different 
laboratories, the importance of absolute quantif ication, where proteins are quantified in 
absolute titre, is becoming increasingly important. There are two commonly used 
techniques for absolute protein quantification, based on either mass spectrometry (MS) or 
immunochemical techniques such as western blotting (WB). MS is generally considered 
the gold standard technique for quantification, but WB can offer greater sensitivity and is 
much more accessible to researchers. Neither are intrinsically quantitative techniques and 
so rely on standards; either isotope labelled peptides or recombinant proteins bearing an 
epitope are used for MS or WB respectively. To improve the robustness and reproducibility 
of quantitative data it would be advantageous to apply both techniques for orthogonal 
quantification, but due to the very different calibration standards, workflows rarely overlap. 
DOSCATs (Double Standard conCATamers) are novel calibration standards that can unite 
MS and WB workflows, allowing for the quantification of direct comparison of quantitative 
data between the two platforms. DOSCATs, based on QconCAT technology, combine a 
series of epitope sequences concatenated with peptides in a single artificial protein. Stable 
isotope labelled peptide for MS analysis are released upon digestion with an enzyme such 
as trypsin, and intact DOSCATs act to bear multiple epitopes for WB. Also included were 
restricted proteolysis sites that allow for a mobility shift within WB, lending greater flexibility 
to the standard. The aim of this thesis was to develop and optimise the use of DOSCAT 
technology so that they could be used to quantify target proteins in both quantitative 
platforms. 
A DOSCAT protein was designed and constructed to quantify five proteins of the NF-κB 
pathway. The DOSCAT was expressed and purified and the 9/13 peptides and 3/5 epitopes 
included in the sequence were observed by MS and WB respectively, demonstrating the proof 
of concept. However, restricted proteases performed poorly and three antibodies were 
discontinued by the manufacturer, so a second iteration of the NF-κB DOSCAT was 
designed. This was used to calibrate quantification by selected reaction monitoring MS 
(SRM-MS) and automated capillary WB. For three target proteins, protein fold change and 
absolute copy per cell values measured by MS and WB were in excellent agreement. Building 
on this success, another DOSCAT was built for six proteins implicated to be indicative of 
paediatric Streptococcus pneumoniae meningitis infection. All six proteins were quantified by 
SRM-MS although QWB failed to quantify two targets as either DOSCAT or endogenous 
protein was not detected. SRM-MS data agreed very well with previous datasets generated 
for the same samples by label-free MS and QWB using full length standards, however, 
absolute values for DOSCAT calibrated QWB were inconsistent. This could be due to 
antibodies recognising DOSCAT and endogenous protein with different affinities.  
This work demonstrates that DOSCATs can be used as multiplexed, dual purpose 
standards to unite MS and WB workflows. The DOSCAT approach has the potential to 
generate reliable quantitative information particularly relevant for systems biology studies 
and contribute to the desired increase in reproducibility of biological research.  
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Chapter 1: Introduction 
1.1. The rise of targeted absolute protein quantification 
Proteomics is focussed on the study of all proteins within an organism or system at a particular 
time and under specific conditions. When the term proteomics was first coined in the mid-
1990s, the burgeoning field was mostly concentrated on the qualitative analysis of proteins, 
generating lists of proteins contained in samples (Wilkins et al., 1996). Since this time 
proteomics has advanced considerably in terms of technology and focus. In the fields infancy, 
proteomic experiments were conducted using 2D-electrophersis gels (N. G. Anderson et al., 
1996), which although permitted the large-scale cataloguing of proteins, was laborious, costly, 
and technically limited in terms of sensitivity. Subsequently, mass spectrometry (MS) and 
affinity based assays were developed and utilised to study the proteome of complex samples 
in greater depth.  
As development of instrumentation and experimental workflows progressed, the focus of 
experiments shifted from the qualitative to the quantitative analysis of proteins. This gives an 
insight into not only what proteins are present in a sample but at what level they are present. 
Quantitative proteomics can be categorised into two outputs: relative and absolute 
quantification. In relative quantification experiments, protein abundance in a sample is 
reported relative to the amount of the same protein in another sample in terms of a fold-change 
increase or decrease. This type of experiment is commonly used to study global protein 
abundance changes between, for example, healthy control and disease state samples, or 
samples grown under different growth conditions. Whilst useful for the direct comparison of a 
limited number of samples in a single experiment, relative quantification is of limited value 
when it comes to, for instance, the determination of biomarkers protein levels, formation of 
mathematical models of protein interactions (an important facet of systems biology) and the 
elucidation of subunit stoichiometry in protein complexes. Additionally, quantitative values 
from relative quantification experiments are limited to the particular laboratory and samples 
they were derived from and so inter-laboratory comparisons cannot be performed. Therefore, 
interest in absolute quantification, in which proteins are quantified without reference to another 
sample in terms of an absolute titre or copies per cell, has massively increased in the past few 
years. Absolute quantification is commonly associated with a targeted approach, in which a 
group of specific proteins is preselected for analysis. This contrasts with the global proteomic 
methods that are used in qualitative or relative quantification experiments. For example, in 
biomarker discovery pipelines, relative quantification approaches might be used in the 
discovery phase to identify potential proteins based on the highest abundance change, but 
targeted absolute quantification of a selection of these proteins is required on a greater sample 
size for verification and validation. As will be discussed, targeted absolute quantification 
delivers greater sensitivity, selectivity and multiplexing capabilities required for biomarker 
validation as well as the myriad of other applications associated with the approach.  
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There are multiple strategies and workflows available to researchers to achieve both relative 
and absolute quantification, and these can be broadly split into those utilising either MS or 
protein binders to detect and quantify proteins. Both such approaches have advantages and 
disadvantages inherent to them that affects the quality and robustness of the quantitative data 
produced. This thesis is centred around the creation of a novel calibration material, DOuble 
Standard ConCATamers (DOSCATs), that can act as a bridge between MS and affinity assay 
methodologies, uniting the two disparate workflows to improve the accuracy, reproducibility 
and sensitivity of targeted absolute quantification experiments. To understand how this can 
achieved, MS and affinity methodologies will be thoroughly reviewed with regards to 
fundamental technological platforms, differing experimental workflows and reagents utilised. 
The motivations for uniting the two technologies will then be further explored, the principles 
behind DOSCATs explained and the aims of this thesis regarding the development of 
DOSCATs outlined.  
1.2. Protein quantification using protein binders 
For protein detection and quantification, assays based on molecules that bind to proteins with 
high selectivity are routinely used. Their use pre-dates mass spectrometry and their relative 
low cost and ease of use means that quantitative affinity-based assays are still much more 
prevalent than MS assays, despite arguably providing less robust and reproducible data.  
This section will review the different types of protein binders that are now available and the 
key affinity-based techniques, collectively known as immunoassays, which rely on protein 
binders for protein quantification. 
1.2.1. Types of protein binder 
By far the most widely used protein binder in biochemical research is the antibody. Discovered 
in the late 19th century, their ability to bind almost any protein target with high specificity has 
led to their extensive use in molecular biology as a research tool, which extends as far back 
as the 1950s. More recently, antibodies have been employed as therapeutic agents due to 
possessing characteristics such as high specificity, activity and favourable pharmacokinetics 
(Wold et al., 2016). 
The antibody is an integral part of an organism’s immune response to foreign antigens due to 
the ability for antibodies to be produced to bind almost any target. This has come about 
through the evolution of a complex set of mechanisms that alter the DNA of individual B cells, 
the type of lymphocyte where antibodies are produced. Antibodies belong in the 
immunoglobulin (Ig) superfamily, of which there are five classes with the most common being 
immunoglobulin G (IgG) (Schroeder et al., 2010). Structurally, all Igs share similar properties 
in that they contain a constant (Fc) region that provides a scaffold for the antigen binding 
variable (Fab) regions (Figure 1.1). Igs consist of two heavy and two light chains, each of 
which are made up of at least one constant domain and one variable domain. Disulphide 
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bridges formed between conserved cysteine residues in the constant domain link together 
heavy and light chains. At the end of the variable domain resides a hypervariable region made 
up of variable loops linked together by β-strands; it is this that confers specificity to an antigen. 
Variability in amino acid sequence is achieved by the random rearrangement of gene 
segments that code for the variable region in a process known as V(D)J recombination 
(Tonegawa, 1983). A further genetic mechanism, somatic hypermutation, occurs after B cells 
are exposed to an antigen and stimulated to proliferate, during which areas of the Ig gene 
family that code for hypervariable regions are highly prone to mutations leading to amino acid 
sequence diversity (Schroeder et al., 2010). 
 
 
 
Figure 1.1 Structure of an immunoglobulin G (IgG). The molecule is composed of two light (L) 
and two heavy (H) chains, each comprising one variable (V) domain and at least one constant (C) 
domain. Chains are linked by disulphide bonds (SS). Figure adapted from Loureiro et al. (2015). 
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To create antibodies against protein targets for use as research tools, antigens relating to the 
target protein are introduced to an animal (most often rabbit or mice), whose B cells are 
stimulated to produce antibodies against the target. The antigen (or immunogen) can be the 
entire protein or a peptide fragment; when a peptide is used, it is usually coupled to a larger 
protein such as bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH) to ensure 
an immune response is elicited. Antibodies used in research can be divided into polyclonal 
and monoclonal, describing the process in which they were generated. Polyclonal antibodies 
(pAb) are derived from an animal’s blood 2 – 3 months after immunisation, and are a 
heterogenous collection of antibodies from multiple B-cell lineages that recognise different 
epitopes on the same antigen. The crude immune-sera from an animal can be subjected to 
affinity purification to isolate specific antibodies, which can improve pAb specificity and 
minimise cross reactivity. pAbs are relatively cheap and quick to produce and through binding 
multiple epitopes they generally have a high overall affinity for their target and are more 
tolerant of minor epitopes changes such as glycosylation. However, pAbs produced from a 
single batch are finite; pAbs produced using the same immunogen in another animal will 
consist of an entirely different population of antibodies with a potentially very different affinity 
and specificity to the target.  Moreover, the presence of many non-specific antibodies in anti-
sera can lead to problems with cross reactivity and background signal. For monoclonal 
antibody (mAb) production, B cells from immunised animals are removed and fused with a 
myeloma cell to produce immortal hybridoma cells (Köhler et al., 1975). These are cultured, 
cloned and screened for the effectiveness of the antibodies they produce. Clones that produce 
the most effective antibody are cloned and cultured in isolation, providing a constant and 
consistent source of production. In contrast to pAbs, mAbs are homogenous and are highly 
specific to a single epitope. This massively reduces the probability of cross reactivity and 
improves reproducibility across experiments, which is advantageous for quantitative assays. 
Their method of production also means that mAbs are less prone to batch to batch variability 
and as such the consistency of performance can be more certain. However, due to the 
requirement to produce and clone hybridomas, mAbs are more expensive and time-
consuming to produce than pAbs. They are also susceptible to small epitope changes 
preventing binding. Despite their widespread use, there are many shortcomings in using both 
types of antibodies as protein binders. They are inherently unstable and so must be used 
under physiological conditions and stored at low temperatures during their short shelf-life. 
They are slow and expensive to generate in animals and difficult to generate in vitro. The 
requirement of animals for Ab generation raises ethical and welfare issues and means that 
Abs can be raised only to antigens that are immunogenic, ruling out many potential targets 
and accounting for why Abs are only commercially available for a small fraction of the 
proteome. 
The development of protein engineering technologies alongside the development of 
combinatorial libraries and in vitro selection techniques has led to the emergence of novel 
classes of protein binders generated without the need for animal immunisations that confer 
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significant advantages over antibodies (Uhlén et al., 2009). One such class are nucleic acid 
based binders known as aptamers (Stoltenburg et al., 2007). They rely on the principle that 
short DNA or RNA chains of under 100 nucleotides will fold in predictable three-dimensional 
structures capable of binding to target molecules with high affinity and specificity. Aptamers 
have been used in immunoassays (Q. Li et al., 2017; Shin et al., 2010), protein purification 
(Jia et al., 2016), point-of-care diagnostics (Dhiman et al., 2017) and as therapeutics (Ng et 
al., 2006). Aptamers are selected in vitro from large libraries of 1013 to 1015 random 
oligonucleotide sequences using systematic evolution of ligands by exponential enrichment 
(SELEX) (Tuerk et al., 1990). The target molecule is introduced to the library, which by chance 
will contain a population of oligonucleotides that have the necessary structure to bind the 
target. Unbound oligonucleotides are removed and bound oligonucleotides eluted and 
amplified by PCR using primers based on constant regions that flank each random sequence. 
The resultant enriched library is used for the next round of SELEX, and multiple rounds are 
performed until only nucleic acid species with the highest affinity and specificity for the target 
remain. These can be used as a heterogenous aptamer pool or individual aptamers can be 
isolated and sequenced to provide a homogenous population with rigid specificity to a 
particular epitope.  
Protein based binders have also emerged due to the development of in vitro selection 
techniques such as phage display (G. Smith, 1985) and ribosome display (Hanes et al., 1997). 
Antibodies are difficult to express recombinantly as few traditional expression hosts contain 
the cellular machinery and environment required to fold and link subunits. However, smaller 
antibody fragments can be expressed successfully with common examples being the entire 
Fab region or single-chain variable fragment (scFv), which are variable regions from the heavy 
and light chains connected by a short flexible amino acid peptide linker (Frenzel et al., 2013). 
Other types of binders based on protein scaffolds containing a variable region with high affinity 
and specificity to a target have also been developed (Gebauer et al., 2009; Mouratou et al., 
2015). Proteins that demonstrate very high stability, high solubility and high production yield 
in recombinant expression systems are selected as scaffolds. Libraries of scaffold proteins 
can be created, each with a random sequence of residues within the variable region that can 
have many different specificities. For recombinant antibodies, libraries contain the genetic 
information of variable regions of many different antibodies. These libraries can then be used 
with phage display (Clackson et al., 1991; Mouratou et al., 2015; Schirrmann et al., 2011) or 
ribosome display (Edwards et al., 2012; Grimm et al., 2011) techniques to select binders from 
the library with required specificity and affinity for a target. There have been numerous protein 
scaffolds structures developed for use as binders, some of which have become commercially 
available for numerous applications (Dias et al., 2017). The utility of some of these binders in 
immunoassays as either the primary or secondary detection molecule has been demonstrated 
(Jeong et al., 2016; Straw et al., 2013).  
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Aptamers, recombinant antibodies and protein scaffold binders hold many potential 
advantages over antibodies (Stoltenburg et al., 2007). In vitro generation removes the need 
for animals and permits the use of small non-immunogenic or toxic molecules as immunogens. 
Once selected for, they can be chemically synthesised or recombinantly expressed very 
cheaply to provide a consistent source of material, which, due the inherent stability the 
material used, has a prolonged shelf life and can be stored at ambient temperature. Unlike 
antibodies, they can all function in non-physiological conditions and their relatively small size 
allows access to epitopes that larger antibodies may be sterically blocked from binding.  
Despite these clear advantages, the uptake of these novel binders by the research community 
has been slow and they are not yet widely used (Rozenblum et al., 2016). In the case of 
aptamers this is in part due to technical deficiencies in the SELEX process, which requires 
considerable time- and labour-consuming optimisation to produce aptamers with affinity and 
specificity comparable to antibodies (Kanagawa, 2003; Musheev et al., 2006). The use of next 
generation sequencing to better characterise aptamers and improvements in the SELEX 
procedure are hoped to lead to the consistent generation of high-affinity in an efficient manner 
(Gotrik et al., 2016; Rozenblum et al., 2016). Moreover, they are all still relatively young 
technologies and the standardisation of their production, optimisation and utility in 
immunoassays has not yet transpired. As this occurs and their value becomes apparent it is 
likely their uptake by the research community will accelerate, but for now and despite their 
limitations antibodies remain the first choice for protein detection. 
1.2.2. Quantitative immunoassays 
Immunoassays simply describe assays that use protein binders to select a target antigen from 
a complex sample with a high degree of specificity. Immunoassays can be made quantitative 
through the use of calibration standards, which generally take the form of recombinant proteins 
that resemble or are identical the target analyte. The two most widely used assays for targeted 
absolute protein quantification, western blotting (WB) and Enzyme Linked Immunosorbent 
Assay (ELISA) will be discussed here. In the following descriptions antibodies are defined as 
the primary binder, although any of the protein binders described above could and have been 
used instead.  
Western blotting was first described in the late 1970s (Towbin et al., 1979) and the basics 
have not changed much since. Proteins are separated based on their molecular weight by 
SDS-PAGE and transferred to a protein binding membrane such as nitrocellulose or PVDF by 
electrotransfer. Non-specific sites on the membrane are blocked followed by incubation with 
a primary Ab specific to the target and a horseradish peroxidase (HRP) conjugated secondary 
Ab specific to the Fc region of the primary antibody. Exposure of HRP to a peroxide substrate 
yields an enhanced chemiluminescent (ECL) signal that is detected by X-ray film. In its original 
form, WB is a semi-quantitative rather than a quantitative technique due to the limited dynamic 
range afforded by film detection, the high variability of the protein electrotransfer step and the 
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poor throughput and reproducibility resultant from the many manual handling steps required 
(Koller et al., 2005). Since first described, there have been several technological 
improvements that have aimed to improve reproducibility and make the technique truly 
quantitative.  
Improving in the throughput and reproducibility of protein transfer from gel to membrane have 
come from the development of semi-dry transfer methods such as iBlot, which can reduce the 
transfer time from gel to membrane to under 10 minutes (J. M. Silva et al., 2014). Reversible 
stains have been developed that allow for the assessment of protein transfer completeness 
before Ab probing takes places (Antharavally et al., 2004; Colella et al., 2012). Other advances 
have been directed towards improving detection technologies. Cooled charged coupled 
device (CCD) cameras have been used rather than film for hugely improved linear dynamic 
range, although this approach can still be limited by signal saturation. Rather than 
chemiluminescence, detection based on fluorescence has been developed by conjugating 
near infrared dyes to secondary antibodies (Zellner et al., 2008). This massively increases the 
dynamic linear range of detection, although sensitivity can be limited. Fluorescent signal is 
stable for long periods of time, improving reproducibility. Moreover, different fluorescent dyes 
can be used together for multiplexed detection; for example, target protein and a loading 
control such as GAPDH can be analysed together, overcoming the need to chemically strip 
and re-probe the membrane. Fluorescent nanoparticles known as quantum dots have been 
also been used as a multiplexed detection method (Gilroy et al., 2010; Scholl et al., 2009). 
Their surface can be functionalised to bind primary Abs, removing the need for secondary 
antibodies and giving excellent sensitivity. These technological advances have made 
quantitative western blotting (QWB) somewhat routine, however, care must be taken in the 
experimental design, optimisation and data stages to ensure quantitative data are reliable 
(Gassmann et al., 2009; Mollica et al., 2009). Quantification using WB is usually relative, with 
loading controls such as GAPDH or β-actin used to normalise variations in protein load across 
different lanes. Absolute quantification of target proteins by WB using recombinant protein 
standards for calibration has been reported using detection methods based on 
chemiluminescence and CCD camera (Murphy et al., 2009, 2011) or  fluorescence (Bromage 
et al., 2009; Y. V Wang et al., 2007). WB has also been employed for proteome-wide 
quantification through the creation of a Saccharomyces cerevisiae fusion library, in which each 
open reading frame was tagged with a tandem affinity purification (TAP) tag and protein 
detection was achieved through the use of a single anti-TAP tag antibody (Ghaemmaghami 
et al., 2003). 
Other systems have attempted to redesign the western blot process to remove the SDS-PAGE 
and transfer steps as well as automate the entire procedure (Figure 1.2). In one approach 
known as µWesterns, microfluidic systems and microchip electrophoresis are used to perform 
the entire process on tiny glass slides (Hughes et al., 2012). Samples are separated by 
electrophoresis over a short distance (3 mm) in benzophenone-derivatized polyacrylamide 
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gel, which upon irradiation with UV light captures the proteins in situ. Antibody reagents are 
introduced and fluorescent signal is imaged by a CCD camera. Another approach, marketed 
as ‘Simple Westerns’ by ProteinSimple, uses capillaries pre-coated with a benzophenone 
derivative to separate proteins by electrophoresis, which are then crosslinked to capillary walls 
by UV irradiation for in situ analysis. The separating gel is washed away and antibodies are 
flowed through the capillary before luminol and peroxide are used to generated 
chemiluminescent signal, which is detected by a CCD camera (Nguyen et al., 2011; O’Neill et 
al., 2006; Rustandi et al., 2012).  
Compared to ‘classic’ WB these processes are fast (µWestern 10 – 60 m, Simple Western 3 
h), high throughput, use tiny amounts of samples and Ab, have high sensitivity and dynamic 
linear range and are more reproducible due to the minimisation of manual sample handling 
steps and the elimination of the protein transfer step. Both platforms have demonstrated their 
utility since becoming commercially available; µWesterns have recently been used quantify 
proteins in single cells loaded in individual microwells (Sinkala et al., 2017) and Simple 
Western technology has been used for absolute quantification of proteins with a high degree 
of accuracy and reproducibility at sub picogram per nanogram of cell lysate loaded (J. Q. Chen 
et al., 2013; Hamm et al., 2015; Loughney et al., 2014; Rustandi et al., 2015; Xu et al., 2017). 
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Figure 1.2 Schematics for automated western blotting systems. a) Capillary automated WB 
system developed by ProteinSimple and marketed as Simple Westerns (Nguyen et al., 2011). Protein 
separation and detection by antibodies takes place within distinct capillaries, and instruments can 
process up to 96 capillaries in a single automated run. b) Microfluidic western blotting system on 
microchips, marketed as µWesterns (Hughes et al., 2012). Top panel shows three separation 
channels and other panels close-ups of a single channel; each microchip can hold 48 separation 
channels. Both devices can separate proteins by size or isoelectric focusing. Figure reproduced from 
Kurien and Towbin (2015). 
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The ELISA, first developed in 1971 (Engvall et al., 1971; Van Weemen et al., 1971), has 
become the gold standard for protein quantification using protein binders due to the sensitivity, 
accuracy and throughput it affords. As such, diagnostic grade ELISAs against many targets 
have been developed and approved for clinical use. ELISAs are performed on 96-well 
polystyrene plates that can passively bind antigens or antibodies. Detection is achieved using 
a label conjugated antibody, with enzyme labels such as HRP or alkaline phosphatase the 
most common to produce a colorimetric, chemiluminescent or fluorescent signal. 
Different formats of ELISAs have been developed termed direct, indirect and capture (or 
sandwich) assays (Wild et al., 2013). In both direct and indirect assays, the antigen is bound 
to the plate surface and detected by either a labelled primary antibody (direct assay) or a 
primary antibody and labelled secondary antibody (indirect assay). For sandwich assays, a 
capture antibody is bound to the plate surface and specifically binds the target antigen when 
a sample is passed over. Unbound molecules are then washed away and a primary and 
labelled secondary antibody are used to detect the captured antigen. There is an additional 
form of ELISA that the above detection formats can be adapted to, known as competitive 
ELISA. Here, an unlabelled antibody is incubated with a sample and antibody/antigen 
complexes are formed, which are then added to a well pre-coated with the target antigen. 
Unbound antibodies (i.e. those that have already bound antigen in the sample) are washed 
away and bound antibodies are detected. This means that the signal output in inversely 
proportional the amount of target analyte in the sample. Competitive ELISA is especially useful 
for use with crude or complex samples as pre-purification of the antigen is not required. 
Direct ELISA is the fastest technique with the fewest steps, but specific labelled primary Abs 
are required for every target and the lack of signal amplification reduces assay sensitivity. 
Indirect assays offer this signal amplification to improve sensitivity but the addition of a 
secondary antibody raises the chance of cross-reactivity, resulting in non-specific signal. 
Sandwich assays offer the highest sensitivity and specificity as two distinct Abs are used for 
capture and detection. However, this can also be a weakness as these Ab pairs need to be 
identified and very well validated to minimise non-specific binding, which would result in 
inaccurate quantification. Such prior Ab validation is vitally important as unlike WB there is no 
sample separation step to check that Abs are binding to a protein at the expected MW. As 
such, high-grade ELISAs are very time-consuming and expensive to set up and usually limited 
to commercially available kits to clinically relevant targets. 
The classic ELISAs formats are suited to high throughput analysis against a single target 
protein. More recently, multiplexed ELISA systems have been developed that allow the 
detection and quantification of multiple targets at once. These systems can split into planar 
and suspension multiplex assays (Tighe et al., 2015). In suspension assays antibodies are 
immobilised onto fluorescently activated plastic or magnetic microbeads, with the fluorescent 
signature of a bead directly relating to the antibody bound to it. The microbeads are then mixed 
with the sample in the liquid phase, where analyte is captured by the immobilised antibodies. 
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Detection antibodies labelled with a reporter dye are then added. Using flow cytometric 
methods, each bead is analysed individually by lasers which excite the reporters so that the 
type of bead (and so specificity of antibody immobilised to it) and the signal is ascertained. 
Planar assays are analogous to protein microarrays, which have their origins in the fields of 
genomics and transcriptomics, where they have been extensively used for gene expression 
analysis. Such arrays allow for the global quantitative analysis of proteomes. They are much 
like a sandwich ELISA assays; high affinity capture ligands to multiple different targets are 
immobilised onto a solid phase such as a microtitre plate or functionalised glass slide, over 
which a sample is passed. Detection antibodies bind captured analytes and signal generated 
though through direct or indirect methods. 
Both types of multiplex approaches offer advantages over singleplex assays not only in terms 
of increased throughput but also lower sample input and increased dynamic range. Multiplex 
assays have been commercialised (Gupta et al., 2016; Tighe et al., 2015); available planar 
assays on the market include MULTI-ARRAY technology (Meso Scale Discovery) and 
ImmunoCAP (Thermo Scientific), and commercially available suspension assays include 
xMAP (Luminex), Cytometric Bead Array (BD Bioscience) and Multi Bead (Enzo Life Science). 
However, these products all require expensive instrumentation and suffer the same limitations 
as singleplex ELISA in that they require highly validated antibodies for specific detection. 
Furthermore, problems with antibody cross-reactivity becomes more prevalent as multiplexing 
is increased, limiting the amount of proteins that can be detected without compromising 
accuracy. Novel techniques to mitigate the effect of cross reactivity are currently being 
explored (Juncker et al., 2014). For example, ‘DNA barcoding’ techniques such as the 
proximity ligation assay (Lundberg, Thorsen, et al., 2011) or the proximity elongation assay 
(Lundberg, Eriksson, et al., 2011) use DNA molecules as reporters for specific binding. 
Capture and detection Abs in a sandwich assay are tagged with DNA strands that upon both 
Abs binding to the same target molecule are brought into proximity, permitting their ligation or 
hybridization by complementary sequences. These newly formed DNA strands can act as a 
reporter signal upon amplification by PCR. Even with these advances, compared to classic 
ELISA techniques, multiplex technologies are not as mature meaning that the regulatory 
guidelines for the validation of multiplex biomarker assays are not in place and as such there 
are few clinically available multiplex assays (Tighe et al., 2015). 
Both WB and ELISAs can be employed for targeted protein quantification to great effect, but 
it should be noted that the key to accurate and reproducible immunoassays in any format is a 
well validated protein binder. Poor reproducibility of published results has become a major 
issue in research (Begley et al., 2012; Prinz et al., 2011), and this in part has been attributed 
to poor quality antibodies, with studies finding that many commercially available antibodies or 
assay kits lack specificity or otherwise do not meet minimal required standards (Berglund et 
al., 2008; Michel et al., 2009; Rifai et al., 2013). Additionally, some antibodies are application 
specific and validation for one application does not guarantee success on another; for 
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example, an antibody that works in a western blot where proteins are denatured might not 
work in an ELISA where proteins are in their native state and so epitopes possibly sterically 
obscured. The research community has started to tackle this problem by developing standard 
operating practices for antibody validation (Acharya et al., 2017; Uhlen et al., 2016) and 
creating tools to rank antibodies that have been validated (Björling et al., 2008) or previously 
cited in peer reviewed papers (Helsby et al., 2014). Such efforts coupled with the development 
of antibody alternatives should increase the reliability of protein binders and ensure that 
immunoassays continue to be considered for target protein quantification. 
1.3. Protein quantification by mass spectrometry  
Mass spectrometry has emerged as the key technology in proteomics, due to its ability to, 
amongst other applications, rapidly identify and quantify vast number of biomolecules in 
complex samples, identify sites of post translational modifications and elucidate the structure 
of protein complexes (Aebersold et al., 2016). This section will give a brief overview of the 
fundamentals of biomolecular MS, detail the strategies and workflows developed to enable 
protein quantification by MS and finally describe the different data acquisition strategies that 
have been established to enable MS-based targeted quantitative assays. 
1.3.1. Biomolecular mass spectrometry  
At the most basic level, mass spectrometers consist of an ion source, a mass analyser that 
measures the mass to charge ratio (m/z) of ionised molecules and a detector that registers 
the number of ions at each m/z value. The development of two so-called soft ionisation 
techniques, matrix-assisted laser desorption/ionisation (MALDI) (Karas et al., 1987; Tanaka 
et al., 1988) and electrospray ionisation (ESI) (Nohmi et al., 1992; Whitehouse et al., 1985; M 
Yamashita et al., 1984; Masamichi Yamashita et al., 1984) facilitated the routine use of MS 
for biomolecular analysis. This is because mass spectrometers can only detect and measure 
the mass of a molecule after it has been converted into the gas phase; these techniques 
enabled the ionisation and transfer of biomolecules into the gas phase without fragmentation 
so that relatively large molecules such as proteins and peptides could be analysed by MS.  
MALDI uses energy from the laser excitation of a matrix to produce singly charged ions from 
large molecules. A sample is co-crystallised with a matrix solution that strongly absorbs at the 
wavelength of the laser beam. Irradiation of the sample mixture with a laser pulse desorbs 
and ionises the matrix material, transferring matrix and analyte into the gas phase. At this 
stage protons are transferred to analyte molecules, and analyte ions progress through the 
mass spectrometer. MALDI has a rapid sampling speed and is tolerant to sample 
contamination, meaning that it has been used for multiple applications (Chang et al., 2007). 
However, it is a notoriously variable technique (Szájli et al., 2008) and the non-continuous 
nature of sampling makes it incompatible with in-line liquid chromatography (LC) separation, 
meaning that MALDI is not routinely used in quantitative proteomic analysis. 
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The mechanism of ESI can be broken down into three major stages (Kebarle et al., 2009) 
(Figure 1.3). Firstly, the sample solution is passed through a capillary tip, through which a high 
voltage (2.5 – 4.0 kV) is applied. This causes the formation of charged droplets in an elongated 
cone shape known as a Taylor Cone. Secondly, solvent evaporation (caused by elevated 
source temperature and the introduction of nitrogen drying gas) causes shrinkage of the 
charged droplets, which in turn increases repulsion between the charges at the droplet 
surface. When the droplet is reduced to a certain size the Rayleigh limit is met, where the 
surface charge repulsion overcomes the surface tension of the droplet. The resultant instability 
causes the droplet to disperse into many smaller charged droplets in what is known as 
Coulomb fission. This process of droplet disruption continues leading to very small, highly 
charged droplets from which the final stage of ESI takes place, the production of gas phase 
ions that subsequently move into the mass spectrometer. Unlike MALDI, ESI results in the 
formation of multiply charged ions so that large biomolecules come into a m/z range that can 
be measured by MS. Moreover, its mechanism makes it highly amenable to be coupled to 
liquid flow techniques such as LC, making it the preferred ionisation choice in proteomic 
analysis.  
 
 
 
Figure 1.3 Schematic of electrospray ionisation mechanism in positive ion mode. Electric 
charge at the capillary tip causes the formation of droplets, which through solvent evaporation and 
Coulomb fission are reduced to charged gas phase ions that move in to the mass spectrometer. 
Figure reproduced from Banerjee and Mazumdar (2012). 
 
Once in the gas phase, ions are separated based on their m/z in a mass analyser. Types of 
mass analyser commonly used in proteomics include quadrupole, time of flight (TOF) and ion 
traps. It is beyond the scope of this introduction to describe the detailed workings of these 
mass analysers, although they have been thoroughly reviewed elsewhere (Aebersold et al., 
2003; Boesl, 2017; El-Aneed et al., 2009; Glish et al., 2003) and an overview of each will be 
given here.  
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First described in the 1950s, quadrupoles are arguably the simplest type of mass analyser; 
they are made up of four cylindrical rods arranged parallel to one another through which DC 
and oscillating RF electric fields are passed though. The ratio of these DC and AC electric 
fields dictates the motion of ions through the quadrupole; only certain ions of specific m/z 
values will have a sufficiently stable trajectory to pass through the quadrupole to the detector 
at a particular field strength. By systematically altering field strengths specific m/z values can 
be selected for. In comparison to other mass analysers quadrupoles have low mass resolution 
and accuracy, but due to their mode of operation can stay tuned to a particular m/z value for 
a period of time, making them very useful for analysis in targeted experiments.  
In TOF mass analysers, ions are separated based on their velocities in a low-pressure flight 
tube. Groups of ions are accelerated by an electric field of known strength into the flight tube. 
As all ions share the same kinetic energy, those with lower m/z values have a greater velocity 
through the tube and so reach the detector first. Through knowledge of the time taken for an 
ion to hit the detector after acceleration and the distance of the flight tube, the m/z value of 
the ion can be calculated. TOF analysers offer high resolution, sensitivity and mass accuracy, 
but have a low duty cycle (the time the system is actively measuring ions) as sampled packets 
of ions must be cleared of the flight tube before the next packet can arrive (Boesl, 2017). 
There are multiple types of ion trap that all operate on the common principle of capturing 
charged particles and subjecting them to MS analysis. The Fourier-transform ion-cyclotron-
resonance mass spectrometer (FTICR-MS) captures ions in a high vacuum using a magnetic 
field where frequencies of trapped ions can be measured and converted into m/z values 
(Aebersold et al., 2003). FTICR-MS gives very high mass resolution and very high mass 
accuracy, but FTICR instruments are very expensive and require space-consuming high field 
superconducting magnets. A more recently developed type of ion trap, the Orbitrap (Makarov, 
2000), can deliver mass accuracy and resolution comparable with an FTICR instrument 
without the obtrusive hardware requirements (Hu et al., 2005).  
Most modern mass spectrometers used for proteomics are hybrid instruments in that have 
more than one mass analyser, for example quadrupole time of flight (Q-TOF), triple 
quadrupole (QqQ) or Q-Orbitrap (Aebersold et al., 2003). Such instrument design allows for 
the implementation of tandem MS (MS/MS), in which precursor ions of a specific m/z are 
selected (MS1) and then fragmented to produce product ions that are subsequently detected 
by another mass analyser (MS2). Collision induced dissociation (CID) is the method most 
commonly used for the fragmentation of peptides. In CID, ions are accelerated and collided 
with an inert neutral gas such as helium or argon. The kinetic energy generated by these 
collisions is converted into internal energy that results in the dissociation of the most labile 
bonds in the structure; these being the amide bonds along the peptide backbone to produce 
b- and y- ions (Johnson et al., 2015; Mitchell Wells et al., 2005). Higher-energy collisional 
dissociation (HCD) is similar in principle to CID but specifically refers to beam-type CID 
performed in an octopole collision cell. HCD is associated with higher activation energy and 
Chapter 1: Introduction 
 15 
 
shorter activation times that can result in additional fragmentation of b- and y- ions. Another 
type of fragmentation known as electron transfer dissociation (ETD) occurs by the transfer of 
electrons from radical anions to multiple charged ions. This forms an unstable positive radical 
cation, which then fragments at the N–Cα bond, producing c- and z- fragment ions (Coon et 
al., 2005; Qi et al., 2017). Unlike CID, ETD does not result in the removal of labile post 
translational modifications (PTMs) such as phosphoryl groups, making it especially useful for 
studying PTMs in proteomes. 
The final component of the mass spectrometer is the detector, which monitors the charge or 
current produced by an ion when passes or hits a surface. The signal is amplified and 
converted into the form of a mass spectrum. The choice of detector will depend on the type of 
mass analyser; common detectors include the photomultiplier, the electron multiplier and 
micro-channel plate detectors. 
1.3.2. Experimental approaches for quantitative mass spectrometry 
MS based proteomics can be divided into top-down and bottom-up proteomics, in which 
analysis is performed on intact proteins or peptides acting as surrogates for proteins 
respectively. Although quantification strategies for top-down proteomics have been developed 
(Du et al., 2006; Hung et al., 2012; Ntai et al., 2014), approaches are less advanced than 
bottom-up proteomics and indeed the majority of quantitative proteomics workflows are carried 
out at the peptide level. A typical bottom-up proteomics workflow begins with the enzymatic 
digestion of a protein into peptides using an enzyme of known specificity. Trypsin is usually 
used due to its specific C-terminal cleavage of arginine and lysine residues, which typically 
occur in protein sequences at a frequency to produce peptides of ~ 7-35 residues (Swaney et 
al., 2010). Such peptides are an optimal length for LC-MS analysis as they have a mass 
between ~ 600-4000 Da resulting in charged (2+) species between m/z 300 and 2000, which 
are easily detected by MS. Other enzymes used in proteomics experiments include ArgC, 
LysC, AspN, GluC, LysN and chymotrypsin, which can be used individually or in parallel to 
improve sequence coverage of proteins (Giansanti et al., 2016). Following digestion, samples 
are separated in order reduce the complexity of sample entering the mass spectrometer, thus 
increasing proteome coverage and permitting quantification of less abundant proteins. For 
peptide analysis LC is usually employed in-line with the mass spectrometer, so as peptides 
elute they are instantly subjected to ESI and MS/MS analysis. In some instances additional 
sample fractionation is performed beforehand using techniques such as strong anion 
exchange, capillary isoelectric focussing or size exclusion chromatography (Zhang et al., 
2014). Such pre-fractionation can dramatically increase proteome coverage, but the additional 
handling steps can result in a reduction in reproducibility and accuracy. Tandem mass 
spectrometry is commonly performed in data-dependent acquisition (DDA) mode, in which a 
fixed number of precursor ions (for example the top 10 most intense ions in an MS1 scan) are 
selected for fragmentation and analysis by MS2. The fragment ion spectra and m/z value of 
each peptide ion are used to enable confident identification of peptides in the sample, which 
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are then mapped back to proteins. The vast number of fragment ion spectra generated in the 
MS/MS of a complex sample would make such analysis by an individual impossible. The 
routine performance of these data processing steps has been enabled by the development of 
an array of bioinformatic software and databases such as MASCOT and PEAKS (Bruce et al., 
2013). 
The quantification of peptides and proteins identified by MS is complicated by the fact that MS 
is not an inherently quantitative technique. This is due to differences in ionisation efficiency 
between peptides, so the signal intensity of a peptide ion does not relate to its abundance 
(Oss et al., 2010). Moreover, the presence of interfering compounds in a sample matrix can 
also alter ionisation efficiency, reducing reproducibility and limiting the ability to compare 
analytes in different samples (Sarkar et al., 2009). Therefore, several labelling strategies 
based on the use of stable isotope labels (SIL) have been developed to facilitate protein 
quantification by MS (Figure 1.4). These work on the basis that SIL peptides will have the 
same physiochemical properties as analyte peptides, so they will ionise with equal efficiency 
and the MS intensity can be directly compared. 
One group of approaches involves the chemical derivatization of reactive groups in proteins 
or peptides with SILs. Lysine and cysteine side chains as well as the N-terminus of the 
sequence are most commonly used, due the well-characterised conjugation chemistry 
associated with these groups. In the first reported such approach, known as isotope-coded 
affinity tagging (ICAT) (Gygi, 1999), cysteine residues in two samples to be compared are 
derivatized with a heavy or light version of a reagent comprising biotin and a linker region 
capable of incorporating deuterium atoms. After sample combination and enzymatic cleavage, 
derivatised peptides can be isolated by avidin affinity chromatography and analysed by LC-
MS/MS, revealing the identity and quantity of the peptide and which sample it originated from. 
Although initially successful and followed up by a number of studies aiming to improve 
properties of the tag (Hansen et al., 2003; Yi et al., 2005), ICAT is ultimately limited in that it 
cannot detect proteins and peptides that don’t contain cysteine residues. Subsequent labelling 
strategies have targeted the ε-amino group on lysine residues or the N-terminus through N-
hydroxysuccinimide (NHS) chemistry. Such strategies include isobaric tags for relative and 
absolute quantification (iTRAQ) (Ross et al., 2004), tandem mass tagging (TMT) (Thompson 
et al., 2003) and stable-isotope dimethyl labelling (Raijmakers et al. 2008; Boersema et al. 
2009). iTRAQ and TMT utilise isobaric tags that are of the same mass but produce different 
fragment ions upon MS/MS analysis, thus acting as reporter ions for peptides in a specific 
sample. Peptides from different samples are tagged with different isobaric tags, pooled and 
analysed by LC-MS/MS. This determines the peptide sequence and abundances of the 
reporter ions are used to quantify peptides relative to other samples. Multiple samples can be 
analysed at once by this approach; iTRAQ is available in 4- or 8-plex and TMT in 10-plex. 
Such approaches, though, are relatively expensive and time-consuming, and quantitative 
accuracy can be compromised by interfering ions, especially in complex samples (H. Li et al., 
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2017). Dimethyl labelling offers a fast and inexpensive alternative by converting primary 
amines in all peptides to dimethylamines using isotopomers of formaldehyde and 
cyanoborohydride. This creates peptides of slightly different masses in up to three samples, 
which can then be mixed and differentiated by MS/MS. The low-cost and ease of the labelling 
reaction is a major advantage, although the use of deuterium in the label can lead to retention 
time shifts in differentially labelled peptides (S. Wang et al., 2007). 
As well as labelling peptides through chemical means, SILs can be introduced metabolically 
during cell growth. In the most popular metabolic labelling method, stable isotope labelled 
amino acids in culture (SILAC) (Ong et al., 2002), cells are cultured with [13C6] or [15N7] labelled 
arginine and lysine, which are directly incorporated into proteins as they are synthesised. 
Labelled and unlabelled samples are mixed and peptides from each sample discriminated by 
the mass shift resultant from the label. SILAC ensures that every peptide is labelled at the 
earliest point in the workflow, minimising sample handling errors leading to improved 
reproducibility. However, multiplexing capabilities are limited and the workflow is time-
consuming and expensive.  
The approaches described above all result in relative quantification. For absolute 
quantification, a different strategy based on stable isotope dilution (SID) is required. A SIL 
peptide standard of known concentration is added to the sample, acting as an internal calibrant 
so that analyte concentration can be determined based on the difference in signal intensity. 
Peptides chosen to act as standards are known as quantotypic; such peptides are unique to 
the proteome of interest, do not contain residues that are likely to be subject to post-
translational or chemical modifications and are readably detectable by LC-MS/MS. Multiple 
approaches to deliver SIL peptides into the sample have been developed (Figure 1.5). 
Absolute quantification (AQUA) peptides are chemically synthesised with isotope labels and 
can be spiked into samples before or after proteolytic digestion (Kettenbach et al., 2011). 
There is no limit as to the number of AQUA peptides that can be spiked into a single sample, 
although costs can become prohibitive when large numbers of proteins are to be analysed. 
Additionally, some peptides can be difficult to chemically synthesise, which could be an issue 
when quantifying small proteins containing a limited number of Q-peptides. A relatively low-
cost strategy to produce many SIL peptides for multiple proteins is to use a quantification 
concatamer (QconCAT) protein (Beynon et al., 2005; Julie M Pratt et al., 2006). QconCATs 
are artificial recombinant proteins that concatenate several Q-peptides into a single sequence 
that is expressed heterologously in E.coli grown in isotopically enriched media. The QconCAT 
protein can then be affinity purified, quantified, and added to a sample prior to digestion so 
that the SIL peptide standards are released during proteolysis. This approach facilitates a 
large degree of multiplexing using a single standard and the utilisation of biosynthesis permits 
the generation of peptide sequences that were unavailable by chemical synthesis. The utility 
of multiplexing using QconCATs has been demonstrated through the absolute quantification 
of the entire Saccharomyces cerevisiae proteome  (Lawless et al., 2016) and various protein 
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pathways and networks (P. Brownridge et al., 2013; Carroll et al., 2011; Messiha et al., 2014), 
amongst others. A drawback of the QconCAT approach is the potential for differential 
proteolysis between the QconCAT and analyte proteins due to different local environments 
around cleavage sites (P. Brownridge & Beynon, 2011). Missed cleavages would lead to 
inaccurate protein measurements, however this can be mitigated by adding natural flanking 
sequences to either side of tryptic peptides in the QconCAT sequence, maximising the 
possibility of equivalent digestion (Cheung et al., 2015).  
 
 
 
 
 
Figure 1.4 Workflows for relative quantitative proteomics. In metabolic labelling techniques such 
as SILAC, labels are introduced by growing cells in stable isotope enriched media so samples can 
be combined very early in the workflow, thus reducing sample handling variations. In chemical 
labelling techniques samples are combined are protein digestion and peptide labelling. Quantification 
is performed at the MS/MS level for iTRAQ compared to the MS level for other techniques. Label-
free strategies use precursor ions intensities or spectral counting to determine peptide abundances 
between runs. Figure reproduced from Engholm-Keller and Larsen (2013). 
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Figure 1.5 Isotope dilution strategies for absolute quantitative proteomics. Schematic of the 
workflow for absolute protein quantification detailing different types of stable isotope labelled 
standard and where in the workflow they are introduced to the sample. Protein standards such as 
PSAQ are introduced pre-fractionation (if carried out) and pre-digestion. Quantification concatamers 
(QconCATs) are introduced just prior to digestion and peptide standards just before MS analysis. 
Quantification is achieved by comparing the peak areas of extracted ion chromatograms (XIC) from 
unlabelled endogenous and labelled standard peptides. Figure reproduced from Brun et al. (2009). 
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Other approaches use protein rather than peptides as standards. The protein standards for 
absolute quantification (PSAQ) methodology utilises full length SIL proteins expressed and 
added to the sample prior to digestion (Brun et al., 2007). The Full-Length Expressed Stable 
Isotope-labeled Proteins for Quantification (FLEXIQuant) workflow builds on this by 
expressing protein grown in wheat germ extract, allowing the quantification of PTMs (Singh et 
al., 2009). Methods using protein standards are considered the most accurate for 
quantification as digestion between standard and analyte is highly likely to be equivalent. 
Additionally, fractionation of standard and analyte prior to digestion is permitted allowing 
greater sensitivity to be achieved. However, there is limited potential for multiplexing due to 
the great cost and time required to prepare a unique protein standards for each protein. 
Although label-based methods allow for accurate quantification of proteins, they require costly 
reagents and the requirement for peptide standards means that absolute quantification cannot 
be performed on a proteome level. To overcome this, label-free approaches have been 
developed for relative and absolute quantification of the proteome. Label-free workflows are 
based on counting the number of spectra that are matched to a peptide (spectral counting), 
or comparing precursor ion intensities (Figure 1.4). Spectral counting methods are based on 
the observation that the number of peptide spectral matches (PSMs), the number of distinct 
peptides identified and the sequence coverage for a protein all correlate with protein quantity 
(H. Liu et al., 2004; Rappsilber  Ryder, U., Lamond, A. I., Mann, M., 2002). Therefore, 
quantification of a protein is achieved by summing the number of MS2 spectra that are 
matched against its peptides. Popular spectral counting methods include Exponentially 
Modified Protein Abundance Index (EMPAI) (Ishihama et al., 2005) and Absolute Protein 
Expression (APEX) (Braisted et al., 2008; Lu et al., 2007). However, spectral counting is 
associated with poor linear dynamic range due to saturation effects, poor reproducibility due 
to DDA sampling, misassignment of peptide ions that are shared between proteins and an 
intrinsic bias towards more abundant proteins (Bantscheff et al., 2012; Grossmann et al., 
2010). Ion intensity methods are based on the observation that there is excellent correlation 
between peptide concentration and MS1 signal intensity over a linear range greater than four 
orders of magnitude (Bondarenko et al., 2002; W. Wang et al., 2003). For quantification, all or 
a subset of peptides for a protein are chosen and their MS1 ion intensities aggregated through 
summation or averaging peptide fold changes. Widely used ion intensity methods include Hi3 
(or Top3) (J. C. Silva et al., 2006) and Intensity Based Absolute Quantification (iBAQ) 
(Schwanhäusser et al., 2011). For Hi3, quantification is based the observation that the 
average signal intensity of the top 3 most intense peptide ions is correlated with the total 
amount of a protein in a sample (Ahrné et al., 2013; Grossmann et al., 2010; J. C. Silva et al., 
2006). Absolute quantification using Hi3 is made possible by comparing analyte signal to 
spiked-in reference peptides or the total amount of protein injected into the instrument (Ahrné 
et al., 2013). Protein quantification using iBAQ is achieved by summing intensities of all 
peptides for a specific protein, which is then divided by the number of theoretically observable 
peptides to estimate protein level (Schwanhäusser et al., 2011). Compared to spectral 
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counting, ion intensity methods have been shown to be more accurate and reproducible 
(Ahrné et al., 2013; Arike et al., 2012). Both Hi3 and iBAQ have been employed for global 
proteome quantification across a range of samples, demonstrating their utility for quantifying 
a large number of proteins in a single experiment at a relatively low cost (Bantscheff et al., 
2012; Megger et al., 2013).  
Label-free quantification is considered less accurate and precise than quantification achieved 
using stable isotope labels, especially for low abundance proteins (P. Brownridge, Holman, et 
al., 2011; Krey et al., 2014). However, the nature of labelling experiments limits quantitative 
throughput and multiplexing and so the quantification of an entire proteome in a single LC-
MS/MS would be very difficult using a labelling approach. Label-free methods certainly have 
their place in the proteomics toolkit, especially in discovery experiments where high sample 
throughput is more important than accuracy. However, for absolute protein quantification 
where accuracy, precision and a low limit of detection is key, such as biomarker verification 
studies, targeted approaches using SIL standards are still considered the gold standard 
approach.  
1.3.3. Acquisition strategies for quantitative mass spectrometry 
Although highly useful for protein discovery, shotgun MS proteomic workflows based on DDA 
do not have the high sensitivity, quantitative accuracy and reproducibility required for the 
absolute quantification of targeted proteins (Holman, Sims, and Eyers 2012). Mass 
spectrometers used in DDA mode for quantitative analysis generally have a low duty cycle 
due to continuous ionisation and the process of precursor ion selection; whilst one packet of 
product ions is being analysed peptides eluted from the column are lost, leading to the loss of 
information and thus a low number of points across the chromatographic peak. This translates 
into decreased accuracy and poor sensitivity. Additionally, the stochastic nature of precursor 
ion selection can lead to different peptides being selected for fragmentation for similar 
samples, reducing reproducibility. As peptide ions with the highest intensity are selected for 
fragmentation and MS2 analysis, there is an inherent bias towards the analysis and 
quantification of the most abundant proteins, limiting the dynamic range of analysis. Due to 
the many limitations of DDA, targeted MS techniques have been developed that when used 
in conjunction with SIL strategies can quantify proteins with exquisite selectivity and high 
reproducibility (Figure 1.6).  
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Figure 1.6 Acquisition strategies for targeted MS proteomics. a) Schematic diagrams of MS 
configurations for SRM, PRM and DIA. In SRM, a precursor ion for a specific peptide is selection in 
Q1 and transmitted to q2 for fragmentation by CID; specific product ions resultant from target peptide 
fragmentation are selected in Q3 for detection. PRM follows the same first two steps as SRM but all 
product ions are monitored by a HR/AM mass analyser. In DIA, all precursor ions within a defined 
m/z window are selected in Q1, fragmented in q2 and all product ions are monitored by a HR/AM 
mass analyser. The process is repeated through the full MS1 m/z range in a stepwise fashion. b) 
Comparison of SRM, PRM and DIA for targeted quantification. DIA is the least time-consuming 
technique to set up and the best for multiplexing, but lacks sensitivity, specificity and reproducibility. 
SRM and PRM perform as well as one another, other than PRM being more selective due to the use 
of a HR/AM mass analyser. The sensitivity comparison between SRM and PRM is based on 
quantification of the relatively small number of target peptides (e.g. ~50 peptides) in a single analysis. 
Figure reproduced from Tujin Shi et al. (2016). 
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Selected reaction monitoring (SRM) is such an approach that has been used extensively to 
study small molecules (Kondrat et al., 1978), but it has only recently been adopted for 
proteomics where its qualities have been swiftly recognised (Marx, 2012; “Method of the Year 
2012,” 2013). SRM is typically performed on a triple quadrupole mass spectrometer, with two 
quadrupoles acting as selective mass filters and the other as a collision cell for ion 
fragmentation. In an SRM experiment, ions are delivered to the first quadrupole through which 
only precursor ions of a specific m/z value can pass through. These precursor peptide ions 
are then subjected to low energy CID in the second quadrupole. The resultant product ions 
are transferred into the third quadrupole, which only permits a specific product ion of a single 
m/z value through to the detector. This combination of precursor and product ion m/z values 
(known as a transition) alongside knowledge the chromatographic retention time of the 
peptides makes SRM an exquisitely selective technique. Moreover, multiple transitions can 
be monitored in a single run, which allows for a high degree of multiplexing, especially when 
SRM is scheduled so that peptides are monitored in a specific time window relating to when 
they elute from the LC column. SRM has become a mature technology with clarity on its 
background, implementation and limitations, and as such has been used with SIL peptides in 
for targeted quantification in many studies (Vidova and Spacil 2017; Holman, Sims, and Eyers 
2012).  
SRM is capable of quantifying proteins down to 50 copies per cell in S. cerevisiae (Picotti et 
al., 2009), however, this is a function of being able to load many cells onto a column. In human 
plasma or serum, commonly used for the detection of biomarkers as it is easily obtained, SRM 
can routinely detect proteins in the µg/mL range. As most biomarkers are in the pg/mL range, 
this is clearly insufficient. To improve sensitivity, sample enrichment using affinity reagents 
has been developed in what has become known as ‘immuno-SRM’. Affinity enrichment can 
be performed at the protein or peptide level. The development of Stable Isotope Standards 
and Capture by Anti-Peptide Antibodies (SISCAPA) methodology relies on the development 
of anti-peptide antibodies to enrich analyte and SIL standard peptides post-digestion. Anti-
peptide Abs can be immobilised to a column or magnetic beads, sample passed over and the 
unbound fraction washed away, and bound peptides eluted for MS analysis (N. L. Anderson 
et al., 2004, 2009). SISCAPA has been used to detect proteins down to the low ng/mL level, 
for example FGF15 at a LOD of 0.1 ng/mL in mouse plasma (Katafuchi et al., 2015) and a 
TIMP1 glycoform at 0.8 ng/mL in human serum (Yeong et al., 2009). The protein level 
immunoenrichment of samples, termed Mass Spectrometric Immunoassay (MSIA) uses 
antibodies against a protein or particular protein isoform for enrichment before digestion and 
has been used to detect protein down to similar levels (Gauthier et al., 2015; Krastins et al., 
2013). Sensitivity has been further improved through tandem affinity enrichment approaches, 
in which samples are enriched first at the protein level, and then again at the peptide level 
post-digestions. Using this approach β-NGF was quantified in human serum down to 0.7 
pg/mL (Neubert et al., 2013), representing a 10-fold increase in sensitivity compared to regular 
immuno-SRM techniques. Immuno-SRM techniques have great potential to improve 
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sensitivity of targeted SRM experiments, but are limited in their multiplexing ability as exposing 
a sample to multiple Abs at one time increases the possibly of non-specific binding, thus 
increasing noise and decreasing sensitivity (Tujin Shi et al., 2016). They also require the rapid 
generation of affinity regents against protein and peptide targets; approaches using 
recombinant antibody fragments (Whiteaker et al., 2014) and aptamers (Zhao et al., 2011) 
have been proposed to fulfil this. There remains the fact, though, that affinity enrichment incurs 
additional expense, increases experimental time, and raises the potential for variability 
through extra sample handling steps. As an alternative, antibody-independent methods for 
improving SRM sensitivity have been developed. In an approach known as PRISM (high-
pressure, high-resolution separations with intelligent selection and multiplexing), samples are 
separated by high-resolution reversed-phase capillary LC and analysed by multiplexing SRM, 
which when combined with immunoaffinity depletion of abundant proteins detected plasma 
proteins at 50 – 100 pg/mL levels (T. Shi et al., 2012). Building on this, two-dimensional (2D) 
high-resolution reversed-phase LC using low and high pH RP-LC in succession to fractionate 
first samples and then resultant fractions has led to the quantification of proteins at 10 pg/mL 
levels in non-depleted serum (Nie et al., 2017). This matches and even outperforms 
immunoassays in terms of sensitivity, but the method requires highly complex sample 
preparation and fractionation that limits sample throughput, and unless carefully controlled 
through automation would not be highly reproducible (Figure 1.6b).  
A major limitation with SRM is the development time required to define optimal peptides, assay 
parameters and assay characteristics for a high quality SRM assay. Tools and software have 
been developed to aid with the selection of peptides and assay parameters such as 
CONSeQuence (Eyers et al., 2011), Peptide Atlas (Deutsch et al., 2008), SRMAtlas 
(Kusebauch et al., 2016) and Skyline (MacLean et al., 2010), but the process of assay 
validation to reach the highest standards set by the community (Carr et al., 2014) is still a time-
intensive task. 
There have been technological developments that aim to maintain the selectivity and 
sensitivity of SRM whilst improving development time and throughput. The development of 
hybrid instruments with high-resolution and accurate-mass (HR/AM) mass analysers, such as 
quadrupole-Orbitrap and quadrupole-TOF mass spectrometers, has facilitated the 
development of new targeted MS modes. Parallel reaction monitoring (PRM) (Gallien et al., 
2012; Peterson et al., 2012; Schilling et al., 2015) is similar to SRM in that precursor ions of a 
specific m/z value are isolated by a quadrupole and fragmented by CID or HCD. The full 
MS/MS spectra (rather than a specific fragment ion) for the precursor ion is then acquired in 
the HR/AM mass analyser. Fragmenting every product ion improves assay selectivity and 
removes the need to select transitions for each peptide, making the assay less time-
consuming to set up. Studies using PRM on Orbitrap and TOF instruments have shown it to 
have equivalent accuracy, sensitivities, signal linearity, dynamic range reproducibility and 
repeatability compared to SRM (Kockmann et al., 2016; Ronsein et al., 2015; Schiffmann et 
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al., 2014; Schilling et al., 2015). However, these results were obtained using relatively simple 
samples with few co-eluting peptides, so MS acquisition parameters could be set towards their 
optimum (i.e. high maximum fill time and high orbitrap resolving power). In more complex 
samples where peptide co-elution is increased or where a greater degree of multiplexing is 
required, these acquisition parameters must be adjusted, which ultimately affects sensitivity, 
accuracy and reproducibility (Bourmaud et al., 2016; Gallien et al., 2014; Tujin Shi et al., 2016). 
Novel dynamic acquisition strategies that rely on the real-time adjustment of PRM acquisition 
parameters based on the detection of spiked-in SIL peptides have been used to quantify up 
to 600 peptides in complex samples (Gallien et al., 2015), although the accuracy of 
reproducibility of such methods remains to be seen (Tujin Shi et al., 2016). Although currently 
less-established than SRM, PRM offers great promise due to its superior assay performance, 
and may eventually replace SRM as the gold standard for targeted quantification experiments 
if future studies show that recognised performance metrics for quantitative measurements can 
be met (Carr et al., 2014).  
Both SRM and PRM are limited in their multiplexing ability, making global proteome 
quantification in a single run impossible. To overcome this, targeted analysis based on data 
independent acquisition (DIA) modes have also been developed. In DIA, all peptides ions 
within a defined m/z window are isolated in a quadrupole and fragmented together by CID or 
HCD. All product ions are then analysed by HR/AM mass analysers and the process is 
repeated throughout the full m/z range in a stepwise fashion. Since first being described 
(Venable et al., 2004), significant advances in DIA have been made through the development 
of new generation HR/AM mass spectrometers and different acquisition techniques to take 
advantage of the improved MS performance (H. Li et al., 2017; Tujin Shi et al., 2016). Once 
such technique, known as  Sequential Windowed Acquisition of all THeoretical mass spectra 
(SWATH), has particularly garnered attention as a method for proteome-wide quantification of 
target proteins (Gillet et al., 2012). In SWATH, a wide, slightly overlapping precursor mass 
range is used, resulting in fast scan times for the entire mass range so that peptides are 
measured 8 – 10 times across their chromatographic elution profile. The resultant highly 
complex MS/MS spectra (referred to as digital maps) are deconvoluted post-acquisition using 
spectral libraries built from fragment ion spectra. For each target peptide these contain m/z 
values for the precursor and selected fragment ions, the relative intensities of fragment ions 
and retention time data for the peptide (Schubert et al., 2015). SWATH-MS has been used 
with label-free (Y. Liu et al., 2015; Mcqueen et al., 2015), chemical labelling (Russell et al., 
2016) and SIL label standards (Y. Liu et al., 2013; Nakamura et al., 2016) to perform relative 
and absolute quantification in a wide range of samples (Anjo et al., 2017). When compared 
with SRM and PRM, protein fold changes and dynamic range have been shown to be similar 
using SWATH, but sensitivity up to 10-fold lower (Gillet et al., 2012; Y. Liu et al., 2013). 
Another study using a limited number of peptide analytes and SIL standards showed that SRM 
and PRM outperformed SWATH in terms of accuracy and precision, especially for low 
abundance proteins (Kockmann et al., 2016).  
Chapter 1: Introduction 
 26 
 
SWATH and DIA techniques in general have great potential for proteome-wide targeted 
quantification. For targeted analysis of a limited number of proteins, however, DIA is currently 
inferior to the gold standard SRM in terms of accuracy, sensitivity and reproducibility. These 
metrics could be improved with sample fractionation or depletion of the most abundant 
proteins, but these introduce additional sample handling steps that increase variability. Future 
development in instrumentation such as increased scan speeds, improved resolution and 
employing ion mobility to add an extra dimension of sample separation may improve DIA for 
targeted analysis, but this remains to be seen.  
1.4. DOSCATs as double standards 
Out of all the reviewed methods for targeted protein quantification using mass spectrometry 
and immunochemistry, SRM analysis with SIL standards is recognised as the gold standard 
for absolute quantification. Immunochemical methods are practised much more prevalently, 
though, with WB extensively used in a semi-quantitative manner and increasingly used for 
absolute quantification with the aid of improving technology. Whilst ELISAs are superior for 
quantification, the development time and expense associated with developing new well 
validated ELISAs means that the range of potential targets does not match that of WB.  
Western blotting, although a much-maligned method for protein quantification, does hold some 
advantages over SRM (Table 1.1). It is generally seen as more sensitive and is much more 
accessible to the general research community due to its relatively low cost and ease of use. 
Additionally, WB is often requested by reviewers for orthogonal validation of MS-generated 
proteomics datasets without any evidence for the analytical equivalence of both methods 
(Aebersold et al., 2013). Therefore, there is a motivation to explore the performance of 
quantitative WB compared to MS. However, directly comparing WB and MS outputs within a 
single workflow is difficult due to the different calibration standards used (recombinant proteins 
and SIL peptides for WB and MS respectively). DOSCAT technology aims to bridge the gap 
between the two techniques by acting as a double standard for WB and MS analysis.  
DOSCATs continue the trend started by QconCATs of using protein engineering to create 
artificial proteins to improve MS-based analyses, other examples being QCAL (Eyers et al., 
2008), QCAL-IM (Chawner et al., 2012) and RePLiCAL (Stephen W Holman et al., 2016) 
proteins as standards for assessing and normalising instrument conditions across repeat runs. 
DOSCATs are artificial protein designed in silico and expressed recombinantly in E.coli, and 
function by concatenating epitope sequences for WB analysis from multiple proteins so that 
the standard is recognised by multiple antibodies. They also embed peptides from the same 
proteins for MS analysis, thus acting as a single multiplexed standard for WB and MS 
quantification. They can be spiked into the sample pre-digestion, so the sample can be taken 
down both MS and WB workflows, facilitating the seamless integration of the two workflows 
and the direct comparison of outputs from both techniques. 
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This will allow for a fair assessment of the quality generated by WB compared to a MS gold 
standard. Moreover, orthogonal quantification of target proteins in a unified workflow will 
improve quantitative accuracy and utilise the best attributes of the two platforms. Techniques 
orthogonal to WB, such as MS, has been proposed to validate antibody specificity, and 
DOSCAT technology would be well placed to aid in this process.  
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Table 1.1 Comparison of western blotting and mass spectrometry for target absolute protein 
quantification. 
Parameter Western blotting Mass spectrometry (SRM) 
Sensitivity Can routinely detect pg/mL 
protein in complex samples  
Capable of detecting µg/mL 
protein in complex samples, 
although this can be improved to 
pg/mL by sample 
enrichment/depletion/fractionation 
Reproducibility Highly variable technique with 
many manual handling steps, 
although new automated 
techniques drastically improve 
this 
Highly reproducible; typical %CV 
< 20% 
Selectivity Dependent on specificity of the 
antibody 
Use numerous parameters: 
peptide elution time, multiple 
transitions 
Quantification Classic methodology semi-
quantitative at best although 
technological advances and 
automation make the 
technique quantitative  
Gold standard for quantification 
Ease of use Assays requires optimisation 
but technically simple 
methodology 
Requires experienced operators 
to optimise and execute assay 
Cost Low equipment and reagent 
costs, although some 
instrumentation can be 
expensive e.g. CCD camera  
Significant upfront and ongoing 
investment in instrumentation, 
maintenance and associated 
expertise  
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1.5. Aim and objectives 
The overarching objective of this thesis is to develop DOSCAT technology to demonstrate its 
utility in quantifying a set of target proteins in a complex sample. To achieve this, there are 
several landmark aims that must be met. Firstly, the principles of DOSCAT design must be 
established and refined; for example, the rationale behind the selection of epitopes and 
peptides and how they are assembled within the protein sequence. Secondly, the DOSCAT 
must be shown to express recombinantly in E.coli and that the epitopes and peptides 
contained within it can be detected in WB and MS respectively. Finally, the DOSCAT can be 
deployed in a dual-quantitative workflow and data from both platforms compared. 
The first results chapter is concerned with the initial design and proof of principle of a DOSCAT 
in a model system. The next two result chapters’ detail how two separate DOSCATs can be 
deployed to quantify target proteins in complex samples. Throughout the results chapters 
unforeseen challenges that arise during the deployment of DOSCAT are addressed and 
solutions discussed. Finally, chapter 6 discusses the potential for commercialising of DOSCAT 
technology with an emphasis on intellectual property and bringing the technology to market. 
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Chapter 2: Materials and methods 
2.1. Harvesting, counting and sonication of SK-N-AS cells 
SK-N-AS cells between passages 7-14 were grown to 80% confluency in 75 cm2 flasks in 
Minimum Essential Media (37 °C, 5% CO2/humidity). In each set of experiments a set of three 
cultures were stimulated with 10 ng/mL TNFα (Calbiochem, UK) for a period of 24 h. At the 
same time media was replaced on the unstimulated cells without added TNFα. To harvest 
cells, media was aspirated and adherent cells were washed three times with sterile PBS (5 
mL). Cell dissociation buffer (Sigma, UK) (1 mL) was added and the cells placed in the 
incubator at 37°C for 5 min. PBS (137 mM NaCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM 
KCl, pH 7.4) (4 mL) was added to each flask and the contents of each flask transferred to 
individual 15 mL Falcon tubes. Cells were dispersed by repeated uptake and aspiration from 
a 5 mL pipette and 50 µL of cell suspension was removed and added to an equal volume of 
0.4% (w/v) trypan blue in PBS. Immediately after mixing, dye suspension (10 µL) of cells was 
pipetted into each of the two chambers of a counting slide and cell numbers counted in a TC10 
cell counter (Bio-RAD, Hemel Hempstead, UK). The counter gave a direct reading of the total 
cells/mL and the viable cells/mL of suspension. Cells were harvested by centrifugation at 160 
x g (Eppendorf, Cambridge, UK), supernatant removed and cell pellets stored at -20°C. Cell 
pellets were re-suspended in 25 mM ammonium bicarbonate (Sigma) (not pH adjusted) at 100 
µL/1 x 106 cells and sonicated on ice using three 10 sec pulses at 30% amplitude delivered 
from a 3 mm probe of a Sonics Vibra Cell™ (Jencons Scientific Ltd, UK). Benzonase nuclease 
(Merck Millipore, UK, #70746) (2.5 U/100 µL cell lysate) was added and the cell lysate was 
held on ice and not fractionated further.  
2.2. Collection and processing of CSF  
CSF was collected with ethical approval and with informed consent as described by Gómez-
Baena et al. (2017). 
2.3. Preparation of competent E. coli cells 
BL21 E.Coli cells were streaked onto a culture plate containing LB agar (Merck, Germany) 
and incubated at 37 °C overnight. A single colony from this culture was used to inoculate 10 
mL LB broth (Merck, Germany), which was incubated overnight at 37 °C. LB broth pre-warmed 
at 37 °C (100 mL) was inoculated with 1 mL of the overnight culture and grown at 37 °C with 
shaking until an absorbance at 600 nm of 0.5 was reached. The culture was incubated on ice 
for 10 min and 50 mL of the culture centrifuged at 4,000 rpm, 5 min, 4 °C. Supernatant was 
discarded and cell pellets resuspended in 40 mL ice cold 0.1 M CaCl2, incubated on ice for 20 
min, and centrifuged 4,000 rpm, 5 min, 4 °C. Supernatant was discarded and the cell pellet 
resuspended in 1 mL 0.1 M CaCl2. Cells were then used for transformation immediately or 
stored with 15% glycerol at -80 °C.  
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2.4. Transformation of E.coli cells 
Genes for DOSCAT protein were optimised for expression in Escherichia coli, synthesised 
and ligated into a pET21a plasmid vector (Eurofins Genomics, Ebersberg, Germany). The 
DNA was diluted to 1 ng/µL in TE buffer (1 mM EDTA, 10 mM Tris-HCl, pH 8.0) and 5 ng (5 
µL) DNA added to 150 µL competent E.coli cells and the mixture incubated on ice for 45 min. 
Cells were heat-shocked by placing them in a 42 °C water bath for 30 sec followed by 
incubation on ice for 2 min. A 1 mL volume of LB broth pre-warmed at 37 °C was added to the 
cells and this was incubated at 37 °C for 60 mins. Cells were centrifuged at 5,000 rpm, 5 mins 
and the cell pellet resuspended in 200 µL LB broth. Transformed cells (100 µL) were spread 
onto culture plates containing LB agar with 50g/mL ampicillin (Sigma, A9518) and incubated 
at 37 °C overnight. If not being used immediately for expression, glycerol stocks were created 
by inoculating 10 mL LB broth, 50 µg/µL ampicillin with a single transformed colony and 
incubating at 37 °C overnight with shaking. In a sterile cryovial, 1 mL of the overnight culture 
was added to 0.5 mL sterile 60% glycerol, gently mixed and stored at -80 °C. 
2.5. Expression and purification of stable isotope labelled DOSCATs 
A single colony of BL21 DE3 E.coli transformed with plasmid DNA was used to inoculate 10 
mL LB broth, 50 µg/µL ampicillin and incubated for 6 h at 37 °C with shaking. A 100 µL volume 
of this culture was added to 10 mL minimal medium (48 mM Na2HPO4, 22 mM KH2PO4, 8.6 
mM NaCl, 19 mM NH4Cl, 1 M MgSO4, 0.1 M CaCl2, 20% glucose, 0.5% (w/v) thiamine) 
containing 50 µg/µL ampicillin and incubated overnight at 37 °C with shaking. Minimal medium 
with amino acids was prepared with 0.1 mg/mL [13C6]Arg/[13C6]Lys (Sigma), 0.1 mg/mL 
hydrophilic amino acids and 0.2 mg/mL hydrophobic amino acids. A 4 mL volume of this 
overnight culture was used to inoculate 200 mL minimal media with amino acids containing 
50 µg/µL ampicillin, which was incubated at 37 °C. When the culture OD at 600 nm reached 
0.6, expression was induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG, Alfa Aesar, B21149) and the cells were grown for a further 3 h. E.coli cells were 
separated from culture media by centrifuging at 3500 x g, 15 min, 4°C. Cell pellets from 50 
mL culture were resuspended in 2.5 mL sonication buffer (50 mM NaPO4, 25 U/mL benzonase 
nuclease, 1 x Complete EDTA-free protease inhibitor tablet (Roche, #11836170001), pH 8.0). 
Cells were sonicated on ice using 10 sec pulses at 30% amplitude delivered from a 3 mm 
probe of a Sonics Vibra Cell™ until 130 joules was reached.  
For purification, the E.coli lysate was centrifuged at 6000 g, 8 min, 4°C to separate insoluble 
and soluble fractions. DOSCATs were present in the insoluble inclusion body pellets, which 
were solubilised by incubating for 30 min in 4 mL 20 mM NaPO4, 0.5 M NaCl, 10 mM imidazole, 
6 M guanidine hydrochloride, pH 7.4. Inclusion body samples were filtered using a 1.20 μm 
syringe filter (Milliex GP, Merck Millipore, UK) before purification of the His-tagged DOSCAT 
on a 1 mL His-trap HP column (equilibrated in the solubilisation buffer, above) using the ÅKTA 
start system (GE Healthcare, USA). Bound proteins were eluted by applying a linear gradient 
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of 0-100% elution buffer (20 mM NaPO4, 0.5 M NaCl, 0.5 M imidazole, 6 M guanidine 
hydrochloride, pH 7.4) over 20 min at a flow rate of 1 mL/min. Eluted fractions containing 
DOSCAT were pooled and dialysed against 50 mM ammonium bicarbonate, 1mM DTT 
(Melford Laboratories Ltd, MB1015), pH 8.5. RapiGest SF (Waters, UK) was added to the 
storage buffer at a final concentration of 0.1% (w/v) to reduce DOSCAT adsorption to plastic 
surfaces. DOSCAT solution was aliquoted and stored in low bind tubes (Corning, USA) at -
20°C.  
2.6. Expression of M-DOSCAT-i 
The immunogen M-DOSCAT-i did not express using the protocol described in section 2.5, and 
so alternative cell lines were used: SL BL21, C43 (DE3), BL21(DE3)-pLysS (pLysS), Rosetta-
pLysS (Rosetta) and Rosetta-gami-pLysS (Rosetta-gami). The M-DOSCAT-i plasmid was 
transformed into all cells as previously described. Agar and LB broth (both Merck Millipore) 
contained 1% glucose and 50 µg/mL ampicillin (Sigma, A9518) for all cell strains, with the 
following additions for some cell strains. For Rosetta and pLysS cells 35 µg/mL 
chloramphenicol (made up in 100% ethanol) was added and for Rosetta-gami 35 µg/mL 
chloramphenicol, 10 µg/mL tetracycline (made up in 75% ethanol) and 15 µg/mL leucine 
(made up in MilliQ H2O) was added. After transformation cells were cultured in the appropriate 
agar overnight at 37°C and a single colony used to inoculate 10 mL of the appropriate LB 
media, which was cultured overnight at 37°C with shaking. This overnight culture (1 mL) was 
used to inoculate 100 mL of the appropriate LB media, which was cultured at 37°C with 
shaking and expression induced by 0.5 mM IPTG when the culture OD at 600 nm reached 
0.6. 
2.7. Protein concentration determination 
Protein was assayed using a modified Bradford assay. SK-N-AS cell lysate and DOSCAT 
were diluted 1:50 and 1:100 in Milli-Q (18Ω) water and 100 µL of each sample added to a 
microtitre plate in duplicate followed by the addition of 200 µL protein assay reagent (Thermo 
Fisher Scientific, Cramlington, UK). The plate was read at 600 nm on a microplate reader 
(Multiscan) using Ascent software (Thermo Fisher Scientific) and protein concentrations 
interpolated from a BSA standard curve. 
2.8. Restricted proteolysis of DOSCAT 
The DOSCAT protein was incubated with either TEV protease (Invitrogen), TVMV protease 
(Biomol, Germany), human RV3C protease (GE Healthcare), factor Xa, thrombin (Sigma) or 
enteropeptidase (Novagen) using the following reaction buffers and conditions specific to each 
protease. TEV and TVMV proteolysis was carried out in 50 mM Tris-HCl pH 8.0, 0.5 mM 
EDTA, 1 mM DTT at 30°C. RV3C proteolysis was carried out in 50 mM Tris-HCl pH 7.0, 150 
mM NaCl, 1 mM EDTA, 1 mM DTT at 4°C. Enteropeptidase proteolysis was carried out in 20 
mM Tris-HCl pH 7.4, 50 mM NaCl, 2 mM CaCl₂ at RT. Factor Xa proteolysis was carried out 
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in 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 5 mM CaCl2 at RT. Thrombin proteolysis was carried 
out in 20 mM Tris-HCl, 150mM NaCl, 25 mM CaCl2, pH 8.0 at RT. All incubations were carried 
out overnight, with time points taken for SDS-PAGE analysis as described in the text.  
2.9. In-gel trypsin digestion 
Bands were excised from SDS-PAGE gels stained with Comassie Brilliant Blue (PhastGel 
Blue, GE Healthcare, 17051801). Gel pieces were reduced in 100 µL 100 mM DTT for 15 mins 
at 60°C and then alkylated by the addition of 7 µL 250 mM IAM (Sigma, #1002483822) for 30 
mins at RT in the dark. The reaction was quenched by the addition of 3 µL 100 mM DTT and 
incubation at RT for 5 mins. The supernatant was removed and the gel piece washed twice in 
500 µL ammonium bicarbonate with 10 mins shaking at RT each time. The gel piece was then 
dehydrated in 100 µL 100% ACN with 15 mins shaking at RT. This was then removed, residual 
ACN evaporated through air drying and 30-50 µL 0.02 µg/µL trypsin in 40 mM ammonium 
bicarbonate added to the gel piece. After 15 mins incubation at RT 50-100 µL 40 mM 
ammonium bicarbonate in 5% ACN was added so as to completely cover the gel piece. The 
sample was incubated at 37°C overnight (16-18 h) with gentle shaking. Following this an equal 
volume of 100% ACN was added to the solution and the incubation continued for 20 mins. 
The gel pieces were briefly spun down and the supernatant collected and speed-vacced to 
remove ACN. 
2.10. In-solution trypsin digestion  
Samples were diluted in 25 mM ammonium bicarbonate and proteins were denatured by the 
addition of Rapigest (0.1% w/v) and heating at 80°C for 10 min. Samples were reduced 
(addition of 10 µL 60 mM DTT and heating at 60°C for 10 min) and alkylated (addition of 180 
mM iodoacetamide and incubation at RT for 30 min in the dark). In digests containing 
DOSCAT, up to 2 pmol of [Glu1]-Fibrinopeptide B (Waters) was added. Mass spectrometry 
grade trypsin (Promega, USA) was reconstituted in 50 mM acetic acid to 0.2 µg/µL and 10 µL 
added to digests followed by incubation at 37°C for 4.5 h. At this stage an additional 2 µg 
trypsin was added and the sample incubated at 37°C overnight. The digestion was ended and 
RapiGest SF removed by acidification (1.5 µL trifluoroacetic acid followed by incubation at 
37°C for 45 min). Digests were made up to 225 µL by the addition of acetonitrile:water (2:1) 
and precipitate (resultant from the breakdown of RapiGest SF) removed by centrifugation 
(13,000 g, 30 min, 4°C). Supernatant was removed from the precipitate pellet and carried 
forward for use as sample.   
2.11. SDS-PAGE 
SDS-PAGE was performed as described by Laemmli (1970), unless otherwise stated in the 
text. Samples were mixed 1:1 with 2x reducing sample buffer (100 mM Tris-HCl pH 6.8, 4% 
(w/v) SDS, 0.2% (w/v) broophenol blue, 20% (v/v) glycerol, 200 mM DTT) and heated at 95°C 
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for 5 min. Samples were run on 12% or 15% (specified in the text) SDS-PAGE gels at 200V 
for 45 min. Protein bands were visualised with Coomassie Brilliant Blue. 
2.12. Western blotting  
Samples separated by SDS-PAGE were transferred electrophoretically to nitrocellulose or 
PVDF membrane using Towbin transfer buffer (25mM Tris, 192mM Glycine, 10% methanol) 
and either a constant voltage of 100 V for 1 h at RT or a constant current of 150 mA, 4 °C 
overnight (referred to as overnight transfer). Membranes were blocked in 5% milk in TBS (50 
mM Tris-HCl, 150 mM NaCl, pH 7.4) solution for 1 h, incubated with primary antibody in TBS-
T (1x TBS, 0.01% Tween 20) for 3 h at RT and then washed 3 times for 5 min in TBS-T. For 
chemiluminescent detection membranes were incubated with a HRP conjugated anti-mouse 
or anti-rabbit secondary antibody in TBS-T for 1 h at RT, washed 4 times for 5 min in TBS-T 
and following a final 5 min TBS wash incubated with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific) for 5 min. Bands were imaged using film 
(Fuji) or CCD camera (Fujifilm LAS-3000). For fluorescent detection, membranes were 
incubated in the dark with a near infra-red fluorophore conjugated secondary antibody 
(IRDye® 680RD, Li-COR Biosciences) for 1 h at RT, washed as described above and imaged 
using an Odyssey SA scanner (Li-COR Biosciences) detecting in the 700 nm channel. 
2.13. Automated capillary western blotting and data analysis 
Automated capillary western blotting was performed on Wes instrumentation (ProteinSimple, 
CA). Samples were prepared for analysis per the ProteinSimple user manual. All reagents 
were provided by ProteinSimple other than the primary antibody. Samples were mixed at a 
4:1 ratio with a 5 x master mix containing SDS (exact concentration unknown as master mix 
composition proprietary), 40 mM DTT and fluorescent molecular weight standards and heated 
at 95 °C for 5 min. Samples plus biotinylated molecular weight standards (ProteinSimple) were 
loaded along with blocking solution, wash buffers, primary antibodies, horseradish-peroxidase 
conjugated secondary antibodies and chemiluminescent substrate into a plate prefilled with 
stacking and separation matrices. Fully automated western blotting was performed using the 
Wes system; proteins were separated by electrophoreses at 375 V for 25 min, immobilised to 
the capillary by proprietary UV crosslinking and incubated with primary and secondary 
antibodies for 30 min each. Chemiluminescent signal was captured by a charge-coupled 
device camera and the resulting image was analysed by Compass software (ProteinSimple).  
2.14. Quantification of labelled DOSCAT using Glu-Fib standard 
Samples were analysed using nanoAcquity UPLC™ system (Waters) coupled to a Xevo™ 
TQS triple quadrupole mass spectrometer (Waters) in SRM mode with Q1 and Q3 operating 
at unit mass resolution. Digested sample (1 µL) was loaded onto a trapping column (C18, 180 
μm x 20 mm, Waters) using partial loop injection for 3 min at a flow rate of 5 μL/min with 0.1% 
(v/v) formic acid. The sample was resolved on the analytical column (nanoACQUITY UPLC 
Chapter 2: Materials and methods 
 
 35 
 
HSS T3, C18, 75 μm x 150 mm x 1.8 μm column, Waters) using a gradient of 97% A (0.1% 
(v/v) formic acid) 3% B (99.9% (v/v) acetonitrile, 0.1% (v/v) formic acid) to 60% A 40% B over 
30 min at a flow rate of 300 nL/min followed by washing with buffer B and re-equilibration. 
SRM analysis was performed using an electrospray voltage of 3000 V and a source 
temperature of 80°C. [Glu1]-Fibrinopeptide B was detected by measuring three transitions of 
both isotopic variants over the entire course of the chromatographic run. Quantification was 
performed by integrating extracted ion chromatograms in heavy and light channels and 
comparing the two.  
2.15. Quantification of peptides by SRM and data analysis 
Quantification was performed on a Xevo™ TQS triple quadrupole mass spectrometer coupled 
to a nanoAcquity UPLC™ system (Waters) (using the parameters described above). Analysis 
was performed using the same settings as previously described in scheduled SRM mode in 
which 15 data points were acquired over a 30 sec chromatographic peak within a 4 min 
window. Collision energy was optimised for each peptide (Supplementary Table 1).  
Samples were prepared so that 1 µg cell lysate with either 1 fmol or 0.1 fmol DOSCAT were 
analysed by SRM methodology. Samples were prepared by serial dilution of the master mix 
sample with the cell lysate only digest. Both isotopic variants of each target peptide were 
analysed by three transitions. The final transition list was divided in two runs to achieve a 
minimum dwell time of 30 msec with each sample being analysed with both transition lists.  
Data were analysed by Skyline (MacLean et al., 2010) and absolute quantification values were 
calculated from the standard:analyte ratio and the known concentration of internal stable 
isotope labelled standard. Quantification as copies per cell was derived from knowledge of the 
number of cells loaded onto the column and the loading of the accurately quantified DOSCAT 
standard.  
2.16.  Tandem Mass Spectrometry and data analysis 
LC-MS/MS was performed on a nanoAcquity chromatography system coupled to either 
Synapt G2 (Waters) or LTQ-Orbitrap Velos (Thermo Fisher Scientific) instruments, or a 
Ultimate 3000 nano system (Dionex/Thermo Fisher Scientifc) coupled to a QExactive (Thermo 
Fisher Scientific) instrument. 
For the nanoAcquiity system, samples were trapped onto a Symmetry 
C18 precolumn (180 m id, 20 mm long, 5 m particles) (Waters Corporation) over 3 min, at 
a flow rate of 25 µL/min in 2% (v/v) ACN /0.1% (v/v) formic acid. Bound peptides were 
resolved on a nanoAcquity UPLC C18 column (75 µm id, 150 mm long, 3 µm particles) at 
300 nL/min over a 60 min linear gradient from 3 to 85% (v/v) ACN in 0.1% v/v formic acid.  For 
the ultimate 3000 nano system, samples were loaded onto a trap column (Acclaim PepMap 
100, 2 cm x 75 µm inner diameter, C18, 3 µm particle size, 100Å pore) at 5 µL/min with an 
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aqueous solution containing 0.1% (v/v) TFA and 2% (v/v) ACN. After 3 min, the trap column 
was set in-line with an analytical column (Easy-Spray PepMap® RSLC 15 cm × 75 µm inner 
diameter, C18, 2 µm, 100Å) (Dionex/Termo Fisher). Peptides were eluted by using an 
appropriate mixture of solvents A and B. Solvent A was 0.1% (v/v) formic acid in HPLC-grade 
water, and solvent B was 0.1% (v/v) formic acid in HPLC grade acetonitrile 80% (v/v). 
Separations were performed by applying a linear gradient of 3.8% to 50% solvent B over 35 
min at 300 nL/min followed by a washing step (5 min at 99% solvent B) and an equilibration 
step (15 min at 3.8% solvent B). 
The LTQ-Orbitrap Velos was operated in data-dependent acquisition mode. The 20 most 
intense multiply charged ions were sequentially fragmented at 35% of normalized collision 
energy. Precursors selected were dynamically excluded for 20 s. The QExactive was 
operated in data-dependent acquisition mode. Following a full MS scan between m/z 350 to 
2000 (mass resolution of 60,000 FWHM at m/z 200), a data-dependent top-16 method MS2 
analysis was performed with a target value of 1 x 105 ions determined with automatic gain 
control. Precursor ions were isolated with an isolation window of m/z 1.2, with scans acquired 
at a mass resolution of 30,000 FWHM at m/z 200 and dynamic exclusion of 20 s. The Synapt 
G2 instrument was operated in data-independent acquisition mode (MSE).  
Raw data for all instruments were converted into a *.mgf format peaklist file by Proteome 
Discoverer 1.1 (Thermo Fisher Scientific, Waltham, MA) using default parameters. 
Independent *.mgf files for each sample were searched against a database containing 
sequences of all DOSCAT iterations with MASCOT search engine (version 2.5.1, Matrix 
Science), using trypsin as specific enzyme, carbamidomethylation of cysteine as fixed 
modification, methionine oxidation as variable modification and one trypsin missed 
cleavage, a mass tolerance of 10 ppm for precursors and 0.6 Da for fragment ions. The 
false discovery rate (FDR) was calculated using the decoy database tool in MASCOT.  
2.17. MALDI-TOF mass spectrometry 
Samples were mixed 1:1 (v/v) with a 10 mg/mL solution of α-cyano-4-hydroxycinnamic acid in 
50% ACN, spotted onto the MALDI target plate and air-dried. MALDI-TOF analysis was 
performed on an Ultraflex instrument (Bruker) operated in positive ion mode. Spectra were 
acquired at a laser energy of 40-70% of the maximum energy with 4000 shots per spectrum 
and a laser repetition rate of 1000 Hz. Spectra were acquired between m/z values of 700 and 
4000. Data were analysed using FlexAnalysis to generated peak lists, which were searched 
against an in-house DOSCAT sequence database using Mascot.  
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Chapter 3: Proof of principle of a DOSCAT approach 
3.1. Introduction 
As with any novel technology, feasibility of the approach must be established to show that it 
has practical potential. Therefore, the first stage of the work is to design and use a DOSCAT 
to quantify a set of proteins in a well-defined model system. This includes the establishment 
and refinement of DOSCAT design principles, optimisation of protein expression and 
purification, and finally, a demonstration that the standard can be used to successfully 
calibrate both quantitative WB and SRM-MS experiments.  
If western blotting using DOSCAT is to be routinely used for absolute protein quantification, it 
is important to understand how the multiple variables inherent to the technique contribute to 
quantitative accuracy and reproducibility. Therefore, another component of the proof of 
principle work will be determine the best method to execute a quantitative WB. Different WB 
methodologies and their advantages and disadvantages have been reviewed extensively in 
Chapter 1. Western blotting using ECL or fluorescent detection and, more recently, automated 
capillary WB, are the most routinely used methods for protein quantification. These three 
platforms will be evaluated in terms of their characteristics to deliver the best quantitative 
results, permitting an informed choice of the optimal technique to use with DOSCAT for future 
quantitative experiments.  
As part of a model system to test the DOSCAT principle, proteins involved in NF-κB signaling 
were selected. The signaling pathways governing NF-κB activation are well-studied (Figure 
3.1) and through the regulation of a wide spectrum of genes they are implicated in 
inflammation, immune response and disease (Hoesel et al., 2013; Karin, 2009; Lawrence, 
2009). The NF-κB transcription factors are made up of Rel-family proteins including p50, 
RelA/p65, p52 and RelB (Hayden et al., 2012). In unstimulated cells, these proteins are 
inactivated by the binding of the inhibitory kappa B family of proteins, including IκBα, IκBβ and 
IκBε (Karin et al., 2000), or by forming a complex with p100. In the canonical pathway, cell 
stimulation (from, for example, growth factors, proinflammatory cytokines and antigen receptor 
binding) leads the activation of the IκB kinase (IKK) complex. This phosphorylates IκBs, 
leading to their poly-ubiquitination and subsequent degradation in the proteasome 
(Palombella et al., 1994; Scherer et al., 1995). This has the effect of activating the NF-κB 
transcription factors p65 and p50 through their translocation to the nucleus where they bind to 
DNA and influence gene expression (Karin et al., 2000). In the non-canonical pathway, the 
activation of different receptor classes causes the activation of the NF-κB inducing kinase 
(NIK), which phosphorylates and activates IKKα. This goes on to phosphorylate p100 leading 
to its ubiquitination and partial degradation to p52, which in complex with RelB activates gene 
expression. 
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Figure 3.1 The canonical and non-canonical NF-κB signalling pathway. a) In the canonical 
pathway lipopolysaccharides (LPS), tumour necrosis factor α (TNFα) or interleukin-1 (IL-1) activate 
Toll-like receptors (TLRs), tumour necrosis factor receptor (TNFR) and interleukin-1 receptor (IL-1R) 
respectively. This leads to IKKβ activation in the IKK complex, which then phosphorylates IκBα 
leading to its polyubiquitination and degradation in the proteasome. The NF-κB complex is then free 
to translocate to the nucleus and activate gene transcription. b) The non-canonical pathway; the 
activation of B-cell activation factor (BAFFR), CD40, receptor activator for nuclear factor kappa B 
(RANK) or lymphtoxin β-receptor (LTβR) leads to the NIK-mediated activation of IKKα, which 
phosphorylates p100 leading to its degradation to p52, allowing p52-RelB heterodimers to active 
gene transcription. Figure adapted from Hoesel and Schmid (2013). 
 
 
Designing a DOSCAT that targets proteins contained in the NF-κB pathway has several 
advantages. As the molecular and regulatory mechanisms involved in NF-κB mediated 
signaling are so well understood, it lends itself as an ideal model system for the proof of 
principle quantification experiments. The change in abundance of target proteins upon 
perturbations by specific signaling events is well profiled, so there is a benchmark to test the 
results from DOSCAT mediated quantitation against. Moreover, no studies to date have 
quantified in copy per cell terms the NF-κB proteins in a cell, so there will be additional value 
in generating quantitative data using this system for systems biology and mathematical 
modelling projects. An additional advantage to using a well-studied system is the abundance 
of analytical reagents (specifically antibodies) to detect proteins, which is critical when 
designing a DOSCAT.  
The aim of this chapter is to complete the early design and optimisation work required to 
demonstrate that the DOSCAT approach is viable and potentially a useful technology. Using 
five target proteins from the NF-κB pathway, DOSCAT design principles will be outlined and 
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expression and purification protocols optimised. The utility of a DOSCAT approach will be 
determined by testing whether peptides contained within DOSCAT are detectable by MS and 
whether epitopes contained within its sequence can be recognised by target antibodies.  
Furthermore, three different WB methods most appropriate for quantitative work will be 
assessed to determine which has the best analytical properties for protein quantification. 
3.2. Results and discussion 
3.2.1. Analysis of quantitative western blot techniques 
For absolute protein quantification by immunoblotting, it is important to understand the 
characteristics of different immunoblotting platforms so an assessment can be made as to 
which is be most suitable for quantification. Three different western blot platforms were tested. 
Two of these were classic WB, where following electrotransfer to PVDF membrane the 
detection step was performed through either an HRP linked secondary antibody and electro-
chemiluminescence captured by a CCD camera, or a near infra-red fluorophore linked 
secondary antibody that can be detected by digital imaging (LI-COR). The third technique was 
based on automated capillary blotting using the Wes system (Protein Simple). Each platform 
was evaluated in terms of inter- and intra- assay variability, linear range and sensitivity. 
Three QconCAT proteins of differing molecular weights were selected as a training set (Table 
3.1). Each protein contained a C-terminal His tag, allowing for all proteins to be detected using 
the same His-tag antibody. The three proteins were quantified by a Bradford assay and 
combined at an equimolar ratio into a single master mix, which was serially diluted and loaded 
in replicates across the same gel (ECL, n = 4; LI-COR, n = 3, Wes, n = 3). An extended dilution 
series was run for the LI-COR and Wes systems as an increased dynamic range compared 
to classic ECL was expected. For both classic WB approaches densitometry on the bands 
was performed using Odyssey software (LI-COR) and for Wes the associated Compass 
software (Protein Simple) was used for analysis. This experiment was replicated twice for 
each platform. Exemplar blots for each platform are displayed in Figure 3.2. It should be noted 
that for capillary WB the Compass analysis software generates a pseudo-gel image, in which 
the intensity of each band is relative to the most intense signal on the gel image. For this 
reason, relatively weak signals are not always visible on the gel without adjusting the image 
contrast, which can distort the more intense bands. Therefore, bands are not observable for 
lower concentrations of master mix even though a signal was measured. 
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Table 3.1 QconCAT proteins used as a training set for western blot analysis. 
Protein Molecular weight 
(kDa) 
Stock 
concentration 
(pmol/µL) 
DBK1 87.8 2.3 
CC02 60.0 3.4 
LS1 30.7 15.2 
 
 
The signal for each concentration point was first averaged across technical repeats within a 
single blot, and this value was averaged for all blot replicates (Figure 3.3). The response 
between concentration and signal was not identical between proteins (see difference in slope 
gradients), suggesting that either the protein concentrations within the master mix or the signal 
response was inaccurate. To assess this, a sample of the master mix was analysed by SDS-
PAGE alongside each individual protein (Figure 3.4). The relative signal for the individual 
QconCAT proteins agreed with their measured concentrations, with LS1 being the most 
intense followed by DBK1 and CC02. However, the master mix clearly did not contain an 
equimolar mix of each QconCAT as intended. The signal for CC02 was the most intense, with 
the signal for DBK1 and LS1 about 50% and 20% of this respectively. This would account for 
the observed differences in signal response; the gradient of the slopes generated by 
automated WB analysis closely followed this distribution. This was not the case for ECL and 
LI-COR results, though. This could be explained by signal saturation effects limiting the 
maximum signal so that even though more protein is present, the measured signal and 
response over a concentration range is similar. 
The results from the SDS-PAGE gel suggests that protein concentrations in the master mix 
were inaccurate. This makes an accurate assessment of assay sensitivity in terms of an 
absolute value difficult. However, linearity and dynamic range can be directly compared 
between the three platforms. As mentioned, signal saturation at higher protein concentrations 
is evident for classic ECL, with r2 values of 0.93 and below, representative of a small linear 
dynamic range. An improved dynamic linear range was obtained by fluorescent detection for 
DBK1 and LS1 with r2 > 0.97, but for CC02 the fluorescent signal saturated when more than 
0.5 pmol protein was loaded. The linearity of response for automated WB was very good 
across all three test proteins (r2 > 0.97), however, the linear signal falls away at lower 
concentrations of proteins, which indicates a lack of sensitivity compared to fluorescent and 
ECL detection. 
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Figure 3.2 Analysis of QconCAT master mix using ECL, fluorescent (LI-COR) and automated 
capillary western blotting (Wes). A master mix of the QconCATs DBK1, CC02 and LS1 was 
prepared and a dilution series created in sample buffer. For ECL and fluorescent WBs the master 
mix was separated by SDS-PAGE, transferred onto PVDF membrane, probed with anti-His tag 
antibody at a 1:1000 dilution and detected using ECL or fluorescence (using the LI-COR system) as 
described in methods. Automated capillary WB was performed on Wes instrumentation using the 
same anti His-tag primary Ab at a 1:100 dilution as described in methods. 
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Figure 3.3 Signal response in different WB platforms for QconCAT proteins. Signal at each 
concentration point was determined by densitometry (for ECL and LI-COR data) or by Compass 
software (for Wes data) and averaged across technical repeats within a single blot, with this value 
being averaged for all blot replicates (n = 2). Error bars represent standard error, n = 2.  
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Figure 3.4 SDS-PAGE analysis of test QconCAT proteins and master mix. An equal volume of 
each QconCAT stock (DBK1, CCC02 and LS1) was mixed 1:1 with SDS sample buffer and analysed 
by SDS-PAGE, as was the QconCAT master mix containing a supposedly equimolar amount of each 
protein. The numbers on the right denote the densitometric ratio of the proteins in the master mix 
normalised to the signal of the CC02 band in the master mix lane only.  
 
 
To find the intra assay variability, the coefficient of variance of technical repeats at each 
concentration was calculated. These CVs were averaged across the multiple gel replicates to 
give an average CV for each concentration point (Figure 3.5). Generally, intra-assay variability 
increased as less protein was loaded and the resultant signal approached the noise. The LI-
COR system performed substantially worse than the other two systems tested, with CV > 20% 
in almost all cases. Classic ECL and the Wes system performed equivalently at higher 
concentrations of protein, but the performance on Wes was maintained down to the smallest 
amount of protein loaded. The mean signal of all technical repeats was calculated, and the 
variance in terms of % CV across different gel replicates was used to assess inter-assay 
variability at each concertation point (Figure 3.6). Again, variability increased as protein load 
decreased and out of the three platforms LI-COR performed the worst. Across the full range 
of protein loaded, lowest levels of inter assay variability were observed on the Wes system.  
This work has compared classic WB using either ECL or fluorescent detection with automated 
WB, showing that the automated platform Wes offers improved inter-assay and intra-assay 
variability and good signal linearity and dynamic range. 
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For two proteins LI-COR demonstrated the best signal linearity across the range of protein 
concentrations tested. The lack of linear response for CC02 when measured by fluorescence 
is unusual, and there does not seem to be an obvious explanation. Both of the other platforms 
rely on electrochemiluminescene for detection, which is known for its limited linear dynamic 
range due to signal saturation (Elbaggari et al., 2008; Taylor et al., 2013). Fluorescent 
detection does not have this limitation and has shown to vastly improve linearity compared to 
classic ECL (Zellner et al., 2008). The data presented here (other than for CC02) would agree 
with this, although the difference with automated WB is much subtler. A caveat to this is the 
very low signal at the lowest protein concentrations detected by automated WB. These are 
essentially below the sensitivity limit and so affect the coefficient of determination value. If 
these data points were removed Wes would perform as well as LI-COR detection, albeit not 
with equivalent sensitivity. It may well be possible that the linear response would continue 
above the amount of protein loaded in these experiments, so further experimentation would 
be required to determine the full dynamic linear range of both systems.  
The intra- and inter- assay CVs measured in this experiment agree well with previous studies 
that have assessed variability in automated WB and classic WB using ECL detection (J. Q. 
Chen et al., 2013; Loughney et al., 2014; Rustandi et al., 2012). It has been demonstrated 
that the majority of error in electrophoresis and blotting experiments is introduced by the 
operator (Koller et al., 2005), so it is no surprise that the Wes system, which automates all of 
the process other than sample preparation, performs the best out of the three platforms. What 
is less clear is why the LI-COR system performs so poorly in this experiment. The LI-COR 
system would be expected to perform as well or better as ECL detection, but this was not the 
observed result. The LI-COR and ECL experiments were performed at different times, so it is 
of course possible that multiple factors (reagent and buffers stability, protein transfer, antibody 
binding etc.) combined to give poor reproducibility on the given day. Error may also have been 
introduced in the densitometric analysis; fluorescent detection resulted in a higher background 
and non-specific bands (Figure 3.2) that may have interfered with accurate measurement of 
signal intensity. A more accurate assessment of variability between ECL and fluorescent 
detection methods could be obtained performing electrophoresis, transfer and immunoblotting 
together, and splitting the membrane prior to the detection step (secondary antibody 
incubation onwards).   
Although this study gives a good insight into the best platform for quantitative WB is it limited 
by the relatively small number of proteins, antibodies and replicates used. Different antibodies 
and proteins may engender different results, and whilst the number of replicates performed 
here was limited by the available resources, increasing them would allow for a proper 
statistical assessment of differences between the techniques. Additionally, there are many 
more variables in a western blot that went untested in this experiment, such as primary and 
secondary antibody concentration, incubation and development times and electrotransfer 
settings.  
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Despite these limitations, there is a clear suggestion from the data that out of the three 
platforms tested automated WB using Wes offers the best properties for quantitative work. 
Moreover, compared to classic western blot approaches, automated WB is much faster (3 h 
vs ~ 2 days) and more economical. This raises the prospect of reproducible, high-throughput, 
quantitative assay that could be calibrated using DOSCAT technology.  
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Figure 3.5 Intra assay variability for each western blot platform. Variability in terms of % CV for 
each concentration point was calculated from technical repeats on each gel replicate (ECL n = 4; LI-
COR, Wes n = 3). Error bars represent standard error between gel replicates, n = 2. Note that CC02 
at 0.125 pmol was not detected on one of the ECL blots, so a standard error calculation was not 
possible. 
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Figure 3.6 Inter assay variability for each western blot platform. Technical repeats for each 
concentration point across a single gel were averaged and the variance between gel replicates (n = 
2) was calculated in terms of % CV. 
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3.2.2. NFκB-DOSCAT design, expression and validation 
Five target proteins involved in NF-κB signaling were selected; p65, RelB, IκBα, IκBβ and IκBε. 
For each protein, an epitope sequence for a specific antibody and at least two quantotypic 
peptides were selected and concatenated into a single sequence to create what will be 
referred to as the NFκB-DOSCAT.  
The selected antibodies and the epitopes used in the NFκB-DOSCAT are summarised in 
Table 3.2). The selection of epitopes to include in the NFκB-DOSCAT was driven by the 
commercial availability of antibodies for which the epitope was known and well characterised. 
This can be difficult to obtain from antibody manufacturers as they are not always willing to 
disclose peptide immunogen sequences or epitope mapping results due to commercial 
sensitivity. Some manufacturers would, however, disclose the amino acid around which the 
epitope was centered. Based on this information, the epitope region for DOSCAT was defined 
as the 25 amino acids either side of the disclosed central residue in the endogenous protein 
sequence. Since the average immunogen sequence is approximately 15 - 20 amino acids 
(Hancock et al., 2005), there was confidence that this approach would allow for the inclusion 
of the true epitope. As well as having epitope sequence data, the antibody itself must be well 
validated, although this is not always possible, especially on less well studied proteins. For 
each selected antibody, there was accompanying western blot data (provided by the 
manufacturer) to demonstrate the antibody detected a single protein at the expected molecular 
weight within a complex sample (e.g. cell lysate).  
Established criteria for selecting Q-peptides, developed through multiple quantitative 
proteomics studies employing stable isotope labelled peptides, were used to choose Q-
peptides to be included in the NFκB-DOSCAT. Firstly, the data repositories PeptideAtlas and 
Global Proteome Machine were accessed and peptides that met the criteria laid in Chapter 1 
were shortlisted for inclusion. Using the data repository approach peptides could not be 
identified for IκBα and RelB, so other peptides were selected based on their PeptideSieve 
score and predicted observability. Since the design of the NFκB-DOSCAT, other tools have 
become available for the selection of Q-peptides. The consensus prediction system 
CONSeQuence uses four independent machine learning algorithms to select Q-peptides that, 
based on their physiochemical properties, are predicted to have the best detectability in an 
ESI-MS experiment (Eyers et al., 2011). More recently developed is SRM ATLAS, a database 
of validated SRM assays for 99.7% of the human proteome (Kusebauch et al., 2016). SRM 
coordinates for up to five peptides per protein are contained in the database, allowing for rapid 
identification of optimal Q-peptides. For the design of future DOSCATs, these tools could be 
employed together to maximise the possibility that a peptide will ionize efficiently and 
quantitative data will be obtained. To each selected Q-peptide a flanking region of 3 amino 
acids from the endogenous sequence were added to either end of the peptides. This strategy 
has been shown to improve quantitative accuracy by equalising digestion efficiency between 
standard and analyte (Cheung et al., 2015).  
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In addition to the peptide and epitopes to enable quantification, several restricted specificity 
endopeptidase sites were included in the NFκB-DOSCAT design. This allowed for the 
possibility of shifting the electrophoretic mobility of NFκB-DOSCAT in QWB, conferring greater 
flexibility if standard and analyte had overlapping motilities, or introducing the possibility of 
multiplexing to measure two analytes within a single lane. Four endopeptidase were selected 
(Figure 3.7); each being frequently applied to cleave fusion tags from recombinant proteins 
and so widely available commercially as well as with a well-defined cleavage site that was not 
present in any target analytes.  
Q-peptides, epitopes and restricted specificity endopeptidase sites were arranged in silico 
(Figure 3.7). The exact positions of Q-peptides and epitopes was arbitrary, with peptides for 
the same protein mostly grouped together and epitopes spaced out evenly throughout the 
NFκB-DOSCAT sequence. The endopeptidase sites were inserted between epitopes in such 
a way so that the two proteolytic fragments generated would not have a similar electrophoretic 
mobility shift as a target analyte when detected by the same antibody. At the N-terminus, a 
methionine initiator residue followed by short sacrificial peptide to protect true Q-peptides from 
exoproteolytic activity were added. Following this, the sequence of [Glu1]-Fibrinopeptide B 
(Glu-Fib, EGVNDNEEGFFSAR) was added to enable quantification of the NFκB-DOSCAT 
itself against a commercially available Glu-Fib standard. A hexa-histidine tag was added to 
the C terminus to enable purification. 
 
 
Table 3.2 Antibodies selected for use with NFκB-DOSCAT. 
Protein Antibody Clonality Immunogen data 
p65 CST #3034 Rabbit polyclonal Centred around 
Ser276 
RelB CST #4954 Rabbit polyclonal Centred around 
Ser424 
IκBα CST #9242 Rabbit polyclonal Centred around Arg29 
IκBβ CST #9248 Rabbit polyclonal Centred around 
Arg155 
IκBε CST #9249 Rabbit polyclonal Centred around 
Gly205 
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The genes for the NFκB-DOSCAT were codon optimised for E.coli and cloned into pET21a 
vectors (Eurofins Genomics), which were transformed into BL21(DE3) E.coli cells. Cells were 
grown in minimal media containing [13C6]Arg/[13C6]Lys (Figure 3.8a) and expression was 
induced during mid-log phase by the addition of 1 mM IPTG (Figure 3.8b). The cell pellets 
were lysed by sonication and fractionated into soluble and insoluble fractions by centrifugation. 
Analysis of both fractions by SDS-PAGE revealed that the NFκB-DOSCAT was contained in 
the insoluble fraction. The insoluble fraction was solubilised in a strong chaotrope (6 M 
guanidine hydrochloride) and purified by Ni-NTA affinity chromatography (Figure 3.9a). The 
NFκB-DOSCAT was eluted over four fractions, which were pooled and dialysed in a 50 mM 
ammonium bicarbonate, 1 mM DTT storage buffer. Western blots using an anti his-tag 
antibody were used to demonstrate NFκB-DOSCAT purity (Figure 3.9b). Degradation 
products were visible at high (100 ng) loadings only, indicating that the degradation rate was 
low. As most of the NFκB-DOSCAT was intact and any degradation products could be 
approximately quantified as a fraction of total protein, degradation was not deemed a problem 
that would affect future quantitative experiments. Purified NFκB-DOSCAT was subjected to 
trypsin digestion and the peptides analysed by MALDI-TOF mass spectrometry (Figure 3.10). 
MS1 ions were searched against a database containing the NFκB-DOSCAT sequence using 
Mascot, with 44% sequence coverage. Out of the 13 Q-peptides built in to DOSCAT, 9 were 
observed by MALDI-TOF MS, with additional peptides from epitope and endopeptidase 
cleavage regions also visible. Furthermore, when searched against human and E.coli 
databases there were no significant protein matches were found, indicating that were no 
contaminants present. 
For the first time a DOSCAT has been successfully expressed and purified, and subsequent 
analysis has demonstrated that the protein is intact with minimal degradation and that the 
expected sequence is correct. As they are designed on similar principles, it was predicted that 
DOSCATs would behave in a similar manner to QconCATs, and this is what was observed. 
The NFκB-DOSCAT accumulates in inclusion bodies, which is consonant with previous 
observations of over 10 years of expression with QconCAT constructs (P. J. Brownridge et 
al., 2012). As the NFκB-DOSCAT is an artificial protein designed de novo, there is not the 
same evolutionary pressure as there is on ‘real’ proteins to be soluble; therefore, upon 
expression in E.coli it accumulates into insoluble inclusion bodies (Fahnert et al., 2004; Kane 
et al., 1988). This does not present a problem in that DOSCATs do not need to be folded and 
it can in fact be advantageous as it acts as a pre-purification step. The expression and 
purification protocols developed for QconCATs can be directly transferred to DOSCATs with 
minimal changes, raising the prospect for fast, simple expression for future DOSCATs. 
Not all Q-peptides were observed by MALDI-TOF analysis, which may be explainable by the 
limitations of using MALDI for ionisation. It is known that MALDI is a highly variable ionisation 
method that is heavily influenced by the matrix used, sample complexity and amount and types 
of peptides that are present within the sample (Szájli et al., 2008). MALDI displays a 
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preference for arginine-containing peptides (Krause et al., 1999), which is reflected in the 
observed results. It is possible that when analysed with LC-ESI-MS the peptides are readily 
observed for their use for quantification is permitted. 
 
 
 
Figure 3.8 Expresion of NFκB-DOSCAT. a) Growth of transformed E.coli cells as measured by 
optical density at 600 nm. b) SDS-PAGE analysis of time points from E. coli culture containing NFκB-
DOSCAT plasmid, grown in minimal media containing [13C6]Arg/[13C6]Lys for 3 h after inoculation, 
with expression induced by 1 mM IPTG at indicated time point.  
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Figure 3.9 NFκB-DOSCAT purification. a) SDS-PAGE analysis of starting matrial, flow through, 
washes (W) and eluted fractions (E) resultant from NFκB-DOSCAT purification on a Histalon column; 
b) Western blot of purified NFκB-DOSCAT; a dilution series of purified NFκB-DOSCAT was 
separated by SDS-PAGE, transferred onto nitrocellulose membrane and probed with an anti His-tag 
antibody.  
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3.2.3. NFκB-DOSCAT utility in western blotting  
Once the NFκB-DOSCAT had been expressed and validated, the next step was to test if it 
could be detected in a western blot by the chosen NF-κB antibodies. Using a classic western 
blot approach, the NFκB-DOSCAT was detected by p65 and RelB antibodies but not by the 
antibodies to IκBβ or IκBε (Figure 3.11). There were additional non-specific bands above and 
below the expected molecular weight of the NFκB-DOSCAT that could be attributed to 
aggregation and degradation products, which would be noticeable when high amounts of 
protein are loaded. It should be noted that at this point stocks of the IκBβ antibody had been 
depleted, and the product line had in the interim been discontinued by the manufacturer. For 
this reason, it could not be used in subsequent experiments. 
As future quantitative experiments were to be performed using automated western blotting, 
the remaining antibodies were tested in this platform using NFκB-DOSCAT and SK-N-AS cell 
lysate. The Wes system has different performance characteristics to a classic western blot, 
so initial experiments were performed to optimise methodologies and protein loading. Dilution 
series of NFκB-DOSCAT and SK-N-AS were loaded and probed with the RelB antibody. A 
clean signal was obtained for SK-N-AS cell lysate (Figure 3.12a), but not for NFκB-DOSCAT 
when loaded on its own (Figure 3.12b). At higher loadings of NFκB-DOSCAT (2 and 0.2 ng/µL) 
there were ‘dips’ in the electropherogram trace that were characteristic of protein burn out. 
This is where there are such high levels of protein loaded in the capillaries the ECL substrate 
is used up almost instantly before an image can be captured. Peaks present at 37 and 55 kDa 
may represent degradation products. In all traces, there was a constant signal above 100 kDa 
that scaled with the amount of NFκB-DOSCAT loaded. It was hypothesised that the observed 
signal was the NFκB-DOSCAT forming non-specific interactions with the capillary wall during 
electrophoresis rather than resolving to a clean peak. To test this, NFκB-DOSCAT was made 
up in buffers containing SDS, urea and SK-N-AS cell lysate. SDS and urea can act to disrupt 
protein-surface interactions, whereas the cell lysate would act as a complex background to 
minimise any interactions taking place. The addition of 2% SDS or 1 M urea had no effect on 
protein adsorption (Figure 3.12c), however, when the NFκB-DOSCAT was combined with cell 
lysate, a clear band for NFκB-DOSCAT and endogenous protein was observed (Figure 3.12d). 
Despite having a molecular weight of 77.5 kDa, the electrophoretic mobility of NFκB-DOSCAT 
in automated capillary WB was observed to be 100 kDa. 
Based on this result, a dilution series of NFκB-DOSCAT was spiked into SK-N-AS cell lysate 
and probed with each antibody (Figure 3.13). Using p65, RelB and IκBα antibodies, distinct 
bands for the NFκB-DOSCAT and the endogenous protein were observed. However, only 
endogenous protein was detected by the IκBε antibody. Some variability between individual 
capillaries was observed, a result of the capillaries’ independence of one another, which can 
lead to unequal protein load or slight variations in antibody binding. This can be resolved by 
the addition of system control antibodies provided by the manufacturer, which detect a protein 
with an electrophoretic mobility of 26 kDa contained in the sample buffer. This can be used as 
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a loading control to normalise signal between capillaries. This experiment also allowed for a 
preliminary assessment of signal linearity and intra-assay variability when using NFκB-
DOSCAT and a complex sample. NFκB-DOSCAT calibration curves exhibited excellent 
linearity, and signal variability between technical repeats of endogenous proteins was low 
(Figure 3.14).  
These experiments demonstrate that by inserting multiple different epitope sequences into a 
DOSCAT protein, different antibodies can be used to detect a DOSCAT in classic and 
automated western blot formats. This is the first time multiple epitopes from different targets 
have been detected in a single protein.  
The NFκB-DOSCAT was not detected by the IκBβ antibody; however, as it was not possible 
to test whether the antibody detected endogenous protein in cell lysate, it is difficult to say 
whether this is the fault of the NFκB-DOSCAT design or a poor antibody. The antibody for 
IκBε, however, detected endogenous protein but did not detect NFκB-DOSCAT in any 
experiment. As both endogenous protein and NFκB-DOSCAT were denatured and linearised 
as part of the sample preparation process, it is unlikely that the epitope in NFκB-DOSCAT was 
sterically shielded from the antibody, as can be the case in other immunoassays like ELISA. 
It is most likely that the epitope included in NFκB-DOSCAT did not reflect the actual epitope 
to which the antibody binds. Epitope details supplied by the manufacturer consisted of an 
amino acid around which the epitope was centered, and 25 amino acids around this central 
residue were included in NFκB-DOSCAT. Either the central residue data supplied was 
inaccurate, or the actual epitope was more than 25 residues away. Being a polyclonal 
antibody, however, it would be expected that at least some of the antibody population would 
bind to an area close to the central residue, unless there was a specific region further away 
that was particularly immunogenic. This is only speculation, though, and without details of the 
actual immunogen used or epitope mapping experiments it is difficult to say with any certainty 
why NFκB-DOSCAT was not detected. It does, however, highlight the importance of sourcing 
antibodies for which the epitope is well characterised and published before committing to 
make any DOSCAT protein. 
Results using automated capillary western blotting indicate that DOSCATs have a propensity 
to readily adsorb to surfaces. This is not an unusual characteristic for proteins and peptides, 
especially at low concentrations (Suelter et al., 1983). Proteins are complex molecules and 
their tendency to bind to a surface depends on many factors such as amino acid composition, 
properties of the surface and properties of the local environmental (temperature, pH, buffer 
composition) (Rabe et al., 2011). By combining a DOSCAT with a complex matrix, other 
proteins are introduced that compete for and block surface binding sites, massively reducing 
DOSCAT adsorption. Whether this property is specific to the NFκB-DOSCAT or will be 
common to other DOSCATs produced in the future or remains to be seen.  
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Figure 3.11 Detection of DOSCAT by NF-κB antibodies. Compositie image formed from multiple 
western blots of the NFκB-DOSCAT using each of the NF-κB antibodies for detection. The NFκB-
DOSCAT was run on SDS-PAGE, transferred to nitrcellulose membrane, incubated with each 
antibody and ECL signal detected by film.  
 
 
Figure 3.12 Optimisation of NFκB-DOSCAT detection on Wes. Electropherograms and gel views 
(inset) resultant from the analysis of the following by automated capillary western blotting, using an 
anti-RelB antibody for detection: a) dilution series of SK-N-AS cell lysate; b) dilution series of NFκB-
DOSCAT; c) NFκB-DOSCAT (0.02 ng/μL) with no additives (blue trace), with 2% SDS (green), or 
with 1 M urea (grey); d) NFκB-DOSCAT (0.02 ng/μL) spiked into 0.05 µg/µL SK-NA-S cell lysate with 
no additives, with 2% SDS (green), or with 1 M urea (grey).  
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Figure 3.13 Detection of NFκB-DOSCAT by capillary WB using NF-κB antibodies. NFκB-
DOSCAT was spiked into 0.2 mg/mL SK-NA-S cell lysate at various concentrations, serially diluted 
with the cell lysate as a diluent and analysed by automated capillary western blotting using each of 
the available NF-κB antibodies. System control (SC) protein contained within the sample buffer was 
also detected in tandem by a specific antibody to aid with signal normalisation across capillaries.  
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Figure 3.14 Linearity and intra-assay variability of DOSCAT and endogenous proteins 
detected by capillary WB. NFκB-DOSCAT spiked into 0.2 mg/mL SK-NA-S was analysed by 
capillary WB using each of the NF-κB Abs; the chemiluminescent signal of the NFκB-DOSCAT was 
plotted as a function of its concentration and the correlation coefficient calculated (top panels). The 
mean value and variation of the signals for technical repeats (n = 6) of detected endogenous proteins 
was calculated (bottom panels).  
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3.2.4. Restricted proteolysis of NFκB-DOSCAT to effect mobility shift 
The NFκB-DOSCAT contains cleavage sites for four proteases of restricted specificity. To 
assess protease cleavage, NFκB-DOSCAT was incubated with each of the specific proteases 
at concentrations and temperatures recommended by manufactures and the literature.  
Samples were taken at various time points during the incubations and run on SDS-PAGE to 
assess cleavage. Both TEV protease and RV3C protease cleaved NFκB-DOSCAT to produce 
fragments at the expected molecular weights, but the cleavage specificity for the other two 
proteases was less clear (Figure 3.15). Proteolysis by thrombin generates many products, 
which amongst them may include the expected NFκB-DOSCAT cleavage products at 70 kDa 
and 7.5 kDa (highlighted by the boxes). However, these fragments get less intense over the 
course of the reaction and are not visible overnight incubation. Digestion with Factor Xa also 
produces many fragments that degrade further over time, meaning that it is difficult to interpret 
the results from the gel. It is possible that the fragment at 33 kDa is visible after overnight 
incubation, however whether there is a fragment a 44 kDa is less clear.  
Only two of the proteases used have shown results as expected. TEV and RV3C proteases 
have previously demonstrated their ability to cleave protein completely with a high level of 
specificity (Advance, 2005; Eliseev et al., 2004; Rigaut et al., 1999; Senger et al., 1998), an 
outcome that is mirrored in the results obtained here. Both belong to the picornavirus 3C-like 
protease family, with long consensus sequence that if altered result in a major reduction in 
cleavage (Cordingleys et al., 1990; Dougherty et al., 1989).  
Although commonly use to cleave fusion tags from recombinantly expressed proteins 
(Abdullah et al., 2005; Hefti et al., 2001), both thrombin and factor Xa have demonstrated poor 
specificity when incubated with NFκB-DOSCAT. There is evidence that both these proteases 
recognise sequences other than their commonly published consensus sequence (Jenny et al., 
2003). It has been suggested that Factor Xa has a very loose selectivity, and as well as 
recognising the sequence IEGR, it may cleave at sequences as diverse as XXGR, X(G/A/S)R 
and XX(L/W/F/Y)R (Bianchini et al., 2002; He et al., 1993; Hsu et al., 2008). This would mean 
there are as many as 10 additional sites within DOSCAT that Factor Xa could cleave at, which 
would provide an explanation for the observed results. The consensus sequence of thrombin 
is longer than that of Factor Xa at 6 amino acids (LVPR/GS; cleavage at C-terminal of R), 
which would suggest a higher degree of specificity. Although there is a strong preference for 
Pro in P2 and Arg in P1 (Gallwitz et al., 2012; Petrassi et al., 2005), the amino acids in other 
positions can be less restricted (Gallwitz et al., 2012). Within the NFκB-DOSCAT sequence 
there are two other regions at which thrombin may also cleave. The first, KVPR/GS is in a 
region that forms two IκBα Q-peptides and their flanking regions. Other than substituting Lys 
for Leu at P4 this is identical to the consensus sequence. There is a preference for aliphatic 
acids at this position (Backes et al., 2000; Petrassi et al., 2005), and only negatively charged 
residues are known to diminish activity (Gallwitz et al., 2012). Therefore, it is highly likely that 
thrombin would cleave this sequence. The other potential cleavage sequence is PAPR/AG. 
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Although P4 is not an aliphatic residue, this is not an absolute requirement and studies have 
shown that Pro occupy this position whilst activity is maintained (Gallwitz et al., 2012). Ala 
being at the P3 and P1’ position and Gly at P2’ would also still permit thrombin cleavage 
(Gallwitz et al., 2012; Petrassi et al., 2005; Stephens et al., 1988). It can therefore be 
concluded that this is another viable cleavage site for thrombin. Taken together, these three 
sites of cleavage could result in up to 9 distinct fragments being produced, consistent with the 
observations by SDS-PAGE.  
 
 
 
Figure 3.15 Digestion of NFκB-DOSCAT by restricted specificty proteases. NFκB-DOSCAT (10 
µg) was incubated with a) 0.5 units (U) TEV protease; b) 0.2 U, 0.5 U or 1.0 U RV3C protease; c) 
0.05 U, 0.02 U Thrombin; d) 0.1 U Factor Xa. Samples were taken at indicated time points and 
analysed on a 12% SDS-PAGE gel. Expected band sizes of proteolytic fragments are displayed in 
black when the fragments were observed or in red where they were not observed.  
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3.3. Conclusions 
This work defines the first time a DOSCAT standard has been designed, expressed and 
purified in a recombinant system. Furthermore, the utility of DOSCAT as a dual standard has 
been demonstrated in that the Q-peptides and epitopes contained in the NFκB-DOSCAT can 
be observed by MALDI-MS and western blotting respectively. Additionally, it has been shown 
that compared to classic western blotting using ECL or fluorescent detection, automated 
capillary western blotting offers much improved characteristics for absolute protein 
quantification.  
Despite the encouraging results, some results highlight shortcomings in the NFκB-DOSCAT 
design that need to addressed. Out of five epitopes inserted into the NFκB-DOSCAT 
sequence, only three were recognised by target antibodies. Additionally, 3 of the antibodies 
used have now been discontinued by the manufacturer: p65, IκBβ and IκBε. This highlights 
the importance of antibody selection prior to finalising a DOSCAT sequence and committing 
to express the protein. Ideally, antibodies that are used will have been raised using a peptide 
immunogen, the sequence of which has been published by the manufacturer or, the antibody 
binding site would be known through epitope mapping experiments. This would take away any 
guesswork associated with selecting epitope sequences to use in a DOSCAT. Another aspect 
of DOSCAT design that did not perform to expectations was the inclusion of restricted 
protease sites; only two out of four proteases cleaved NFκB-DOSCAT specifically at one site. 
Factor Xa and thrombin have a cleavage sequence that is less rigid than that of TEV and 
RV3C protease. Therefore, there were sites in NFκB-DOSCAT that by chance that Factor Xa 
and thrombin recognised, leading to many fragments being produced. These two proteases 
will not be used in future, and when selecting other proteases greater care will be taken to 
fully understand all possible cleavage sequences and not accidently include additional 
protease binding sites in the DOSCAT sequence that may be contained in epitopes or Q-
peptides. 
Due to these limitations, this NFκB-DOSCAT will not be used to in experiments to quantify the 
target protein by western blotting and SRM-MS. Instead, a second iteration of DOSCAT will 
be designed to incorporate new antibody epitopes and restricted protease sites to replace 
Factor Xa and thrombin. The protocols for expression and purification validated in this chapter 
will be used again, and, when it comes to performing quantitative experiments, automated 
western blotting will be used alongside SRM-MS with confidence. This will test whether QWB 
and SRM will generate agreeable quantitative data, the next big test for DOSCAT technology.  
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Chapter 4: Quantification of NF-κB proteins using DOSCAT  
4.1. Introduction 
The results from the initial proof of principle work (Chapter 3) were encouraging in establishing 
the potential of using DOSCATs in both MS and WB assays. The original objective was to use 
a DOSCAT to quantify target proteins in the NF-κB pathway, however, limitations in NFκB-
DOSCAT design prevented this aim from being achieved. Therefore, a re-design of NFκB-
DOSCAT was required to incorporate new epitopes and protease cleavage sites. Section 4.2. 
sets out the design, expression, purification and use of a second iteration of NFκB-DOSCAT, 
termed NFκB-DOSCAT-2, to quantify the five target proteins. This is described through a 
paper published on the matter in a peer reviewed journal (Bennett et al., 2017). Additional 
data that was not contained in this paper, detailing optimisation work and demonstrations of 
the wider utility and application of NFκB-DOSCAT-2, is presented in section 4.3.   
When designing a QWB experiment, several parameters must be optimised to ensure 
accurate quantification. Antibody conditions must be optimised so that the antibody is at 
saturating conditions, meaning that any observed signal changes can only be due to changes 
in analyte amount. Ideally, the amount of protein loaded would be in the linear dynamic range 
of the assay and consideration must also be given to data analysis and normalisation 
(Gassmann et al., 2009; Taylor SC, 2014).  Furthermore, calibrant stability is key in 
quantitative assays; degradation, proteolysis or loss of material through adsorption to surfaces 
can lead to inaccurate quantification. Degradation of proteins can occur during long-term 
storage, sub-optimal pH or temperature or freeze-thaw cycles (Cao et al., 2003; R. J. Simpson, 
2010). Proteolysis is an issue when the calibrant is spiked into a cell lysate that has not been 
treated with protease inhibitors. Endogenous proteases may be active within the lysate and 
act upon the calibrant protein. Protein adsorption to surfaces such as plastic tubes is a well-
known phenomenon, especially when proteins are at low concentrations (Rabe et al., 2011), 
and adsorption has been observed in the previous iteration of NFκB-DOSCAT.  
Protein adsorption occurs in two stages: 1) reversible adsorption to a surface which is driven 
primarily by electrostatic and hydrophobic interactions, 2) conformational change leading to 
irreversible adsorption (Norde et al., 1995). The protein undergoes conformation change and 
denaturation after initial adsorption, so that more regions of the protein previously hidden by 
folding are exposed and able to interact with the surface (Moulin et al., 1999). Protein 
adsorption can be affected by the local environmental conditions (pH, temperature etc.), 
properties of the protein itself or by those of the surface material (e.g. plastic or glass) (Rabe 
et al., 2011). To prevent or reduce adsorption, the properties of the surface or local 
environmental conditions can be altered. Addition of detergents or high salt concentrations (J. 
A. Smith et al., 1978), addition of proteins such as bovine serum albumin (Felgner et al., 1976; 
K. J. Kramer et al., 1976), or coating tubes with polyethylene glycol (PEG) or siliconizing 
reagents have all been described to prevent protein interactions with surfaces. Different 
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surface materials and additives will be trialled to ascertain which if any can prevent DOSCAT 
adsorption. The intrinsic stability of DOSCAT and its stability when spiked into cell lysate will 
also be assessed. In addition, the optimal values for QWB parameters will be experimentally 
determined. 
As well as this assay optimisation, the validity and flexibility of DOSCAT technology outside 
of internally calibrated automated capillary western blotting must be demonstrated. Although 
automated capillary western blotting can offer superior reproducibility and quantitative 
accuracy, many researchers do not have access to this technology and instead use classic 
WB with ECL or fluorescent detection. It is therefore important to demonstrate that DOSCAT 
can be used in this format, and that quantitative values generated can be favourable compared 
against those derived by automated QWB and SRM-MS. The calibration strategy used in 
quantitative assays is important; internal calibration (when standard is spiked into the sample) 
is favoured as it accounts for matrix effect, losses that may occur in sample preparation and 
drift in instrument performance (Oliveira et al., 2010; Sargent, 2013). However, in some 
scenarios internal calibration will not be possible and an external calibration method will be 
used. Therefore, NFκB-DOSCAT-2 will be used in a classic western blot using fluorescent 
detection (due to improved signal linearity over ECL) and its performance as a calibrator when 
used external to the analyte assessed. 
 
 
  
Chapter 4: Quantification of NF-κB proteins using DOSCAT 
 
 65 
 
4.2. DOSCATs: Double standards for protein quantification (Bennett et al. 
2017, Scientific Reports) 
The text and figures in section 4.2 are a direct replication of the paper “DOSCATs: Double 
standards for protein quantification” published in Scientific Reports, 2017 (Bennett et al., 
2017). The manuscript and figures for the paper were prepared by myself and I am the first 
author of the paper. A reprint of the paper can be found in the Appendix. Note that the 
DOSCAT referenced in the manuscript refers to the NFκB-DOSCAT-2 iteration. 
4.2.1. Abstract 
The two most common techniques for absolute protein quantification are based on either mass 
spectrometry (MS) or on immunochemical techniques, such as western blotting (WB). 
Western blotting is most often used for protein identification or relative quantification, but can 
also be deployed for absolute quantification if appropriate calibration standards are used. MS 
based techniques offer superior data quality and reproducibility, but WB offers greater 
sensitivity and accessibility to most researchers. It would be advantageous to apply both 
techniques for orthogonal quantification, but workflows rarely overlap. We describe DOSCATs 
(DOuble Standard conCATamers), novel calibration standards based on QconCAT 
technology, to unite these platforms. DOSCATs combine a series of epitope sequences 
concatenated with tryptic peptides in a single artificial protein to create internal tryptic peptide 
standards for MS as well as an intact protein bearing multiple linear epitopes. A DOSCAT 
protein was designed and constructed to quantify five proteins of the NF-κB pathway. For 
three target proteins, protein fold change and absolute copy per cell values measured by MS 
and WB were in excellent agreement. This demonstrates that DOSCATs can be used as 
multiplexed, dual purpose standards, readily deployed in a single workflow, supporting 
seamless quantitative transition from MS to WB. 
4.2.2. Introduction 
Accurate quantification of proteins is of critical importance in cell biology, proteomics, clinical 
biomarker discovery and systems biology. Two very different approaches to quantification are 
routinely adopted; those based on mass spectrometry (MS) and those based on 
(semi)quantitative western blotting (sqWB). The two methods differ, both in the technical 
demands and in the complexity of the associated equipment, as well as the confidence in 
quantitative data generated.  
Mass spectrometric methods are considered to be the gold standard for targeted protein 
quantification (Aebersold et al., 2013; Lawless et al., 2016; Ong et al., 2005). However, capital 
investment and the expertise required in setting up and executing an MS assay means that it 
is less widely used than sqWB. For relative MS quantification, there is increasing application 
of label-free quantification based on the intrinsic signal intensity of individual peptides (derived 
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from a digested protein) or of label-mediated quantification in which stable isotope labels are 
used to discriminate between two or more conditions, discriminated by the mass shift either 
at the level of the peptide ion or at the level of fragment ions generated within the mass 
spectrometer. Label based quantification methods are commonly used in conjunction with a 
targeted MS approach known as selected reaction monitoring (SRM). SRM utilises triple 
quadrupole mass spectrometers to perform two levels of mass selection, at the level of both 
precursor and product ion, giving much improved selectivity and sensitivity over global, 
‘discovery’ proteomic approaches. Semi-quantitative western blotting is, by contrast, readily 
delivered with a small investment in equipment, and in most laboratories, requires extended 
sequences of manual processing steps (although there are instrumentation developments that 
automate the method). Although considered a semi-quantitative technique for relative 
quantification of signal intensity, sqWB is commonly used to draw quantitative conclusions 
despite the lack of calibration standards, rigorous (and standardised) methodology, and 
consistent data analysis (Gassmann et al., 2009; Taylor et al., 2013). However, direct 
comparison of sqWB results between groups is problematic as the data (effectively, the 
intensity of an antibody–reactive band that is generated by different chemistries and measured 
using different imaging devices) are dimensionless and highly variable (inter-assay) despite 
high levels of care and skill by the researcher. This limitation is likely to have contributed to 
the lack of reproducibility in pre-clinical data, which has a high cost in terms of wasted effort 
and delayed progress (Freedman et al., 2015; Mobley et al., 2013). Many papers that report 
sqWB data do not include exhaustive data that defines the specificity of the antibody-antigen 
interaction, linearity of response or evidence that the immunoreactive band is the target 
antigen. Indeed, it is common practice in publication of sqWB results to crop western blot 
images to the region of interest, thus obscuring other regions of cross-reactivity. In sqWB, 
quantification is usually relative, where one condition is compared with a second, ideally run 
on the same gel and developed as a single blot.  
For absolute quantification, calibration standards based on stable isotope labelled proteins or 
peptides (for MS) or epitope bearing proteins (for WB) are required. Isotope standards for MS, 
based on relatively short tryptic peptides, are not suitable for western blot quantification, such 
that MS-based and WB workflows rarely overlap. Ideally, there would be readily deployable 
techniques to converge technologies, raising standards in quantitative output. There is a 
continuing need for appropriate calibration standards in the western blot workflow, thereby 
creating genuinely quantitative western blotting (QWB). Further, it would be ideal if calibration 
standards were capable of deployment across both MS and QWB workflows. This crossover 
would allow for validation of the orthogonal techniques and comparison of data between the 
two most common quantitative techniques. Moreover, QWB could be used to improve 
characterisation of research antibodies (sensitivity, dynamic range, limit of detection, 
consistency of batches, specificity), which is currently problematic (Bordeaux et al., 2010; 
Michel et al., 2009) and a major factor in the irreproducibility of pre-clinical science (Taylor et 
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al., 2013). Indeed, the use of orthogonal techniques such as MS to validate antibody specificity 
has been proposed by an international working group of scientists (Uhlen et al., 2016).  
It is easy to understand why western blotting is the preferred method (Pubmed searches 
reveal approximately 5,000 citations using the terms ‘SRM or MRM’, compared to over 
250,000 using the terms ‘western blot’ or ‘western blotting’), as it is readily deployable in most 
laboratories and does not require access to either the specialist instrumentation or the cognate 
expertise that is needed to develop an MS-based method. However, there is considerable 
scope for studies that compare and explore the comparative performance of the two 
approaches. Indeed, it is a common experience with MS-based proteomics studies that 
reviewers request ‘validation’, implicitly meaning western blotting, without any evidence for the 
ability of both methods to deliver comparable data sets (Aebersold et al., 2013). In pursuit of 
reliable approaches to quantitative western blotting, there is merit in comparison of such 
approaches with an orthogonal method, such as those based on mass spectrometry. Further, 
QWB methods give added information about electrophoretic mobility (crudely indicative of 
protein mass), information that is absent from ‘bottom-up’ proteomics. 
We have previously designed and employed artificial proteins to solve problems in MS-based 
analyses, including QconCATs (Beynon et al., 2005) for absolute quantification and QCAL 
(Eyers et al., 2008), QCAL-IM (Chawner et al., 2012) and RePLiCal (Stephen W Holman et 
al., 2016) as universal standards for MS-based techniques. In particular, we developed 
QconCAT proteins to facilitate multiplexed protein quantification by MS (Beynon et al., 2005; 
Julie M Pratt et al., 2006). QconCATs are artificial genes encoding proteins that are 
concatenations of (usually tryptic) peptides from multiple proteins (typically up to 25) that act 
as ‘quantotypic’ standards when the calibrator protein is expressed in bacteria and labelled 
with stable isotope amino acids (P. Brownridge, Holman, et al., 2011). After co-digestion of 
the analyte (in a biological sample) and the QconCAT, the resultant pairs of unlabelled 
(analyte) and labelled (standard) peptides can be analysed by mass spectrometry, permitting 
accurate quantification of the analyte protein abundance.  
Here, we extend QconCAT principles to design DOSCATs (‘DOuble Standard conCATamers’, 
dual-purpose calibration standards for MS-based quantification and/or QWB), also designed 
de novo and expressed heterologously in Escherichia coli. DOSCATs concatenate epitope 
sequences from one or more proteins recognised by multiple antibodies. They also embed 
quantotypic peptides (Q-peptides) for MS quantification of the same proteins (Figure 4.1) and 
thus act as a single multiplexed standard that can be used for MS-based or QWB 
quantification. For added flexibility, the epitopes can be interspersed with restricted specificity 
endoproteolytic sequences, which permit generation of quantification standards of optimal 
mobility in sized-based or charge-based separation platforms. The DOSCAT design includes 
a His-tag for purification and [Glu1]-Fibrinopeptide B (Glu-Fib) sequence for quantification of 
the standard (Simpson and Beynon 2012) and contain at least two Q-peptides for each target 
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protein, chosen according to well-defined criteria (Brownridge et al. 2011; Holman, Sims, and 
Eyers 2012). It is axiomatic that the epitopes can only be used if they are relatively short 
peptide sequences, either used as an immunogen or identified as the linear sequence that is 
recognised by a monoclonal antibody. The aim of this work is to demonstrate that DOSCATs 
can be used as a calibration standard across both SRM and QWB workflows to deliver 
equivalent quantitative results.  
 
 
 
Figure 4.1 Principle of DOSCAT design. Peptides for MS-based quantification and antibody 
epitopes are selected for each target protein and sequences concatenated into a single artificial 
protein (DOSCAT). Tag sequences for quantification and purification of DOSCAT are inserted at 
each terminus. Restricted specificity endopeptidase sites are interspersed throughout the sequence 
so as to permit generation of quantification standards of optimal mobility during sized-based 
separation analysis. 
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4.2.3. Results and Discussion 
DOSCAT design, expression and purification 
For DOSCATs, epitopes for a small panel of antibodies are inserted into the protein in addition 
to Q-peptides so that the standard can be deployed across both MS and QWB workflows. A 
minimum of two Q-peptides were chosen for each target protein based on a well-defined 
process (P. Brownridge, Holman, et al., 2011; Steven W Holman et al., 2012). The data 
repositories PeptideAtlas (http://www.peptideatlas.org/) and Global Proteome Machine 
(http://www.thegpm.org/) were initially consulted and peptides identified. Where peptides 
could not be identified using this approach (for IκBα and RelB), peptides were selected on the 
basis of a computational prediction of their quantotypic propensity based on physio-chemical 
properties and predicted observability (PeptideSieve score 
(http://tools.proteomecenter.org/wiki/index.php?title=Software:PeptideSieve)). For all 
selected Q-peptides uniqueness in the proteome was confirmed by BLAST searches. Each 
peptide was supplemented with natural flanking sequences of 3 amino acids in length as a 
strategy to improve quantitative accuracy by equalising digestion efficiency between standard 
and analyte (Kito et al., 2007) (Table 4.1). For p65 and IΚBβ, selected Q-peptides were 
adjacent in the protein sequence so flanking regions were not possible or required. Epitopes 
included in the DOSCAT sequence were chosen based on the immunogen sequence supplied 
by the manufacturer (Table 4.2). Where the precise immunogen sequence was disclosed by 
the manufacturer, this was used in the DOSCAT - this was the case for IκBβ and IκBε. For 
some antibodies, only the specific residue around which the epitope was centred was 
disclosed and in these instances, up to 25 amino acids flanking each side of the central residue 
in the protein sequence were used to ensure inclusion of the epitope in the DOSCAT 
sequence. This was required for the epitopes for p65, RelB and IκBα. 
To introduce the possibility of manipulation of mobility in QWB, several restricted specificity 
endopeptidase sites were included in the DOSCAT design. These sites were selected based 
on the primary sequence specificity and the commercial availability of the protease. Four 
endopeptidases were used (Table 4.3) and for each, the target sequence was unique to a 
single site in the DOSCAT and was absent from any of the target proteins. Cleavage sites 
were inserted into the sequence between epitopes so that proteolysis would generate two 
fragments that could be detected by different antibodies and which would have a different 
electrophoretic mobility to the parent DOSCAT, permitting a mobility shift to prevent overlap 
between standard and analyte. Additional amino acids were added at the N-terminus to 
provide an initiator methionine and a sacrificial N-terminal region as well as [Glu1]-
Fibrinopeptide B peptide (EGVNDNEEGFFSAR) for MS-based quantification of the standard3. 
A hexahistidine tag was added at the C-terminus to allow affinity purification. Once the protein 
sequence was designed (Figure 4.2a) and the codon optimised gene was synthesised, the 
DOSCAT was expressed successfully in E.coli in minimal medium (Figure 4.2b), accumulating 
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in inclusion bodies, and after solubilisation in a chaotrope was readily purified by Ni-NTA 
affinity chromatography (Figure 4.2c).  
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Table 4.3 Restricted specificity endoproteases used and their cleavage sequence inserted 
into DOSCAT. 
Protease Manufacturer Cleavage sequence 
Tobacco etch virus (TEV) Invitrogen, USA ENLYFQG 
Human rhinovirus 3C (RV3C) GE Healthcare, UK LEVLFQGP 
Tobacco vein mottling virus 
(TVMV) 
Biomol, Germany TVRFQS 
Enteropeptidase Novagen, UK DDDDK 
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Figure 4.2 Design of a DOSCAT for quantification of members of the NFκB pathway. (a) Protein 
map of the NF-κB DOSCAT. Green boxes represent quantotypic peptides, red boxes define the 
extent of antibody binding epitopes and purple boxes the Glu1]-Fibrinopeptide B calibration peptide 
at the N-terminus and the His6 purification tag at the C-terminus. Arrows indicate the location of 
cleavage sites for each of the specific proteases (TVMV, tobacco vein mottling virus protease; RV3C, 
human rhinovirus 3 C protease; EP, enteropeptidase; TEV, tobacco etch virus protease. SDS-PAGE 
analysis of (b) E. coli culture time points 2–6 h after inoculation, with expression induced by IPTG 
after 3 h and (c) pre-purification starting material (SM) alongside elution fractions 1–7 from His-Trap 
column using an elution gradient 0–100% elution buffer over 20 min. (d) Western blot analysis of 
50 ng purified DOSCAT using an anti His-tag antibody. (e) DOSCAT peptide map highlighting Q-
peptides identified (green) and not identified (white with cross) by MS/MS, alongside the MS1 total 
ion chromatogram signifying the elution profile of each Q-peptide. (f) Mass spectra and SRM 
chromatogram for a representative Q-peptide demonstrating high stable isotope labelling efficiency. 
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Validation and performance in QWB and SRM 
After purification, the DOSCAT was homogenous on SDS-PAGE and western blotting using 
an anti His-tag antibody (Figure 4.2d) confirmed that there was no proteolysis of the protein 
during expression or purification. Moreover, western blotting using p65 and RelB antibodies 
(the epitopes to which are at the N-terminal end), demonstrated there was no degradation or 
fraying at the N-terminus of the protein (Figure 4.3).  After expression and purification, the 
DOSCAT was subject to tryptic digestion and the peptides were analysed by LC-MS/MS on a 
Synapt G2. This confirmed that the protein sequence was correct with 83% sequence 
coverage and 11 of the 13 nominated Q-peptides being identified by LC-MS/MS (Figure 4.2e). 
The peptide DAGADLDKPEPTCGR was not identified due to a miscleavage event at the N 
terminus. Only the miscleaved peptide, containing the preceding residues DDDDK, the 
cleavage site for enteropeptidase, was detected. It is known that acidic residues around the 
scissile bond can inhibit proteolysis (Lawless et al., 2012; Siepen et al., 2007); therefore, it is 
likely that the sequence context around the peptide was the reason for the miscleavage. Care 
should be taken in placing Q-peptides next to such residue sequences when designing future 
iterations of DOSCATs and this observation casts doubt on the utility of enteropeptidase as a 
restricted specificity proteinase in this application. Additionally, the peptide 
SPLHLAVEAQAADVLELLLR was not detected either by database searching or in the raw 
data. This was further investigated by running the same DOSCAT digest on a QExactive 
Orbitrap instrument. The peptide was detected by database searching and in the raw data, 
but with a signal intensity ~0.1 % of the base peak intensity. This lack of detectability on two 
separate instrument platforms confirm poor ionisation efficiency or fragmentation of the 
peptide after ionisation. When the DOSCAT was expressed in minimal media containing 
[13C6]Lys and [13C6]Arg as the sole source of these amino acids, complete labelling (> 99%) 
of the protein was confirmed by the examination of MS1 data and extracted ion 
chromatograms (Figure 4.2f). 
For a DOSCAT to be used for the accurate quantification of target proteins, complete and 
equivalent digestion of standard and analyte is crucial. Although it is possible that peptides 
may be released more quickly from either standard or analyte, the rate of digestion in both 
should reach a plateau before analysis (P. Brownridge & Beynon, 2011). To ascertain whether 
there was complete release of Q-peptides from the DOSCAT, the standard was spiked into 
SK-NA-S cell lysate and the digestion mixture was sampled at regular intervals. Rates of 
excision of standard and analyte peptides varied, but in all instances the proteolysis attained 
a stable plateau before the end of the overnight incubation period (Figure 4.4) Differences in 
the rate of digestion between standard and analyte are thus rendered moot by the simple 
expedient of establishing conditions that allow the reactions to proceed to completion. 
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Figure 4.3 Classic gel-based western blot of DOSCAT and SK-NA-S cell lysate. Samples were 
separated on a 12% SDS-PAGE gel, transferred onto nitrocellulose membrane and incubated with 
anti p65 and RelB antibodies. 
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Figure 4.4 DOSCAT digestion. Time course analysis showing the release of each peptide used for 
quantification during tryptic digestion. Stable isotope labelled DOSCAT and SK-N-AS lysate was co-
digested, with samples taken at a series of time points and analysed by SRM-MS. Displayed are 
signal intensities normalised to the final time point for heavy (DOSCAT) and light (endogenous) 
peptides (top), and the ratio of heavy to light peptide at each time point (bottom). 
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To define the transition coordinates of the SRM assays, a tryptic digest of the DOSCAT was 
analysed by LC-MS/MS using a Q-TOF mass spectrometer. For each peptide, MS/MS 
fragmentation data were used to identify optimal transitions for each peptide (Figure 4.5).  
These transitions were then used to build a scheduled SRM profile and a programme of timed 
transitions resulted in cleanly isolated peaks specific for all but two of the Q-peptides (Figure 
4.6). To determine performance in a complex matrix, DOSCAT was spiked in SK-NA-S lysate 
at concentrations over a 1000-fold range and analysed by SRM. The signal linearity varied for 
each peptide, with some peptides exhibiting a linear relationship of the entire measured range. 
Moreover, the limits of detection (LOD) (based on a signal to noise ratio of 3) also differed for 
each peptide (Figure 4.7) with an average LOD of 100 amol. Based on the number of cells 
loaded onto the column, this corresponds to about 10,000 copies per cell.    
To validate the DOSCAT for western blotting, dilution series of the standard protein were 
loaded onto the capillary western blotting system and were detected independently by each 
of the five commercial antibodies (Figure 4.8). Sensitivities varied for different antibodies, 
ranging from 5 amol to 1.5 fmol in each lane, defined as the lower limit of quantification. Based 
on the number of cell equivalents that were loaded into the capillaries, this equates to about 
1000 copies per cell for the lowest limit of detection. IκBε could not be quantified using this 
methodology as the antibody did not detect the epitope in DOSCAT. However, when used 
against SK-NA-S cell lysate in both capillary and classic western blotting, the antibody 
detected a band at ~90 kDa (data not shown), very different from the expected molecular 
weight (53 kDa). We conclude that the antibody was unreliable and it was not used in further 
experiments. 
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Figure 4.5 MS/MS spectra of DOSCAT Q-peptides. Tryptic digest of DOSCAT was analysed by 
MSE by a Q-TOF mass spectrometer. Observed product ions chosen for analysis by SRM-MS are 
highlighted in red.  
 
  
Chapter 4: Quantification of NF-κB proteins using DOSCAT 
 
 80 
 
 
Figure 4.6 Summary of scheduled SRM-MS assays for Q-peptides contained in DOSCAT. 
Extracted ion chromatogram from SRM-MS analysis of 1 fmol digested DOSCAT loaded onto the 
column, detailing the peak intensity and retention time for all Q-peptides for which scheduled SRM-
MS assays were built. Inset: DOSCAT peptide map illustrates all Q-peptides for which SRM-MS 
assays were designed (bright green boxes) out of all observed peptides (pale green boxes) alongside 
product ions monitored for each peptide. Two Q-peptides were not detectable by SRM-MS (white 
box with cross). Inset table contains a detailed list of transitions for each peptide. 
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Figure 4.7 Standard curves for Q-peptides in SRM-MS assays. DOSCAT and SK-NA-S cell lysate 
was co-digested, serially diluted in SK-NA-S cell lysate digest and analysed by scheduled SRM-MS. 
Also displayed are measures of limit of detection (where signal:noise = 2) and linearity of response 
from 10 amol to 10 fmol material on column. 
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Although this DOSCAT met many of the criteria of a dual-purpose standard, the critical test of 
such a standard is in the quantification of endogenous proteins. Specifically, would both QWB 
and MS assays yield acceptable quantification, and secondarily, would the presence of a 
complex background such as a cell homogenate impair the ability to use the standard? 
Further, the migration of the DOSCAT in the capillary QWB system had the potential to lead 
to interference with the signal for the endogenous analyte. To explore a realistic scenario for 
deployment of the artificial dual standard, DOSCAT was spiked into protein extracts of 
unstimulated and TNFα-stimulated SK-N-AS cells. The same cell lysates, spiked with the 
DOSCAT standard, were used for MS or QWB quantification, the difference being that for 
QWB, the spiked lysates with analysed without further treatment, whereas for MS 
quantification, the mixture was reduced, alkylated and proteolysed with trypsin. The DOSCAT 
was accurately quantified against an unlabelled Glu-Fib standard (Simpson and Beynon 2012; 
Brownridge et al. 2012) before subsequent SRM-MS and QWB analysis. 
QWB was performed on the same samples in parallel with SRM-MS. The DOSCAT was 
serially diluted in SK-N-AS cell lysates to create an internal calibration series for each lysate. 
DOSCAT/lysate mixtures were analysed by automated western blotting system with 
antibodies that were specific and had been validated for each of the target proteins. The 
DOSCAT was designed to migrate at an apparent molecular weight (Mr) that differed from 
endogenous target proteins, allowing separation of signal between the exogenous DOSCAT 
standard and endogenous analytes. In practice, we observed some baseline interference at 
very high loadings of standards when the DOSCAT and analyte were similar in mobility, 
leading to less accurate quantification of peak area (Figure 4.9). This was readily resolved by 
restricting the standard data points to exclude the highest internal DOSCAT concentrations 
(Figure 4.10). This adjustment was applied for all target proteins, regardless of similarity in 
mobility between analyte and standard. Moreover, analyte levels were always within the linear 
calibration region of the standard curve. The DOSCAT signals were used to construct 
calibration curves that were linear in all cases (r2>0.98, exemplar in Figure 4.8, all data in 
Figure 4.11).  
For SRM-MS, the extracted ion chromatograms for unlabelled analyte and the labelled Q-
peptide (released from DOSCAT) were used to calculate the amount of analyte present, as 
copy number per cell (cpc) values (using the calculation described in Materials and Methods). 
Protein level quantification values were calculated by averaging peptide values across 
technical replicates and in turn, taking the mean of the values obtained for different peptides. 
More than one peptide per protein was detected for p65 and RelB; for p65 the peptide cpc 
values were in good agreement but for RelB, SGPASGPSVPTGR gave lower cpc values than 
the other peptides (Figure 4.12). This may be due to the proximity of the endogenous peptide 
to the N-terminus or the presence of a previously unknown post translational modification on 
the peptide, and such the peptide was not included in calculating the final cpc value. Despite 
nominating peptides based on experimental evidence, neither IκBβ, IκBε nor the IκBα peptide 
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GSEPWK could be quantified by SRM-MS due to a combination of miscleavage potential in 
the standard, poorly performing peptides and the intrinsic low abundance of the target proteins 
(P. Brownridge, Holman, et al., 2011).  
 
 
 
Figure 4.9 Baseline interference in Wes analysis. Electropherogram trace generated by 
automated western blotting for endogenous p65 and DOSCAT standard highlighting the overlap in 
peak fitting between the analyte and standard. 
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Figure 4.10 Data point exclusion of technical replicates. Quantification values determined by 
quantitative western blotting factored by biological replicate and treatment type (±TNFα) for a) all six 
technical replicates; b) the three technical replicates paired with the lowest spike-in DOSCAT 
concentrations. Percentage value in each panel represents % CV across the technical replicates. 
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Figure 4.11 DOSCAT calibration curves in QWB. Dilution series of DOSCAT standard spiked into 
SK-NAS lysate +/- TNFα was analysed by automated capillary western blotting using four target 
antibodies against DOSCAT. Data presented as mean ± standard error for each treatment type 
(n = 3). 
 
 
 
 
Figure 4.12 Peptide level quantification of target protein. DOSCAT spiked into SK-N-AS lysate 
was digested and analysed by scheduled SRM-MS. Quantification values in copies per cell for each 
detected Q-peptide were determined by analysing heavy:light ratios. 
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Two measures were used to compare the performance of the orthogonal analytical 
approaches. First, each method yielded absolute quantification values in copies per cell. 
Secondly, the changes in protein abundance after stimulation by TNFα could be compared. 
The utility of DOSCAT was demonstrated by quantification of five target proteins in the NF-κB 
pathway using both quantitative platforms. Exposure of cells to the cytokine TNFα significantly 
increases the levels of endogenous RelB and elicits degradation of the inhibitor proteins of 
NF-κB, IκBs (Lawrence, 2009). DOSCAT standardised quantification by SRM-MS or QWB 
were consonant with this expectation, giving confidence to the method. Although only a 
relatively small number of proteins were quantified in this study, agreement in copy numbers 
between the two techniques were improved compared to other studies that have compared 
MS and WB quantification (Kiel et al., 2014; Lawless et al., 2016; Picotti et al., 2009). In terms 
of both copies per cell and relative fold change, quantitative values generated by QWB and 
SRM-MS were in agreement for the 3 out of 5 proteins where comparison was possible (Figure 
4.13a, b). Moreover, both techniques demonstrated high precision with a mean % CV across 
both techniques of 14 % (biological replicates, n=3). This is a clear demonstration that careful 
design of standards, coupled with appropriate technology and experimental design can 
converge these orthogonal methodologies.  
 
 
 
Figure 4.13 Target protein quantification. (a) Comparison of absolute quantification values for 
each target protein as obtained by SRM-MS and QWB. Quantification of IκBβ using SRM was not 
possible. Data presented as mean ± standard error (n = 3). (b) Relative fold change of proteins in 
TNFα treated and untreated SK-NA-S cells as measured by quantitative western blotting (QWB) and 
selected reaction monitoring (SRM-MS). Data are presented as mean ± standard error (n = 3). 
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Accurate protein quantification by orthogonal techniques is desirable to increase accuracy and 
robustness of quantitative data, especially important in systems analysis of specific pathways 
or biomarker validation. Quantification by two methodologies in parallel in a single experiment 
is difficult, though, due to differences in calibration standards. To address this problem we 
have proposed DOSCATs as a single calibration standard to support quantification by both 
QWB and SRM-MS assays across a single workflow. In some instances, QWB allowed 
quantification whereas SRM-MS did not, due to lack of peptide detection at low protein 
abundance and poor peptide ionisation. This further emphasises the value of using orthogonal 
techniques to quantify proteins across a wide dynamic range, or small proteins where options 
for Q-peptides are restricted. In our hands both quantitative platforms demonstrated an 
equivalently high level of precision using DOSCAT, which was within the range typically 
reported for SRM and QWB (using Simple Western technology) assays (J. Q. Chen et al., 
2013; Lawless et al., 2016; Loughney et al., 2014). Using ‘classic’ western blotting, it would 
be anticipated that reproducibility would be lower due to the greater number of manual 
handling steps. With rigorous experimental design and well validated antibodies (Ghosh et al., 
2014; Taylor et al., 2013), there is no reason why similarly equivalent quantitative data could 
be obtained using DOSCAT as a calibration standard.  
Based on well-established QconCAT technology for which much of the route to deployment is 
well characterised (P. J. Brownridge et al., 2012; Scott et al., 2016) (~900 citations citing 
QconCATs are recorded in Google Scholar as of December 2016), the DOSCAT workflow is 
simple to implement (a generic workflow is presented in Figure 4.14). Since the initial 
publication in 2005 (Beynon et al., 2005), over 200 QconCATs have been utilised in a range 
of quantitative studies.  QconCATs differ to natural proteins in amino acid composition (D. M. 
Simpson et al., 2012) and almost always accumulate in inclusion bodies. Expression in 
inclusion bodies can provide a useful pre-purification step but can also create problems of 
insolubility in long-term storage post purification – the use of MS-compatible detergents such 
as RapiGest SF and a low concentration of a reducing agent can minimise such problems (D. 
M. Simpson et al., 2012). The NF-κB DOSCAT expression is resonant with these previous 
observations, and we would expect future DOSCATs to follow this trend. In terms of design, 
selection criteria for Q-peptides are well documented (Brownridge et al. 2011; Holman, Sims, 
and Eyers 2012) and can equally be applied to DOSCATs. Of course, the availability of 
antibodies that are cross-reactive to known linear epitopes is a limiting factor when 
constructing a DOSCAT. However, a search for the term ‘synthetic peptide’ in the CiteAb 
(https://www.citeab.com/) database revealed over half a million antibodies raised to linear 
synthetic peptides. Thus, in an environment that was permissive to collaboration with antibody 
manufacturers, or where custom antibodies are made in-house, these peptide sequences 
could be included in DOSCATs. We encourage antibody manufacturers and suppliers to 
release the peptide sequences used for antibody generation as a contribution to reproducible 
research but also, to ease the construction of standards such as DOSCATs. If restricted 
proteolytic sites are built into the DOSCAT sequence, there is also an element of adaptability 
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in the workflow so that fragments of a predictable electrophoretic mobility are produced upon 
incubation with specific proteases. This not only allows for additional flexibility if the DOSCAT 
standard migrates at a similar mobility to endogenous proteins but the ability to create 
standards containing epitopes separable by limited proteolysis can assist in multiplexed 
protein detection in a single lane or capillary of a western blot. 
DOSCATs offer a new calibration tool for protein quantification by both SRM-MS and QWB 
and unite two disparate workflows by a single calibration standard yielding equivalent 
quantification. Western blotting is one of the most widely used research techniques practised 
by the majority of cell biologists, despite previous limitations in delivering quantitative data. 
The DOSCAT approach has the potential to enhance the rigour of QWB that is more readily 
applied after MS validation, to generate reliable quantitative information particularly relevant 
for systems biology studies and contribute to the desired increase in reproducibility of 
biological research. 
Chapter 4: Quantification of NF-κB proteins using DOSCAT 
 
 90 
 
 
Figure 4.14 Overall DOSCAT workflow. The deployment of DOSCAT quantification can be 
resolved into three phases; design, expression and assay development. This workflow summarises 
the major steps. 
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4.3. Additional results and discussion 
The paper making up section 4.2 describes the deployment of NFκB-DOSCAT-2 to 
successfully quantify target NF-κB proteins. However, additional work was also performed that 
was not included in the manuscript. Section 4.3 contains the details of this work, made up of 
a study of NFκB-DOSCAT-2 stability, the performance of NFκB-DOSCAT-2 when used in both 
classic western blotting with fluorescent detection, or in capillary WB as an external standard, 
and experiments assessing the new restricted proteolysis sites incorporated into NFκB-
DOSCAT-2. 
4.3.1. NFκB-DOSCAT-2 stability 
The stability of a DOSCAT is critical for its use, so a series of experiments were carried out to 
determine NFκB-DOSCAT-2 stability when incubated by itself and in cell lysate, and how 
protein adsorption affects NFκB-DOSCAT-2 concentration.  
To test whether NFκB-DOSCAT-2 was being proteolysed by lysate, NFκB-DOSCAT-2 was 
incubated by itself, with SK-N-AS cell lysate or with heat-inactivated cell lysate over 2 hours 
at room temperature. Samples were taken over a period of 120 mins and analysed by 
automated western blot using a p65 antibody (Figure 4.15). The signal for endogenous p65 in 
lysate stayed constant over the time course, as did the signal for NFκB-DOSCAT-2 spiked 
into cell lysate and heat-inactivated cell lysate. This ruled out proteolysis by cell lysate as an 
explanation for NFκB-DOSCAT-2 loss. When NFκB-DOSCAT-2 was incubated by itself, 
however, the signal decreased significantly over the time course. This suggested that NFκB-
DOSCAT-2 was degrading or adsorbing to the tube surface when not contained in a cell 
extract. To assay potential protein adsorption to plastic tubes, an experiment was designed in 
which NFκB-DOSCAT-2 was passaged through five low bind tubes, with a sample removed 
at each tube (Figure 4.16). To investigate whether it was degrading over time, NFκB-
DOSCAT-2 was incubated at RT and samples removed at time points over 2 hours. All 
samples were analysed by SDS-PAGE and densitometry performed on NFκB-DOSCAT-2 
bands to quantify levels of protein in each sample (Figure 4.17). The tube passage experiment 
demonstrated that a significant amount of NFκB-DOSCAT-2 was being lost as it moved from 
tube to tube. By tube 4 over 80% of NFκB-DOSCAT-2 had been lost relative to the starting 
material (tube 0). The incubation experiment resulted in 40% of NFκB-DOSCAT-2 being lost 
after 2 h. However, no bands relating to degradation products became visible on the SDS-
PAGE gel, so these losses, when taken in conjunction with the tube passage results, were 
attributed to adsorption onto the tube and pipette tip.  
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Figure 4.15 DOSCAT stability during incubation. SK-N-AS cell lysate ± 95°C heating for 10 min 
and DOSCAT were incubated either individually or mixed together for 2 h at RT. Samples were taken 
at time points throughout the time course and analysed by automated capillary western blotting using 
a p65 antibody (top panel). Chemiluminescent signal calculated by Compass software was plotted 
over time (bottom panel). 
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Figure 4.16 Tube passage experiment. Starting material (tube 0) is pipetted through a series of 
tubes or glass vials, with a sample removed at each tube for analysis by e.g. SDS-PAGE. 
 
 
Figure 4.17 DOSCAT tube passage and incubation. NFκB-DOSCAT-2 was either a) incubated for 
2 h or b) passaged through four tubes, with samples taken at each tube or time-point. Samples were 
analysed by SDS-PAGE and densitometry performed to determine signal relative to starting material. 
Chapter 4: Quantification of NF-κB proteins using DOSCAT 
 
 94 
 
In an initial attempt to stop these losses, the surface of the tube was modified. Regular non-
low bind Eppendorf tubes (made from polypropylene) were siliconised using Sigmacote and 
the tube passage experiment was repeated alongside low bind tubes (Figure 4.18). The 
siliconisation technique did prevent losses slightly, however they were still very high (70% 
relative to tube 0). Glass vials, both siliconised and non-siliconised, were then trialled. These 
both performed better than plastic tubes, however over 50% of NFκB-DOSCAT-2 was still 
being lost by tube 5 relative to the starting material (Figure 4.19). The surface material of tips 
was also investigated. Tips were siliconised by pipetting Sigmacote up and down before being 
washed in MilliQ water. A volume of DOSCAT was placed in a siliconized glass vial and the 
entire volume taken up in a siliconized pipette tip before being dispensed back into the vial. A 
sample of DOSCAT was taken and the procedure repeated four more times. Siliconised tips 
performed much better than regular tips (Figure 4.20) with little NFκB-DOSCAT-2 lost over the 
course of the experiment. This indicated that tip material did have an effect, although less 
NFκB-DOSCAT-2 was lost on a tip surface compared to that of a tube. 
As modifying the tube surface had only a limited effect, an alternative approach was tested in 
which Rapigest SF, an acid labile surfactant regularly used in MS workflows, was added to 
the NFκB-DOSCAT-2 solution. Rapigest SF acts like a detergent to solubilise and stabilise 
proteins, but unlike detergents such as SDS or Triton it is compatible with downstream MS 
analysis. Rapigest SF at 0.1% (w/v) was added to NFκB-DOSCAT-2 and the tube passage 
experiment repeated. Losses were limited to <20% of starting material by tube 5, even when 
non-siliconised tubes and tips were used, demonstrating the effectiveness of Rapigest SF to 
prevent DOSCAT adsorption (Figure 4.21). The tube passage experiment was repeated on 
the Wes system to show that Rapigest SF was a compatible reagent with the system (Figure 
4.22). Some detergents such as SDS can affect the running of the capillary WB system 
through inaccurate molecular weight calibration or diminished chemiluminescent signal; 
however, no adverse effects in data quality were observed when Rapigest SF was contained 
in the sample. As observed on the SDS-PAGE gels there were minimal losses throughout the 
tube passage experiment, and the overall signal was higher relative to the non-Rapigest SF 
control, presumably due to fewer DOSCAT losses during dilution from stock material. 
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Figure 4.18 Effect of tube modification on NFκB-DOSCAT-2 adsorption. NFκB-DOSCAT-2 was 
passaged through five Eppendorf low-bind tubes or Eppendorf tubes siliconized using Sigmacote 
and samples at each tube were analysed by SDS-PAGE (left). Densitometry was performed and 
signal relative to starting material was plotted against tube number (right).  
 
 
 
 
Figure 4.19 NFκB-DOSCAT-2 adsorption to glassware. NFκB-DOSCAT-2 was passaged through 
five glass vials with and without siliconized surfaces and samples at each tube were analysed by 
SDS-PAGE (left). Densitometry was performed and signal relative to starting material was plotted 
against vial number (right). 
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Figure 4.20 Effect of tip modification on NFκB-DOSCAT-2 adsorption. Siliconised and non-
siliconised tips were used to take up and dispense a volume of NFκB-DOSCAT-2 from a glass vial. 
A sample of NFκB-DOSCAT-2 was taken and the procedure repeated four times using fresh tips. 
Samples were analysed by SDS-PAGE (left), densitometry performed and signal relative to starting 
material plotted against tube number (right). 
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Figure 4.21 Use of Rapigest SF to prevent NFκB-DOSCAT-2 adsorption. Rapigest SF (0.1% w/v) 
was added to NFκB-DOSCAT-2, which was passaged through five siliconised glass vials or glass 
tubes using regular tips, and five low-bind tubes using siliconised or low bind tips. Samples at each 
tube were analysed by SDS-PAGE (left panels), densitometry performed and signal relative to 
starting material plotted against tube number (right panels).  
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Figure 4.22 Rapigest SF compatibility with Wes system. a) Rapigest SF was added to NFκB-
DOSCAT-2 at varying concentration from 0 – 0.05% w/v and this solution was passaged through five 
low bind tubes using regular tips. Samples at each tube were analysed by SDS-PAGE, densitometry 
performed and signal plotted against tube number. b) NFκB-DOSCAT-2 ± 0.05% w/v Rapigest SF 
was passaged through five low-bind tubes and analysed by automated capillary western blotting 
using a p65 antibody. Chemiluminescent signal relative to starting material was calculated by 
Compass software and plotted against tube number. 
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The tendency for NFκB-DOSCAT-2 to adsorb to surfaces has been demonstrated, as has an 
effective solution in the addition of Rapigest SF to the buffer solution. Understanding this 
property of DOSCATs and how to control it is hugely important, as it gives greater confidence 
in quantitative assays calibrated by a DOSCAT. If the concentration of a DOSCAT (or any 
calibrant) is measured inaccurately, resultant quantification values will also be inaccurate. 
Unlike an SRM experiment, there is not a way to quantify DOSCATs internally in a western 
blot, so it is vital that there is confidence that DOSCAT concentration will not change during 
the QWB workflow. This work has demonstrated that the NFκB-DOSCAT-2 is stable in a buffer 
solution containing Rapigest SF, does not degrade at room temperature and is not proteolysed 
when contained in biological sample; therefore, quantitative values generated by QWB are 
reliable.  
The results presented here are unsurprising as it has been long known that proteins will 
readably adsorb to surfaces (Rabe et al., 2011). Indeed, protein adsorption is a requisite in 
many biological processes such as trans-membrane signalling and control of cell adhesion 
and proliferation (Allan L. T. et al., 2006; Hinderliter et al., 2006). Moreover, within the field of 
medical devices protein adsorption can affect the biocompatibility of an implant leading to its 
premature degradation (Brash et al., 2012). Similar observations were also made with the first 
iteration of NFκB-DOSCAT, which seemed to adsorb to the capillary wall in the Wes system 
(section 3.2.3.). Changing the surface properties of the tubes or tips did not make much 
difference to NFκB-DOSCAT-2 adsorption. Although glass performed slightly better than 
polypropylene plastic here, there is evidence to suggest that the optimal plastic or glassware 
is specific to the protein or peptide and that there is no clear correlation between amino acid 
composition and optimal surface (Goebel-Stengel et al., 2011). Siliconisation of surfaces led 
to a small improvement in protein recovery, but overall losses were still considerable. This 
goes against the view that siliconisation reduces protein adsorption (Seed 2001), although 
other studies have also found siliconisation does not prevent adsorption and in some cases 
actually increases it (Goebel-Stengel et al., 2011). Changing the solvent composition through 
the addition of Rapigest SF all but prevented protein adsorption. This concurs with other 
results that suggest that modifying the solvent rather than the surface is a much more effective 
way to prevent protein-surface interactions (Suelter et al., 1983). This is because efficiency of 
surface treatment may not always be complete, and different proteins will have unique 
affinities for different surfaces.  
Surfactants such as Rapigest SF can improve protein stability (Bummer et al., 2000), and 
Rapigest SF has previously been shown to improve protein solubility during enzymatic 
digestion (Meng et al., 2002; Yu et al., 2003). Protein stability can affect rate of adsorption, as 
the conformation of a folded protein is restricted and the conformational entropy is low (Willem, 
1986). Protein unfolding after initial contact with a surface leads to a conformational entropy 
gain, driving adsorption even at hydrophilic surfaces. It has been demonstrated that a more 
stable protein will be less likely to denature on a surface, so protein adsorption will be lower 
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(Billsten et al., 1997; Karlsson et al., 2005; Malmsten, 1998). As an artificial protein, a 
DOSCAT does not have a defined folded conformation and is inherently unstable, which may 
explain why it will so readily adsorb, even to modified surfaces. By stabilising the 
conformational state of a DOSCAT using Rapigest SF, the rate of irreversible protein 
adsorption has been reduced. A similar phenomenon has been observed using sugar 
excipients to stabilise protein states in solution, thus decreasing adsorption (Wendorf et al., 
2004). 
These experiments give assurances about DOSCAT stability over the short term, but they do 
not address the long-term stability of DOSCATs, nor the effect of pH and temperature on 
DOSCAT stability and adsorption. Further work is required to establish these properties, and 
strategies to mitigate protein loss over time must be conceived. 
4.3.2. Optimisation of QWB assays 
For each protein to be analysed by the Wes system, three parameters were optimised: cell 
lysate concentration, DOSCAT concentration range for the calibration curve and antibody 
concentration.  
To find the optimal antibody concentration, a dilution series of each antibody was run against 
a fixed concentration of NFκB-DOSCAT-2 spiked into SK-NA-S cell lysate. The peak area and 
average baseline was derived using Compass software and the peak area/baseline value 
calculated for each antibody concentration (Figure 4.23). As the antibody concentration 
increases, the signal increases until the point of saturation. A concentration near this 
saturation point common to both endogenous analyte and NFκB-DOSCAT-2 standard was 
chosen and used as the optimal antibody concentration for all future assays. NFκB-DOSCAT-
2 was not detected by the IκBε Ab, so optimal concentration was based on data from the 
endogenous analyte alone. 
The optimal lysate concentration falls within the linear dynamic range of the assay, that being 
between the limit of detection and saturation level. This ensures that changes in signal are 
directly proportional to changes in protein level. To determine the optimal loading 
concentrations a dilution series of TNFα treated and untreated SK-N-AS cell lysate was 
analysed by each antibody (Figure 4.24). Optimal lysate concentration was defined as 0.4 
mg/mL as it fell within the linear dynamic range for each protein. The range of NFκB-DOSCAT-
2 concentration for the calibration curve was then determined for each target protein by 
running a dilution series of NFκB-DOSCAT-2 and probing with each antibody. The signal of 
the endogenous protein at optimal lysate concentration (in both untreated and treated lysate) 
was used to select the range of NFκB-DOSCAT-2, as the endogenous signal should be within 
the range of the calibration curve. This calibration curve range was different for each protein, 
for example p65 ranged from 0-800 amol/µL and IκBα 0-100 amol/µL. 
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Figure 4.23 Antibody concentration optimisation. A dilution series of each antibody was prepared 
and used to analyse 100 fmol/µL DOSCAT spiked into 0.5 mg/mL SK-N-AS by automated capillary 
western blotting. Chemiluminescent signal was calculated by Compass software and plotted against 
each antibody concentration. 
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Figure 4.24 Optimisation of lysate concentration for QWB analysis. Dilutions series of TNFα 
treated and untreated SK-N-AS cell lysate from 0.1 - 1.0 mg/mL were prepared and analysed by 
automated capillary western blotting using the target NF-κB antibodies.  
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4.3.3. DOSCAT as an external standard 
To further demonstrate the flexibility of DOSCAT as a standard, experiments were performed 
to show that NFκB-DOSCAT-2 could be used to calibrate protein quantification when not 
spiked into the sample analyte. DOSCAT surface adsorption is a known problem that is abated 
when it is contained within a complex matrix, therefore, both E.coli and yeast lysate were 
trialled as suitable diluents. Both lysates were prepared and heated at 80°C to inactivate any 
protease activity. After cooling, automated western blotting was performed on each lysate with 
and without spiked-in NFκB-DOSCAT-2, using each of the NF-κB antibodies (Figure 4.25). 
Non-specific binding was observed in E.coli lysate when probed with IκBβ and IκBε antibodies, 
but no signal was detected when yeast lysate was used as a background matrix. NFκB-
DOSCAT-2 was detected when spiked in to both lysates, however, the signal was much 
stronger when yeast lysate was used as a matrix. Due the lack of background signal and 
increased standard signal, yeast lysate was selected as the background matrix for quantitative 
experiments.  
For protein quantification, a NFκB-DOSCAT-2 stock was accurately quantified by digesting 
with Glu-Fib standard and analysis by SRM. The stock was spiked into a heat-inactivated 
yeast lysate matrix containing Rapigest SF and serially diluted in a yeast lysate/Rapigest SF 
diluent. Three biological replicates of TNFα treated and untreated SK-N-AS lysate alongside 
NFκB-DOSCAT-2 standards were prepared for Wes analysis and run using a p65 antibody 
for detection. Within a single QWB experiment, a six-point NFκB-DOSCAT-2 dilution series 
and three technical repeats of each biological replicate were run (Figure 4.26a). The 
experiment was repeated three times. Chemiluminescent signal was calculated using 
Compass software and NFκB-DOSCAT-2 calibration curves were constructed for each 
replicate. The three calibrations curves for each replicate agreed very well with one another 
and linearity was excellent (Figure 4.26b). Using the NFκB-DOSCAT-2 calibration curve within 
the same replicate, endogenous protein was quantified in terms of cpc (using the same 
calculation described in section 4.2.3.). Figure 4.26c displays the cpc values for each sample 
(denoted by shape) across each of the three QWB replicates (denoted by colour). Intra-assay 
variance between the technical repeats in each run was very low; across the technical repeats 
the average CV for untreated lysate was 4.4% and for TNFα treated lysate 8.0%. Inter-assay 
variance for each biological replicate was much higher, ranging from 24.0% (for C2) to 63.8% 
(T3), with an average of 46.4%. It is worth noting that values obtained in the third run (blue 
points in Figure 4.26c) were higher than the other two, which would have an adverse effect on 
overall inter-assay variance. Copy per cell values were quantified across all technical and 
biological replicates to give final cpc values. Compared to values obtained by QWB and SRM-
MS where DOSCAT was employed as an internal standard, measured cpc were higher across 
both TNFα treated and untreated samples (Figure 4.26d). Moreover, overall variance was 
higher, with CVs of 22.7% and 22.5% for untreated and TNFα treated samples respectively.   
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Differences in copy per cell values compared with those generated with internally calibrated 
QWB and SRM-MS could be attributed to inaccurate concentrations of NFκB-DOSCAT-2 
resultant from changes to the workflow. In this experiment, stock NFκB-DOSCAT-2 was 
quantified (by digestion with Glu-Fib and MS analysis) before being added to yeast lysate. 
This gave rise for an opportunity for unaccounted NFκB-DOSCAT-2 losses by adsorption. A 
lower actual concentration of NFκB-DOSCAT-2 than measured would lead to inflated cpc 
values for unknown analyte. Furthermore, for each gel replicate NFκB-DOSCAT-2 was 
transferred into fresh yeast lysate, so differential losses each time would account for the 
increased inter-assay variation. For more accurate quantification and improved reproducibility, 
NFκB-DOSCAT-2 should have been quantified when in the yeast lysate diluent. This highlights 
the careful consideration that must be given to experimental design when dealing with a 
calibrant that is very prone to surface adsorption.  
Owing to the resources that would be required to quantify the entire set of proteins (i.e. 15 
Wes runs compare to 6 for internal calibration), only p65 was quantified. This of course limits 
the ability to draw broad conclusions about accuracy and reproducibility but does offer a proof 
of principle of the specific approach. Despite this, the importance of the results stand in the 
demonstration that a DOSCAT can be used to calibrate a quantitative western blot when it is 
external to the analyte. This is a very useful attribute if a DOSCAT has the same 
electrophoretic mobility as an analyte (and it cannot be suitably adjusted by proteolysis) or if 
non-specific binding interferes with the DOSCAT signal.   
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Figure 4.25 Optimisation of surrogate matrix for DOSCAT. Electropherograms resultant from 
heat-inactivated E.coli and yeast lysate ± 100 fmol/µL DOSCAT analysed by automated capillary 
western blotting using NF-κB antibodies.  
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Figure 4.26 External calibration by DOSCAT in QWB. a) Representative pseudo-gels resultant 
from 0-800 fmol/µL DOSCAT and 0.4 mg/mL ± TNFα treated SK-N-AS cell lysate (biological 
replicates, n = 3; technical repeats, n = 3) analysed by automated capillary western blot using a p65 
antibody. b) DOSCAT calibration curve, presented as mean ± standard error (n = 3). c) Copies per 
cell of p65 calculated using QWB and DOSCAT calibration, factored by gel replicates (colours) and 
sample replicates (shapes). d) Comparison of cpc values of p65 as determined by externally 
calibrated QWB and internally calibrated QWB and SRM-MS. Data presented as mean ± standard 
error (n = 3). 
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4.3.4. QWB using fluorescent detection 
All QWBs using DOSCATs thus far have been performed using automated capillary western 
blotting due to its superior quantitative performance. However, many researchers do not have 
access to this technology, so it is important to demonstrate that a DOSCAT can be used in 
classic WB formats. To do this, NFκB-DOSCAT-2 was used for quantification using the same 
antibodies and cell line, but westerns blots were performed by electro-transfer onto PVDF 
membrane and subsequent fluorescent detection.  
NFκB-DOSCAT-2 was spiked into TNFα treated or untreated SK-N-AS cell lysate and 
DOSCAT concentration accurately obtained by digesting a sample of this mixture with a Glu-
Fib peptide standard and analysing the heavy:light ratio by SRM-MS. The mixture was serially 
diluted 7-fold in a cell lysate diluent and, along with a cell lysate only sample, was run on an 
SDS-PAGE gel, giving an 8-point standard curve and 8 technical repeats. Within a single gel, 
two untreated and two TNFα treated samples (C4, C5, T4, T5) were run and subsequently 
electro-transferred onto a single PVDF membrane together. SK-N-AS cell lysate from different 
biological replicates to those used previously had to be used due to lack of availability of the 
original samples. This would mean that a direct comparison of cpc values would not be 
possible, but it would be a fair assumption that these values should be broadly similar within 
the same cell line. The membranes were blocked together before being cut in half, each half 
containing one untreated and one TNFα treated samples. These were then processed in 
parallel through primary and secondary antibody incubation and wash steps before being 
imaged. This process was repeated for all NF-ΚB antibodies apart from IκBε, which has been 
shown not to detect NFκB-DOSCAT-2.  
Using this experimental set-up NFκB-DOSCAT-2 and endogenous protein was successfully 
detected by all four of the antibodies that were used. An exemplar blot using a p65 antibody 
to detect NFκB-DOSCAT-2 and endogenous protein TNFα treatment is displayed in Figure 
4.27. Using Image Studio software (LI-COR), densitometry was performed on bands and 
calibration curves were constructed based on the NFκB-DOSCAT-2 signal (Figure 4.28). For 
IκBα and IκBβ, signal saturation meant that for certain replicates no signal could be recorded 
and so these data points in the standard curve were omitted. Signal linearity was mostly 
excellent with r2 values of 0.97 and above, although in two cases r2 values were 0.95 and 0.80 
for IκBβ and IκBα respectively. Using these calibration curves the signal for endogenous 
protein was converted to copy per cell values. Across all samples, average intra-assay 
variability in terms of CV was 19.2%, however this ranged from 6.6% to 45.6%. Technical 
repeats and biological replicates were averaged to give final quantification values for each 
protein (Figure 4.29a). Variability between biological replicates of nearly all samples was very 
high (CV > 40%); only IκBβ and IκBα post TNFα treatment had CVs < 20%. This increased 
variability was attributed to biological variation, as values in sample 5 were consistently 
inflated compared to sample 4. Values obtained by fluorescent QWB were compared to those 
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obtained by automated capillary QWB (Wes) and SRM-MS (Figure 4.29b). For p65, RelB and 
IκBβ, quantification values were higher than those previously recorded, however the large 
variance for p65 and RelB made it difficult to accurately assess how well the values agreed. 
Copy per cell values for IκBα agreed well with Wes QWB, but again the error associated with 
the measurement made it difficult to draw firm conclusions.  
This study establishes that DOSCATs can be used in a classic western blot to quantify proteins 
with a good degree of accuracy. Although classic western blotting is not generally seen as 
quantitative, these results demonstrate that with proper calibration, quantification is 
achievable with values that broadly match those generated by gold standard platforms. Not 
having access to the same sample set used in previous quantitative experiments is a clear 
limitation in assessing quantitative accuracy, and this is compounded by the large variability 
in results. Repeating this study with an increased number of samples and performing repeats 
of the same gel would allow for a better evaluation of accuracy and variability.  
 
 
 
Figure 4.27 Quantitative western blotting using NFκB-DOSCAT-2 and fluorescent detection. 
Dilution series of NFκB-DOSCAT-2 spiked into 5 µg SK-N-AS cell lysate analysed by classic western 
blotting, using an anti p65 primary antibody and a fluorescently labelled secondary antibody that was 
detected by Odyssey Fc scanner (LI-COR). 
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Figure 4.28 NFκB-DOSCAT-2 calibration curves in fluorescent QWB. Dilution series of NFκB-
DOSCAT-2 standard spiked into yeast lysate was analysed as an external standard to SK-N-AS cell 
lysate samples by automated capillary western blotting, using four target antibodies against NFκB-
DOSCAT-2. Data presented as mean ± standard error for each sample (n = 3). 
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Figure 4.29 Quantification of target protein by fluorescent QWB. a) Quantification values for 
target proteins derived from fluorescent QWB. Data in bars are mean of biological replicates 
± standard error (n = 2). Data points are mean values from technical repeats of individual biological 
replicates (n = 8). b) Copy per cell values from fluorescent QWB compared to values resultant from 
automated capillary WB and SRM-MS analysis.  
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4.3.5. Restricted proteolysis of NFκB-DOSCAT-2  
This iteration of NFκB-DOSCAT-2 contained four protease cleavage sites (Table 4.3), each of 
which was assessed for specificity and efficiency of cleavage. NFκB-DOSCAT-2 was 
incubated with each of the proteases and samples taken at defined time points, which were 
subsequently analysed by SDS-PAGE (Figure 4.30). As with NFκB-DOSCAT, both RV3C and 
TEV proteases cleaved NFκB-DOSCAT-2 specifically after 4 hours, yielding two fragments of 
a distinct and predictable molecular weight. TVMV protease also specifically cleaved 
DOSCAT, yielding fragments as 67.5 kDa and 8.0 kDa. However, NFκB-DOSCAT-2 was not 
totally digested after overnight incubation, even when increasing amounts of protease well 
above the recommended protease:protein ratio were used. Incubation with enteropeptidase 
resulted in total digestion of NFκB-DOSCAT-2 within 1 hour with no proteolytic fragments 
visible on the gel at any time point. Only the contaminant that is present in the starting material 
is visible post-digestion. The heating of an enzyme during SDS-PAGE sample preparation 
may accelerate its activity, even at the high temperatures used. To investigate whether this 
was happening with enteropeptidase, the enzyme was incubated with NFκB-DOSCAT-2 and 
samples subjected to a TCA precipitation. Precipitate was then resuspended in SDS sample 
buffer and analysed by SDS-PAGE (Figure 4.31). As before, no bands for NFκB-DOSCAT-2 
or expected proteolytic fragments were visible at the time points sampled. This discounted the 
hypothesis that enteropeptidase was being rendered hyper-active by heating. As specific 
cleavage could not be achieved, enteropeptidase was discontinued from further experiments. 
Three out of the four proteases had been shown to cleave NFκB-DOSCAT-2 specifically, 
producing two fragments of differing electrophoretic mobility that could be resolved on an 
SDS-PAGE gel. The next step was to test whether these fragments could be detected by 
antibodies in western blots. NFκB-DOSCAT-2 was digested with each protease, and at each 
time point a sample was removed, diluted and prepared for Wes analysis. Six time points were 
taken for each protease and analysed by the five NF-ΚB antibodies (Figure 4.32). For TEV 
and RV3C proteases, antibodies successfully detected fragments that contained their cognate 
epitope. Fragments of a lower molecular weight had a lower signal intensity than larger 
fragments. For TVMV, the 67.5 kDa was detected by the correct antibodies but the 8 kDa 
fragment was not detected by RelB, most likely as it lies outside of the analytical range of the 
instrument (12 – 240 kDa). The RelB antibody also detected intact NFκB-DOSCAT-2, 
suggesting that digestion was incomplete in this case.  
Compared with the earlier NFκB-DOSCAT, there is a gain in the introduction of protease sites. 
TEV and RV3C proteases worked well, consistent with results observed with the NFκB-
DOSCAT, as did the newly introduced TVMV protease. TVMV is closely related to TEV 
protease and previous studies have demonstrated its high specificity (Nallamsetty et al., 2004; 
Sun et al., 2010), consistent with the results presented here. The totality of proteolysis by 
enteropeptidase would initially suggest the presence of a protease contaminant, due to the 
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high specificity of the canonical cleavage sequence DDDDK. However, using an approach in 
which cellular libraries of peptides substrates were screened, enteropeptidase has been 
shown to have a broader than thought substrate specificity with a strong preference for 
arginine at P1 and one or more Asp or Glu residues at P2 or P3 (Boulware et al., 2006). This 
would introduce many more potential sites of proteolysis in the DOSCAT sequence and may 
explain these results.  
It has been demonstrated that epitopes contained in different proteolytic fragments can be 
detected by antibodies in a western blot, with the expected shift in electrophoretic mobility. It 
would be expected that the chemiluminescent signal for an intact DOSCAT and a proteolytic 
fragment would be the same as there is an equivalent molar amount of epitope loaded on to 
the system; however, this was not the observed result. The reasons for this are not clear, 
antibodies may bind differently to proteolytic fragments than the full length DOSCAT 
sequence, or the results may be an artefact of using the Wes system for analysis. Further 
work that replicated the experiment on different DOSCATs and using classic western blotting 
on proteolytic fragments might help to explain the data presented here.  
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Figure 4.30 Digestion of DOSCAT by restricted specificity proteases. DOSCAT (9 µg) was 
incubated with each protease, samples taken at indicated time points and analysed on a 12% (TEV 
protease, enteropeptidase) or 15% (RV3C, TVMV proteases) SDS-PAGE gels.  
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Figure 4.31 TCA precipitation of enteropeptidase proteolysis. DOSCAT was incubated with 
TVMV protease in the appropriate buffer. Starting material (SM) and samples at indicated time points 
were added to an equal volume of 10% TCA. Precipitate was pelleted by centrifugation and washed 
with acetone twice, acetone evaporated and pellet resuspended in SDS sample buffer for SDS-PAGE 
analysis. 
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Figure 4.32 Western blots of DOSCAT proteolytic fragments. DOSCAT was incubated with each 
protease, samples taken at indicated time points and analysed by automated capillary western 
blotting using each of the NF-κB antibodies. Presented are pseudo-gel views of data generated by 
Compass software.  
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4.4. Conclusions  
The work in this chapter builds on the initial proof of principle work by demonstrating that 
DOSCATs can be utilised to accurately and reproducibly quantify multiple target proteins by 
both QWB and SRM-MS, with quantification values measured by each technique being in 
good agreement. This shows not only that the DOSCAT approach is viable, but both 
automated and classic western blotting, generally only considered semi-quantitative, are as 
analytically rigorous as the current gold standard for targeted quantification. There is also 
flexibility in how DOSCATs can be used, whether spiked-in with a sample or external to the 
sample. Additionally, more has been understood about the properties of DOSCAT, such as its 
propensity to adsorb to surfaces, which will inform how experiments and workflows should be 
designed to minimise inaccuracies arising from erroneous DOSCAT concentration. This all 
represents a successful deployment of DOSCAT technology to fulfil the aims of absolute 
targeted protein quantification by MS and immunoblotting. 
Following on from the NF-κB DOSCAT, the next stage in development will be to design a new 
DOSCAT that will quantify a different set of target proteins in an expanded sample size. Using 
all that has been learnt from this deployment of DOSCAT, it should be anticipated that the 
next deployment will have minimal issues and perform equally in terms of experimental 
accuracy and precision. This will give further assurance of the technique; reinforcing and 
refining design principles, increasing understanding of DOSCAT behaviour at a protein level, 
and having greater confidence in the accuracy and reproducibility of the orthogonal 
techniques.  
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Chapter 5: DOSCAT technology to quantify of putative pneumococcal 
meningitis biomarkers  
5.1. Introduction 
The previous chapter detailed how a DOSCAT could be designed, expressed and utilised to 
quantify target proteins using SRM-MS and automated capillary QWB, yielding results that 
were comparable in accuracy and reproducibility. Whereas this work quantified well studied 
proteins derived from a cell line, there is potentially a lot of value in using DOSCAT technology 
to aid in the rapid quantification of disease biomarkers in complex clinical samples. The advent 
of label-free quantitative proteomics has led to a sharp rise in the identification of putative 
biomarkers for many disease areas, however, few of these biomarkers are translated into the 
clinic for routine testing due to lack of robust verification and validation studies. The next stage 
in the advancement of DOSCATs is to use the technology to quantify potential biomarker 
proteins in a complex sample, further demonstrating how the methodology can be employed 
to improve data quality and existing practices. 
This chapter will focus on the targeted quantification of proteins implicated in the pathogenesis 
of acute bacterial meningitis (ABM) caused by Streptococcus pneumoniae infection. 
Pneumococcal meningitis has a poor prognosis, and is particularly prevalent in sub-Saharan 
Africa where co-infection with HIV further increases the fatality rate (Nyasulu et al., 2011). 
Indeed, Streptococcus pneumoniae infection leading to pneumonia, septicaemia and 
meningitis is estimated to cause approximately 1 million deaths in children under the age of 5 
years every year (O’Brien et al., 2009). Current diagnostic testing is based on Gram stain and 
culture of CSF obtained by lumbar puncture from patients suspected of meningitis, with 
diagnosis also based on several biochemical indicators including an increased white blood 
cell count and increased protein concentration in CSF (Scarborough et al., 2008). However, 
such tests are time-consuming, and as rapid diagnosis and treatment is associated with 
increased survival, there is a clear need for a point of care diagnostic test based on a panel 
of protein biomarkers. Previous studies have employed 2D-electrophoresis based proteomics 
of CSF to identify several proteins associated with pneumococcal meningitis  (Cordeiro et al., 
2015; Goonetilleke et al., 2010; Jesse et al., 2010). However, 2D-electrophoresis can lack 
sensitivity compared to more contemporary LC-MS techniques. More recently, MS based 
label-free quantitative proteomics was used to identify a number of proteins that were 
differentially expressed in the CSF of patients diagnosed with pneumococcal meningitis. A 
subset of these proteins was further analysed by automated capillary western blotting using 
recombinant protein standards, which confirmed the proteomics data and offered a panel of 
putative protein biomarkers; cathelicidin, cystatin C, ceruloplasmin, myeloperoxidase, S100A8 
and S100A9. Other than cystatin C, abundances of these proteins increased in CSF from 
patients with pneumococcal meningitis infection. However, taken in isolation, such changes in 
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protein abundance are not clinically valuable in determining Streptococcus pneumoniae 
infection as most are involved in the innate immune response and reflect a non-specific 
antimicrobial response. They would, therefore, be upregulated in any bacterial infection and 
so not be specific to infection by Streptococcus pneumoniae. Myeloperoxidase is essential for 
the rapid activation of antimicrobial activity in neutrophils upon detection of pathogens through 
catalysing the generation of hypochlorous acid from hydrogen peroxidase and chloride anion 
(Nauseef, 2014). Cathelicidin is an inactive precursor protein that is cleaved by neutrophil 
elastase into antimicrobial peptides that are released from neutrophils when required 
(Kościuczuk et al., 2012; Treffers et al., 2005). S100A8 and S100A9 form a heterodimer 
known as calprotectin, which by sequestering the essential nutrients manganese and zinc at 
sites of infection restricts the ability of pathogens to establish themselves in a host (Brophy et 
al., 2015; Corbin et al., 2008). Ceruloplasmin is a ferroxidase that has been implicated in the 
acute phase response to inflammation, although its exact physiological role is not well 
understood (Gabay et al., 1999; Jain et al., 2011). When analysed together in a panel, it is 
hoped that these proteins along with cystatin C (which is down regulated upon infection) will 
aid the diagnosis of Streptococcus pneumoniae infection with the specificity and sensitivity 
required for a clinical assay. 
The aim of this chapter is to use these six proteins as the targets to be quantified using a new 
DOSCAT, again utilising SRM-MS and automated capillary QWB as platforms for 
quantification. To achieve this, over 40 CSF samples from patients who tested positive and 
negative for pneumococcal meningitis will be used; such an expanded sample set will permit 
a more robust comparison of quantitative performance between the two assays as well as 
demonstrating that DOSCATs can be used in complex samples such as CSF. Moreover, 
quantitative data generated using a DOSCAT can be directly compared to label-free 
proteomics and QWB data generated in the previous study to further validate the approach.  
A weakness with the DOSCAT approach is successfully selecting well validated antibodies 
with defined epitopes that will recognise DOSCATs with the epitope built in to the sequence. 
Although there are now resources available to aid the selection of antibodies that are validated 
and likely to specifically detect endogenous proteins (Björling et al., 2008; Helsby et al., 2014), 
manufacturers do not always disclose epitopes, and when they do, they may not always be 
accurate. As discussed in the previous chapter, selected antibodies did not detect the NFκB-
DOSCAT even though they detected endogenous protein. There is no way to know if the 
antibody will detect a DOSCAT until after it is expressed, and so such failure represents a 
waste of resources and a reduction in experimental output. This limitation could be overcome 
if the epitope sequences built into a DOSCAT were used as an immunogen to create an anti-
DOSCAT antibody. Previously, recombinantly expressed epitopes fragments (PrESTs) have 
been used as immunogens to produce monospecific antibodies for affinity proteomics in 
multiplex by immunising rabbits with up to 10 PrESTs at once (Larsson et al., 2006). The work 
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in this chapter aims to build on this by creating designer proteins that concatenate epitope 
sequences into a single protein that can be expressed recombinantly and used to immunise 
a single rabbit. This would yield a polyclonal serum of antibodies that would recognise the 
epitopes built into a cognate DOSCAT standard, with the added benefit of reducing the 
number of animals required, as a single animal would produce the antibody to detect all 
epitopes. This chapter will attempt to demonstrate the viability of this strategy through the 
design and expression of an immunogen that concatenates the epitopes used in the DOSCAT 
standard against the six protein biomarkers. The immunogen will be used to produce an anti-
DOSCAT antisera of which the specificity and sensitivity to DOSCAT standard and 
endogenous proteins in western blotting will be evaluated.  
5.2. Results and discussion 
5.2.1. Preparation of a meningitis-DOSCAT standard and meningitis-DOSCAT 
immunogen 
Two new constructs were built for this work: a DOSCAT targeting six proteins implicated in 
the pathophysiology of paediatric Streptococcus pneumoniae meningitis infection and a 
protein incorporating the chosen epitopes to act as an immunogen to create an anti-DOSCAT 
antibody. The standard and immunogen will subsequently be referred to as M-DOSCAT-S 
and M-DOSCAT-i respectively. Design principles refined in the previous iterations of NFκB-
DOSCATs were employed in the design of M-DOSCAT-S. A shortlist of candidate Q-peptides 
for each protein were selected using the previously described criteria, and tools such as 
CONSEQUENCE and SRM-Atlas were also used to refine the shortlist so that two or three Q-
peptides for each protein were selected (Table 5.1). Each selected peptide was present in 
SRM-Atlas (Kusebauch et al., 2016) as a peptide that had been observed previously in SRM 
experiments. Each peptide was assessed for potential sites of post-translational modifications 
using NetPhos (Blom et al., 1999) and PhosphoSite plus (Hornbeck et al., 2017) and 
subsequently cross-checked against selected epitopes to ensure that antigenic regions were 
not replicated throughout the sequence.  
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Antibodies were selected primarily on whether data relating to their epitopes were available 
(Table 5.2). Each selected antibody was raised using a known synthetic peptide as an 
immunogen and the sequences of these peptides were inserted into M-DOSCAT-S as the 
epitopes. By using this more specific approach rather than inserting epitopes centred around 
an amino acid, it was hoped that antibodies would be more likely to recognise epitopes 
inserted into the DOSCAT sequence. Compared to NFκB-DOSCAT-2, a higher proportion of 
selected antibodies were monoclonal (3/6), which is preferred as they will bind to a specific 
epitope only, and so non-specific binding to other regions within the DOSCAT will be less 
likely.  Before committing to synthesising the gene for M-DOSCAT-S, the selected antibodies 
were tested against recombinantly expressed target proteins using automated capillary WB 
(Figure 5.1). All target proteins except for cystatin C were detected, although only a low signal 
for the light chain of myeloperoxidase was observed. Increasing amounts of protein loaded 
onto the Wes system with higher concentrations of antibody did improve the signal for 
myeloperoxidase, but cystatin C was still not detected. Cystatin C is an important target protein 
as it is the only protein that increases in abundance in healthy control samples, so it would be 
advantageous for the study if it was kept in the analysis. At the time, no other antibodies with 
a known epitope could be found, but we were in possession of an antibody that was known to 
us to work against the recombinant standard and in CSF samples. As cystatin C is a small 
protein (15.8 kDa), it was decided to include the full protein sequence within M-DOSCAT-S. 
This would ensure that M-DOSCAT-S could be detected by WB, and would also facilitate the 
inclusion of Q-peptides for SRM-MS analysis. The same restricted specificity protease sites 
included in NFκB-DOSCAT-2 were selected except for enteropeptidase, which when 
previously tested resulted in the complete proteolysis of the DOSCAT protein. When 
assembling the sequence for M-DOSCAT-S, the locations of the restricted proteolytic sites 
were chosen to maximise multiplexing capability and to ensure epitopes were not at termini of 
fragments, which may affect antibody binding. As before, His-tag for purification and Glu-Fib 
peptide for quantification were included in the final sequence (Figure 5.2a).  
M-DOSCAT-i was designed as an immunogen to create an anti-DOSCAT antibody that would 
detect epitopes contained in M-DOSCAT-S. Epitopes for four proteins, myeloperoxidase, 
ceruloplasmin, cathelicidin and S100A8, were taken from M-DOSCAT-S and included in the 
M-DOSCAT-i sequence along with a Met initiator at the N-terminus and His-tag at the C-
terminus (Figure 5.2b). No spacer regions were inserted between epitopes as this may have 
produced non-specific antibodies.  
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Table 5.2 Antibodies used with M-DOSCAT-S.  
Protein Supplier Product no. Host species Clonality 
Cathelicidin Abcam ab58387 mouse monoclonal 
Ceruloplasmin Abgent AP7340C rabbit polyclonal 
Cystatin C Novus NBP1-26402 goat polyclonal 
Cystatin C Abcam ab109508 rabbit monoclonal 
Myeloperoxidase Abcam ab45977 rabbit polyclonal 
S100 A8 Abcam ab92331 rabbit  monoclonal 
S100 A9 Abcam ab92507 rabbit monoclonal 
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Figure 5.1 Validation of antibodies against recombinant standards. Electropherograms resultant 
from the capillary WB analysis of recombinant protein standards (loaded onto the Wes system at 0.2 
µg/µL) with their cognate antibody used at a 1:50 dilution. 
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Codon optimised genes for both M-DOSCATs were synthesised, cloned into pET21a vectors 
(Eurofins Genomics) and transformed into BL21 DE3 E.coli cells. As the immunogen did not 
need to be stable isotope labelled, cells transformed with DNA for M-DOSCAT-i were grown 
in LB media at 37°C and expression induced by the addition of 1 mM IPTG when OD at 600 
nm reached 0.6. After 3 h no expression of M-DOSCAT-i was evident (Figure 5.3a), so 
expression was attempted again using minimal media at 37°C, but again, no expression could 
be detected by SDS-PAGE (Figure 5.3a). It was possible that M-DOSCAT-i was degrading 
within the cell after being expressed, so in an attempt to prevent this E.coli cells were grown 
in LB media at 18°C overnight with different concentrations of IPTG to induce expression, 
however there was no indication of protein expression under any of the conditions (Figure 
5.3b). Five different E.coli cell lines were then used: SL BL21, C43 (DE3), BL21(DE3)-pLysS 
(pLysS), Rosetta-pLysS (Rosetta) and Rosetta-gami-pLysS (Rosetta-gami). The pLysS strain 
expresses T7 lysozyme so that basal expression of genes controlled by the lac promoter is 
reduced and the C43 (DE3) strain contains mutations on the lac promoter that reduce levels 
of expression (Miroux et al., 1996; Wagner et al., 2008), thus making both strains more tolerant 
to protein toxicity. The Rosseta and Rosseta gami strains, developed by Novagen, supply 
tRNAs for the rare codons AUA, AGG, AGA, CUA, CCC, GGA, improving expression levels 
for proteins with these codons present. The M-DOSCAT-i plasmid was successfully 
transformed into each cell line, which were grown in LB media containing 1% glucose at 37°C 
with expression induced using 0.5 mM IPTG when OD600nm reached 0.6 and culture was 
continued for 5 h. All cell lines grew as expected except for Rosetta Gami, which did not 
progress past lag phase (Figure 5.4a). In all cases, no expression of M-DOSCAT-i was evident 
(Figure 5.4b). Western blot analysis using a His-tag antibody detected a single protein 
expressed even before the addition of IPTG, although due to failure of the MW markers it is 
unclear if the visible band is at the correct MW for M-DOSCAT-i (Figure 5.4c). However, as 
the bands are present in sample pre-IPTG induction it is likely that they are indicative of a non-
specific contaminant signal. 
Cells transformed with the plasmid for M-DOSCAT-S were grown in minimal media containing 
[13C6]Arg/[13C6]Lys at 37°C and expression induced during mid-log phase by the addition of 1 
mM IPTG. The M-DOSCAT-S protein was expressed after 3 h (Figure 5.5a) and subsequently 
determined to be contained in the insoluble fraction of the E.coli cell lysate. M-DOSCAT-S 
was purified by Ni-NTA affinity chromatography (Figure 5.5b) and dialysed into a 50 mM 
ammonium bicarbonate, 1 mM DTT, 0.1% Rapigest SF (w/v) storage buffer. Concentration 
was estimated by analysing the DOSCAT protein alongside a dilution series of BSA standards 
on an SDS-PAGE gel (Figure 5.5c). As well as further demonstrating the purity of the protein, 
the concentration was estimated to be 0.04 µg/µL, or 0.6 pmol/µL. Purified M-DOSCAT-S was 
digested with trypsin and analysed by MS/MS on an Orbitrap Elite. Sequence coverage was 
high (83%) with all Q-peptides observed (Figure 5.6a). Moreover, labelling efficiency of isotope 
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labelled Arg/Lys was shown to be > 95% (Figure 5.6b). When analysed by automated capillary 
WB, M-DOSCAT-S was detected by all target antibodies apart from S100A8 (Figure 5.7).   
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Figure 5.3 Expression of M-DOSCAT-i in BL21 E.coli cells. SDS-PAGE analysis of time points 
from E. coli culture containing M-DOSCAT-i plasmid, grown in a) LB and minimal media for 6 h after 
inoculation, with expression induced by 1 mM IPTG at indicated time points; b) minimal media at 
18°C overnight, with expression induced by indicated concentration of IPTG 3 h after inoculation, as 
indicated by arrows. 
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Figure 5.4 Expression of M-DOSCAT-i in multiple cell lines. a) Growth curves of each culture 
measured by optical density at 600 nm. Samples from each culture were analysed pre-induction by 
0.5 mM IPTG (Pre) and up to 5 h after induction by b) SDS-PAGE and c) western blot using an anti 
His-tag antibody. 
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Figure 5.5 Expression and purification of M-DOSCAT-S. SDS-PAGE analysis of a) time points 
from E. coli culture containing M-DOSCAT-S plasmid, grown in minimal media containing 
[13C6]Arg/[13C6]Lys for 6 h after inoculation, with expression induced by 1 mM IPTG at indicated time 
point; b) soluble (S) and insoluble (I) fractions of E.coli cell extract, flow through (FT), wash fraction 
(W) and elution fractions 3 – 12 from His-Trap column using an elution gradient 0–100% elution 
buffer over 20 min; c) purified M-DOSCAT-S alongside albumin standards. 
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Figure 5.6 MS verification of M-DOSCAT-S expression. a) M-DOSCAT-S peptide map 
highlighting identified Q-peptides (green) and other peptides (grey) by MS/MS, alongside the MS1 
total ion chromatogram signifying the elution profile of each Q-peptide. b) Precursor ion mass spectra 
from MS/MS analysis and SRM chromatogram for a representative Q-peptide, ALNSIIDVYHK, 
demonstrating high efficiency of stable isotope labelling. 
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Figure 5.7 Detection of M-DOSCAT-S by target antibodies. Electropherogram and pseudo-gel 
images resultant from the capillary western blot analysis of M-DOSCAT-S loaded onto the Wes 
system at 2, 1 and 0.5 fmol/µL and analysed by target antibodies at a 1:50 concentration. 
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In all blots containing M-DOSCAT-S, non-specific bands were observed at 150 kDa that 
weren’t present when CSF alone was run. When analysed by capillary WB without the 
presence of primary antibodies, no signal was observed, confirming that the bands were not 
caused by non-specific detection of E.coli proteins by secondary antibodies (Figure 5.8). 
Instead, their presence was hypothesised to be due to the formation of aggregates in the M-
DOSCAT-S sample. Bands visible at high MW on an SDS-PAGE provided further evidence of 
this (Figure 5.5c). The presence of such aggregates could adversely affect QWB as bands for 
endogenous target proteins would be obscured and there would also be a discrepancy 
between MS quantification of M-DOSCAT-S stock and the signal measured by QWB. This is 
because aggregates would be digested during trypsin digestion and so be included in 
quantification using Glu-Fib peptide. Without knowledge of the proportion of M-DOSCAT-S to 
aggregates in a sample, it would be difficult to correct for this. Therefore, strategies were 
needed to overcome or prevent aggregation.  
Aggregation can be the result of disulphide bond formation between cysteine residues, and 
so reduction of the disulphide bond may disrupt existing aggregates. Sample buffers for SDS-
PAGE and western blotting include DTT, so if aggregates could be removed by modifying 
levels of DTT within the sample buffer this would provide a simple solution as it would just be 
an amendment to the existing WB workflow. Sample buffers containing normal (100 mM) and 
increased (400 mM) concentration of DTT were incubated with M-DOSCAT-S at different 
times and temperatures (Figure 5.9). There was no effect on signal intensity in either M-
DOSCAT-S or aggregates between each sample preparation procedure, even with four times 
as much reducing agent used. This ruled out the approach of modifying sample buffer to 
reverse aggregation. The next approach taken was to attempt to remove aggregates using a 
molecular weight cut off (MWCO) filter. A spin filter with MWCO of 100 kDa was selected, so 
that M-DOSCAT-S would pass through the column but aggregates would not. This was not 
the case however, with both M-DOSCAT-S and aggregates being retained by the filter and no 
protein detected in the flow through (Figure 5.10). Efforts then moved on to prevent M-
DOSCAT-S aggregating in the first place. It was observed that when solubilised in guanidinium 
hydrochloride after purification, no aggregates were present (Figure 5.5b). If disulphide bond 
formation could be prevented at this stage then aggregation might not occur. M-DOSCAT-S 
was purified from cell pellets and whilst still in elution buffer containing Gu-HCl, cysteine 
residues were reduced and alkylated by incubation with DTT and IAM respectively. After 
dialysis into storage buffer, no evidence of aggregation was observed in DTT/IAM treated M-
DOSCAT-S when analysed by SDS-PAGE (Figure 5.11a) or automated capillary western 
blotting (Figure 5.11b). The completeness of cysteine modification was demonstrated by 
analysing M-DOSCAT-S by MS/MS (Figure 5.11c), and modified epitopes within recombinant 
standards were still recognised by all antibodies although the signal was reduced compared 
to unmodified protein (Figure 5.11d).  
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Figure 5.8 Analysis of secondary antibody detection of M-DOSCAT-S. Electropherograms 
resultant from capillary western blot analysis of M-DOSCAT-S (1 fmol/µL) using each of the target 
antibodies (blue traces) or blocking buffer (also referred to as antibody diluent, green traces) as the 
primary antibody. The secondary antibody was either HRP conjugated anti-rabbit or anti-mouse 
dependent on the source of the primary antibody. 
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Figure 5.9 The effect of DTT concentration on M-DOSCAT-S aggregation. M-DOSCAT-S was 
incubated in SDS sample buffer containing 100 or 400 mM DTT and incubated at RT 15 mins, 60°C 
10 mins or 95°C 5 mins before analysis by SDS-PAGE.   
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Figure 5.10 MWCO to remove M-DOSCAT-S aggregates. M-DOSCAT-S was transferred into a 
spin filter with a MWCO of 100 kDa and centrifuged at 15,000 x g, 15 m. Starting material (SM), flow 
through (FT) and retentate was analysed by SDS-PAGE.  
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Figure 5.11 Prevention of aggregation in M-DOSCAT-S by DTT/IAM incubation. M-DOSCAT-S 
contained in elution buffer was incubated with 10 mM DTT overnight followed by 20 mM IAM for 30 
m and dialysed into storage buffer. Treated M-DOSCAT-S was analysed alongside untreated protein 
by a) SDS-PAGE and b) automated capillary western blotting using target antibodies. c) XIC of a Q-
peptide from the MS1 trace of DTT/IAM treated M-DOSCAT-S digested with trypsin and analysed by 
MS/MS, highlighting the completeness of cysteine alkylation. d) Recombinant protein standards ± 
DTT/IAM treatment were analysed by automated capillary WB with their cognate antibody; Compass 
software was used to extract chemiluminescent signal for comparison.  
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The aims of the initial work in this chapter were to design and express a DOSCAT standard 
targeting six proteins implicated in pneumococcal meningitis and an immunogen containing a 
concatenation of epitopes that would be used for the generation of an anti-DOSCAT antibody. 
Whereas the DOSCAT standard expressed well and could be used for further studies, the 
immunogen did not express in multiple cell lines and conditions. Lack of expression of 
recombinant proteins is usually attributed to leaky expression, protein toxicity to the cell, or 
codon bias (Rosano et al., 2014). Leaky expression occurs when promotors are not tightly 
regulated and so proteins are expressed before induction, which can lead to plasmid instability 
and the culture becoming saturated with cells that no longer contain the plasmid. M-DOSCAT-
i, though, was not expressed in cell lines with highly regulated promotors (such as C43 and 
PLysS) that are known to supress leaky expression and express toxic proteins when BL21 
DE3 cells will not (Dumon-Seignovert et al., 2004). This contradicts the view that toxicity of M-
DOSCAT-i prevented expression, compounded by the fact that growth curves for all cell lines 
used were normal when arrested growth or cell death would be expected (Doherty et al., 1993; 
H. Dong et al., 1995). Codon bias describes the differences in the frequency of occurrence of 
synonymous codons in coding DNA, with the tRNA population of a cell closely reflecting this 
bias (Hengjiang Dong et al., 1996). During overexpression, if codons in heterologous DNA are 
significantly different from that of the host, there may be a deficiency in particular tRNAs, 
leading to amino acid misincorporation or translation termination (Gustafsson et al., 2011). 
However, M-DOSCAT-i DNA had been optimised to include high abundance codons as well 
as to minimise mRNA secondary structure features that may prevent translation. Additionally, 
M-DOSCAT-i did not express in several cell lines that have been developed for the expression 
of toxic proteins or mRNA containing rare codons. 
It is therefore unclear exactly why M-DOSCAT-i did not express. Protein degradation is known 
to increase under cell stress, which may explain why cells continued to grow despite protein 
toxicity. Leaky expression or codon bias cannot be completely ruled out despite the protein 
not expressing in cell lines designed to prevent these problems, as they are not completely 
infallible. Some QconCATs fail to express (Beynon and Harman, personal communication, 
2017), although it is difficult to estimate an overall failure rate as not every failure will be 
reported in the literature. As reported here, there is evidence that changing expression 
conditions or cell strains does not overcome lack of QconCAT expression (Russell et al., 
2013), but shuffling the order of peptides in the sequence and resynthesizing the gene can 
(Mirzaei et al., 2008; Russell et al., 2013). This presumably alters the properties of the 
QconCAT, making it less toxic to the cell. For financial and time considerations it was decided 
not to attempt this with M-DOSCAT-i, especially as success was not guaranteed (Mackenzie 
et al., 2016), but it is certainly a viable strategy for future work. Another approach that could 
be considered is the use of cell-free expression systems, which have been employed to 
express proteins recombinantly (Carlson et al., 2012), including QconCATs (Takemori et al., 
2016). In such systems the crucial cellular components for protein synthesis are isolated and 
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expression is carried out in vitro. This approach overcomes the problem of protein toxicity, 
making it an attractive proposition for future studies.  
In contrast to the immunogen, the DOSCAT standard behaved mostly as expected based on 
experiences with previous DOSCATs and QconCATs. This DOSCAT, though, formed higher 
order aggregates after purification, a behaviour which is commonly observed in QconCATs 
but is usually overcome by solubilisation in a chaotrope during the purification workflow (D. M. 
Simpson et al., 2012). Although protein aggregation can originate from several mechanisms, 
intrinsically disordered proteins lacking a unique tertiary structure are much more likely to 
aggregate (Peng et al., 2014; Sigalov, 2010). As DOSCATs and QconCATs are unique 
artificial proteins, they are likely to lack a defined tertiary structure and so aggregate. However, 
M-DOSCAT-S formed aggregates after solubilisation in a chaotrope whereas the NFκB-
DOSCATs did not. Aggregation was overcome by reduction and alkylation of thiol groups, 
suggesting that it was caused by disulphide bond formation. There is the same proportion 
(~1.35%) of cysteine residues in M-DOSCAT-S (8 Cys residues) and NFκB-DOSCAT-2 (9 
Cys residues), but cross-linking only occurred in M-DOSCAT-S. It may be that the unique 
structural properties of M-DOSCAT-S allowed for cysteine residues to come into the required 
proximity to form disulphide bonds whereas this could not occur the NFκB-DOSCATs, for 
example if cysteines were sterically hidden or otherwise unable to contact one another. When 
designing future DOSCATs it would be prudent to take the number of cysteines into account 
and even attempt to model the structure of the protein to see if disulphide crosslinking is likely 
to be an issue. Reduction and alkylation of cysteine overcomes the problem of aggregation, 
but at the cost of chemically modifying the protein and potentially altering antibody affinity for 
the epitope. This is accounted for if the sample (e.g. CSF) is also treated in the same way, as 
the epitopes in standard and analyte will be the same. This will, however, lower the sensitivity 
of QWB assays, potentially limiting the number of proteins that can be reliably quantified by 
the technique. Despite this drawback, in the light of the problem presented and the ease of 
which it can be overcome by DTT/IAM treatment, reduction in sensitivity can be deemed an 
acceptable compromise and so DTT/IAM treatment will be included in all future workflows 
using M-DOSCAT-S. 
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5.2.2. Restricted proteolysis of M-DOSCAT-S 
M-DOSCAT-S contained three protease cleavage sites, the specificity of which had been 
confirmed in NFκB-DOSCAT-2. An initial experiment was performed that aimed to 
demonstrate that the proteases cleaved M-DOSCAT-S with the required specificity when 
using the same conditions that had been successful previously. However, after overnight 
digestion with each protease M-DOSCAT-S was not proteolysed and no proteolytic fragments 
were detected upon SDS-PAGE analysis (Figure 5.12a). The M-DOSCAT-S signal was very 
weak, though, and there was evidence of aggregation in the sample that may have influenced 
proteolytic activity. The experiment was repeated using a fresh preparation of M-DOSCAT-S 
that had not been DTT/IAM treated but did not yet exhibit aggregation (determined by SDS-
PAGE), freshly made protease buffers and increased concentration of proteases. Again, 
though, M-DOSCAT-S remained intact even after overnight incubation (Figure 5.12b). Due to 
time constraints and the need to achieve the primary aim of using M-DOSCAT-S to quantify 
target proteins, further experimentation attempting to accomplish complete digestion was not 
performed. Clearly, there is scope for future work in both optimising protease digests and 
subsequently analysing protease fragments by western blotting.  
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Figure 5.12 Restricted proteolysis of M-DOSCAT-S. a) M-DOSCAT-S (5 µg) was incubated with 
1 U of each restricted protease and analysed on 15% (left) 12% (right) SDS-PAGE gels, using Silver 
stain for protein visualisation. b) M-DOSCAT-S (10 µg) was incubated with 10 U of each restricted 
protease and analysed on a 12% SDS-PAGE gel.  
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5.2.3. Optimisation of quantitative assays 
As previously explained (Chapter 4.3.2), antibody, sample and DOSCAT concentration must 
be optimised for automated capillary QWB. To find optimal antibody concentrations, a dilution 
series of each antibody was run against a fixed concentration of recombinant protein and the 
peak area/baseline value for each antibody concentration was calculated (Figure 5.13). The 
antibody concentration at the saturation point was selected as the optimal concentration and 
used in all future experiments. To assess the range of M-DOSCAT-S to use for calibration 
curves for each target protein, M-DOSCAT-S was spiked into CSF (to provide a suitable matrix 
background) and serially diluted. The signal was linear across the range of concentrations 
measured for all antibodies, and endogenous proteins did not interfere with M-DOSCAT-S 
signal (Figure 5.14).  
The next optimising step involved finding the optimal amount of CSF to load so that resultant 
signal was measurable, fell within the range of the standard curve and was not saturated. 
There was a wide range of total protein concentrations across all CSF samples, evidenced 
when the CSF samples were analysed by SDS-PAGE (supplementary data). Rather than 
normalising each sample for protein concentration, a fixed volume of CSF was to be used as 
any future diagnostic test would be applied to a fixed volume and so the analysis should take 
into account the natural range of protein content between samples. This was consistent with 
the approach taken in the discovery proteomics and WB verification work (Gómez-Baena et 
al., 2017). The abundance of target proteins would differ greatly between samples and sample 
types (case vs control), so samples required different dilutions on a protein specific basis.  
To help guide this process, two CSF samples with the highest and lowest total protein 
concentrations (based on the SDS-PAGE data) were diluted to 1:5 and 1:50, treated by 
DTT/IAM and analysed by automated capillary WB by each antibody (results summarised in 
Table 5.3). S100A9 and MPO were not detected in either CSF samples, indicating a very low 
protein abundance in these samples or a relatively poor antibody that could not detect the 
proteins in a complex background. For other proteins, resultant signals were compared with 
the M-DOSCAT-S titration data and dilutions for CSF samples were selected based on the 
requirement for signal to be in the linear range of the standard curve (Table 5.4). For 
ceruloplasmin, myeloperoxidase and S100A9 it was clear that higher concentrations of M-
DOSCAT-S were required for standard curves to cover all analytes, therefore a titration from 
0 – 100 fmol/µL was performed to demonstrate linearity across this range. For control proteins, 
it was anticipated that target proteins other than cystatin C would be at a very low abundance, 
so no sample dilution was required.  
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Figure 5.13 Antibody concentration optimisation. A dilution series of each antibody was prepared 
and used to analyse 2 ng/µL recombinant protein standard by automated capillary western blotting. 
Chemiluminescent signal was calculated by Compass software and plotted against each antibody 
concentration. The optimal concentrations selected for each antibody for use in the Wes system are 
circled on each plot.  
 
 
 
 
Figure 5.14 Assessment of M-DOSCAT-S linearity in capillary western blot analysis. Pseudo-
gels and standard curves resultant from the automated western blot analysis of 0 – 10 fmol/µL M-
DOSCAT-S using each target antibody.  
Chapter 5: DOSCAT technology to quantify of putative pneumococcal meningitis biomarkers  
 
143 
 
Table 5.3 Optimisation of CSF dilutions for Wes analysis. CSF samples with low and high total 
protein concentration were diluted 1:5 and 1:50 and analysed by capillary WB using each target Ab. 
Integrated peak areas determined using Compass are displayed for each sample and target protein. 
An X denotes that no signal was detected and B/O denotes signal burn out due to excess protein 
loaded onto the capillary. 
Protein CSF sample 
107 1:5 
dilution 
CSF sample 
107 1:50 
dilution 
CSF sample 
140 1:5 
dilution 
CSF sample 
140 1:50 
dilution 
Cathelicidin 1,255,222 88,990 B/O 168,635 
Ceruloplasmin 1,918,261 86,978 B/O 3,067,633 
Cystatin C B/O 1,224,451 B/O 1,611,013 
Myeloperoxidase X X X X 
S100A9 X X X X 
 
 
Table 5.4 Optimal dilutions of CSF samples for capillary WB analysis. 
Protein Case samples 
dilution 
Hospital control 
samples dilution 
Healthy control 
samples 
dilutions 
Cathelicidin 1 in 50 no dilution no dilution 
Ceruloplasmin 1 in 100 no dilution no dilution 
Cystatin C 1 in 20 1 in 40 1 in 40 
Myeloperoxidase 1 in 10 no dilution no dilution 
S100A9 1 in 5 no dilution no dilution 
 
 
 
Using the spectral library generated from the analysis of a tryptic digest of M-DOSCAT-S by 
LC-MS/MS on an Orbitrap Elite, three transitions were selected for each peptide based on 
signal intensity with a preference for product ions with a higher m/z than the precursor ions 
(all MS/MS spectra in supplementary data). A scheduled SRM method was built based on the 
retention time for each peptide, which resulted in all peptides being detected other than 
DGHSLGR. Peaks were mostly of high intensity and cleanly isolated, although 
QIVAGVNYFLDVELGR and TQPNLDNCPFHDQPHLK (both cystatin C peptides) exhibited 
poor chromatography and weak signal compared to other peptides (Figure 5.15a). To attempt 
to explain why these peptides performed poorly, digested M-DOSCAT-S was analysed on a 
QExactive HF Orbitrap instrument and miscleaves and chemical modifications to the peptides 
searched for. DGHSLGR was not detected by database searching or in the raw data, and 
signal for the peptide was very low within the raw data from the Orbitrap Elite run. This lack of 
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detectability on two separate instrument platforms was highly suggestive of poor ionisation 
efficiency or fragmentation. For this reason, DGHSLGR was discarded from future analysis. 
The presence of asparagine deamidation on the remaining two peptides was reported by 
database searching, and this was confirmed by inspecting the raw data (Figure 5.15b).  
The digestion profile of each peptide was assessed in standard and analyte by spiking M-
DOSCAT-S into Streptococcus pneumoniae positive (SPP) CSF and sampling the digestion 
mixture regularly. Two ceruloplasmin peptides, EHEGAIYPDNTTDFQR and 
ENLTAPGSDSAVFFEQGTTR were not observed in the analyte, so a standard:analyte could 
not be calculated, explaining the very low heavy:light ratio for these peptides compared to the 
other ceruloplasmin peptide. Of the 13 remaining peptides, all reached a stable plateau after 
overnight incubation with trypsin (Figure 5.16). This was the expected result, given that spacer 
regions of six amino acids were used around each peptide. To determine signal linearity and 
assay sensitivity in the sample matrix, M-DOSCAT-S was spiked into CSF over a 100-fold 
range and analysed by SRM. Most peptides exhibited a linear relationship across the entire 
range with limits of detection measured between 100 and 250 amol (Figure 5.17). The 
peptides QIVAGVNYFLDVELGR and TQPNLDNCPFHDQPHLK exhibited non-linear 
behaviour, this was due to very low signal intensity resultant from asparagine deamidation, as 
explained above.  
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Figure 5.15 Analysis of underperforming Q-peptides. a) SRM chromatograms of three Q-
peptides that displayed poor chromatography and/or low signal intensity in the analysis of digested 
M-DOSCAT-S by SRM-MS. b) Mass spectra of two Q-peptides resultant from MS/MS analysis of 
digested M-DOSCAT-S, highlighting the presence of asparagine deamidation in both peptides.  
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Figure 5.16 M-DOSCAT-S digestion time course analysis. Time course analysis showing the 
release of each peptide used for quantification during tryptic digestion. Stable isotope labelled M-
DOSCAT-S and a SPP CSF sample were co-digested, with samples taken at a series of time points 
and digestion halted by acidification. Levels of target peptides in samples from each time point were 
analysed by scheduled SRM-MS. Displayed are ratio of heavy (M-DOSCAT-S) to light (endogenous) 
peptides at each time point.   
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Figure 5.17 Q-peptides limit of detection in SRM-MS.  M-DOSCAT-S (10 fmol/µL final) spiked in 
to a SPP CSF background was digested by trypsin, serially diluted in digested CSF and levels of 
each peptide were analysed by scheduled SRM-MS. The response of each Q-peptide from 0 – 10 
fmol M-DOSCAT-S on the column is displayed. 
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5.2.4. Quantification of target proteins in CSF  
Due to the large number and the variable protein concentration of samples, it was decided to 
perform quantitative experiments with the standard external to the analyte. Performing QWB 
using internal standard curves for each sample would require 44 runs compared with 10 for 
external calibration, making it unfeasible in terms of time and money. This is based on a six-
point internal calibration curve being constructed for each of the 35 samples, requiring 210 
data points for each antibody, of which there are five. This totals 1,050 Wes lanes required for 
analysis; a single run can accommodate 24 lanes, thus 44 runs would be required not including 
any repeats that might be needed. For external calibration, all the samples could be analysed 
by a single antibody across two 24-lane runs with six lanes on each run dedicated to the 
DOSCAT standard. For five analytes, this would total 10 runs. SRM-MS analysis could feasibly 
be performed using internal calibration, but external calibration was selected so as to be 
analogous with the QWB experiments. A total of 35 CSF samples were used for analysis, 
made up of 15 hospital controls, 5 healthy controls and 15 SPP patients. 
For QWB analysis using Wes, accurately quantified M-DOSCAT-S was spiked into a CSF 
background (CSF diluted 1 in 40) and serially diluted to levels reflective of endogenous protein 
in CSF samples based on assay optimisation results. CSF samples were also diluted so the 
resultant signal was within the linear range of the assay and the standard curves, such that 
extrapolation was not required. For each Wes run, a six-point standard curve was analysed 
alongside 18 unknown CSF samples, which were run in a random order. This was repeated 
with antibodies for each target protein other than S100A8, which had been shown to not detect 
M-DOSCAT-S (Figure 5.7). M-DOSCAT-S was detected by all antibodies and resultant 
standard curves were linear and highly reproducible across runs (Figure 5.18). However, 
endogenous proteins were not detected in every sample (Figure 5.19). Myeloperoxidase was 
not detected in any SPP or control sample and S100A9 was detected in only 7 SPP samples. 
Cathelicidin was detected in all but one SPP sample, but in none of the control samples. 
Cystatin C was detected in all but one of the SPP and control samples and ceruloplasmin was 
detected in every SPP and control sample. There was a large amount of non-specific binding 
using the ceruloplasmin antibody; to determine if this was irrelevant protein or ceruloplasmin 
degradation fragments, CSF was run on an SDS-PAGE gel and segments around the 
expected ceruloplasmin band cut out for in-gel digestion. Analysis of the digests by MS/MS 
revealed no evidence of ceruloplasmin fragments at lower molecular weights, confirming that 
the observed non-specific were other proteins and could be ignored for the purposes of 
quantification (Figure 5.20). From each Wes run endogenous protein concentration was 
calculated from the calibration curve generated within that run only.    
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Figure 5.18 M-DOSCAT-S standard curves for QWB assays. Pseudo-gels and associated 
standard curves resultant from multiple dilution series of M-DOSCAT-S in a CSF background, run 
alongside CSF analytes in automated capillary western blotting. Raw data were analysed by 
Compass software and standard curves are presented as mean ± standard error (n = 3).  
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Figure 5.19 Western blots of CSF samples. Representative pseudo-gels of eight selected CSF 
samples at various dilutions resultant from analysis by automated capillary western blotting using 
five different antibodies to target proteins. Text under each blot refers to the total number of samples 
in which endogenous protein was detected by each antibody. 
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Orange       
 
Figure 5.20 In-gel digestion and MS/MS analysis of CSF samples. CSF samples were run on an 
SDS-PAGE gel (top) and the highlighted sections subjected to in-gel trypsin digestion and analysis 
by MS/MS. The bottom table summarises whether the protein ceruloplasmin was detected in each 
gel section defined in the above image.  
 
 
For analysis by SRM-MS, M-DOSCAT-S was spiked into the same CSF matrix background 
as used for QWB and serially diluted in CSF to form an eight-point standard curve. Each CSF 
sample was digested with a final dilution of 1 in 10 and analysed by SRM-MS in a random 
order with blanks between samples. The calibration curve samples were analysed in triplicate 
alongside the unknown samples at the beginning, middle and end of the sample list. 
Calibration curves using M-DOSCAT-S signal were constructed for each peptide revealing 
poor reproducibility between the replicates (Figure 5.21). Each replicate was drawn from the 
same sample, so such poor reproducibility is surprising, indicative of a decline in instrument 
performance or sample degradation over time. As the standards were external to the sample, 
there was no way to normalise for the drop in assay performance between samples run at the 
beginning and end of the sample list. Therefore, it was decided to repeat the experiment using 
internal standardisation; this would be more expensive in terms of instrument time but would 
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yield more reliable data. CSF with a final dilution of 1 in 5 was co-digested with either 1 fmol 
and 0.1 fmol M-DOSCAT-S; this amount of standard was calculated to encompass the full 
dynamic range of target proteins. M-DOSCAT-S and CSF mixtures were digested with trypsin 
and to ensure complete digestion samples of each digest and the pellet generated post-
acidification were analysed by SDS-PAGE (Figure 5.22). Undigested protein would precipitate 
upon acidification by TFA, so bands in the pellet samples would indicate incomplete digestion. 
This was evident in eight samples, all of which were SPP samples and so likely to have an 
increased total protein concentration. Digestion of these samples was repeated using an 
increased 1 in 20 dilution of CSF, and repeat analysis demonstrated that this permitted 
complete digestion.  
Digests were analysed by SRM-MS and for each peptide quantification in terms of µg/mL was 
calculated from the ratio of peak areas in heavy and light extracted ion chromatograms (Figure 
5.23). Peptide quantification values across the same protein agreed well in most instances, 
however there were some notable exceptions (Figure 5.24). The cathelicidin peptide 
DGHSLGR was known to ionise poorly and was not detected in heavy or light samples (Figure 
5.15a); it was therefore removed from analysis when calculating protein level quantification. 
As previously observed in the digest time course data, the ceruloplasmin peptides 
EHEGAIYPDNTTDFQR and ENLTAPGSDSAVFFEQGTTR were not detected at all in the 
analyte, explaining the lack of quantification values (Figure 5.15b). These peptides were 
removed from analysis so that ALYLQYTDETFR alone was used for protein level 
quantification. Higher quantification values were measured by the cystatin C peptide 
TQPNLDNCPFHDQPHLK compared to the other two peptides for the protein. However, 
chromatography and signal intensity were good so the peptide was included in further 
analysis. Protein level quantification was calculated by taking the mean of the values obtained 
for different peptides, other than the ones removed for the reasons described.  
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Figure 5.21 External standard curve reproducibility in SRM-MS. Technical replicates of standard 
curves resultant from the SRM-MS analysis of a dilution series of digested M-DOSCAT-S in a CSF 
background, analysed in between CSF analytes over the course of a 5-day acquisition. 
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Figure 5.22 Assessment of CSF digestion by trypsin. CSF samples diluted 1 in 5 and M-
DOSCAT-S (10 fmol/µL final) were co-digested with trypsin, acidified with TFA and centrifuged to 
separate the soluble and insoluble fractions. For all samples the supernatant (SN) was removed and 
the pellet resuspended in 10µL 2 x SDS sample buffer, and both SN and pellet were analysed on 
12% SDS-PAGE gels. Samples highlighted in red boxes demonstrate incomplete digestion. These 
samples were digested again using a 1 in 50 dilution of CSF and analysed by SDS-PAGE (bottom 
right panel). 
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Figure 5.23 SRM-MS analysis using internal standardisation. Extracted SRM chromatograms for 
each Q-peptide from M-DOSCAT-S (red) and endogenous analyte (blue) resultant from the 
scheduled SRM-MS analysis 10 fmol M-DOSCAT-S spiked into SPP CSF sample #30.  
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Figure 5.24 Peptide level quantification of target proteins. Quantification values for each 
detected Q-peptide were determined by analysing heavy:light ratios and converting to µg/mL for each 
sample. Data are from SPP samples only and presented as mean ± standard error (n = 15). 
 
Quantification using QWB was possible for four proteins, whereas SRM-MS quantified all 
proteins. In some control samples, specific proteins were below the limit of detection in both 
assays and so quantification was not possible. Quantification by both QWB and SRM-MS 
resulted in similar relative quantification between SPP and control samples; moreover, protein 
fold changes were in the direction expected, in all proteins except cystatin C increased in SPP 
samples (Figure 5.25). Absolute quantification values, though, were remarkably different 
between the two platforms (Figure 5.26). Other than for ceruloplasmin, values obtained by 
QWB were substantially lower for cystatin C (~ 8-fold lower) and cathelicidin (~ 20-fold). As 
the differences were not consistent across all proteins, it was unlikely that there was a 
systematic error in M-DOSCAT-S concentration causing the discrepancy. It was hypothesised 
that proteases in CSF were degrading the DOSCAT at either the peptide or protein level, 
leading to inaccuracies in SRM or QWB assays respectively. To assess potential proteolysis 
at the peptide level, digested M-DOSCAT-S was spiked into four different undigested CSF 
samples at RT, and samples removed at 0, 1 and 4 h into 5% TFA for instant protein 
denaturation. SRM-MS analysis of the samples revealed that whilst there was a drop in signal 
intensity between the digest starting material and the first time point in the incubation, there 
was no drop in signal intensity throughout the incubation for most peptides (Figure 5.27). For 
some peptides, the signal intensity fluctuated or appeared to increase throughout the 
incubation, however this can be ascribed to inaccuracies in the measurement of peak area 
Chapter 5: DOSCAT technology to quantify of putative pneumococcal meningitis biomarkers  
 
157 
 
due to a low signal to noise ratio. The initial signal loss can be attributed to adsorption of 
peptide to plastic tubes and tips during the spike-in process, so it was concluded that CSF 
was not proteolysing M-DOSCAT-S peptides. To investigate proteolysis at a protein level, 
intact M-DOSCAT-S was incubated with CSF at room temperature and at 0, 1 and 4 h samples 
were removed, incubated with Wes sample buffer at 95°C to inhibit proteolysis and 
subsequently analysed by automated capillary WB (Figure 5.28). When contained within a 
CSF matrix the signal intensity for M-DOSCAT-S was decreased and the electrophoretic 
mobility shifted compared to M-DOSCAT-S on its own. There was no decrease in signal 
intensity throughout the incubation, however. As M-DOSCAT-S had been spiked into a 
relatively high concentration of CSF (diluted 5-fold dilution against 40-fold dilution used for the 
standard curve samples), it was likely that the mobility shift of M-DOSCAT-S was due to 
increased total protein concentration and matrix effect rather than proteolysis of the standard. 
Proteolysis of M-DOSCAT-S at both a peptide and protein level was therefore ruled out as an 
explanation for the QWB results.  
 
 
Figure 5.25 Target protein quantification summary. Quantification data for each target protein 
resultant from the analysis of SPP and control CSF by SRM-MS and automated capillary WB using 
M-DOSCAT-S as a calibrant. Boxplots display median, 25% and 75% quantiles, and spread of data. 
Individual data points represent specific CSF samples. Blank plots with ‘no data’ represent occasions 
in WB analysis where the antibody did not detect endogenous protein in any CSF sample. 
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Figure 5.26 Platform comparison of absolute quantification. Quantification values for each 
sample as derived by SRM-MS and QWB were plotted against one another and modelled using linear 
regression. Gradient of the slope and r2 values are displayed for each plot.  
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Figure 5.27 Incubation of Q-peptides with active CSF. Digested M-DOSCAT-S incubated with 
CSF for 0, 1 and 4 h alongside a digest independent of CSF incubation (SM) was analysed by SRM-
MS. Displayed are mean values of signal intensity for each Q-peptide ± standard error (n = 4). 
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Figure 5.28 Incubation of M-DOSCAT-S with active CSF. M-DOSCAT-S alone and M-DOSCAT-
S spiked into SPP CSF (#30) was incubated for 4 h at RT, with samples removed at 3 time points. 
Top panels: pseudo gels resultant from the capillary western blot analysis of WB of each time point 
sample using antibodies against two target proteins. Bottom panels: Chemiluminescent signal 
intensity as calculated by Compass software for each time point sample. 
 
 
Two other datasets resultant from the related proteomics study (Gómez-Baena et al., 2017) 
were available to compare quantitative values generated by M-DOSCAT-S. Hi3 label-free 
quantification was possible using the MS data as samples had been mixed 1:1 with 50 fmol/µL 
of yeast alcohol dehydrogenase as a reference protein and quantification performed as 
previously described (J. C. Silva et al., 2006). The study also contained data from QWB 
experiments, using full length recombinant protein standards for calibration. These QWB 
experiments used the same set of CSF samples as described earlier (15 SPP and 20 control), 
whereas the label-free experiments used a different set of 16 CSF samples (8 SPP and 8 
control). Quantification values for SPP samples only were averaged across all samples and 
compared between platforms (Figure 5.29). For all six proteins, concentrations obtained by 
Hi3 quantification and SRM-MS agreed very well. Quantitative values derived by QWB, 
however, were much more variable in a protein dependent manner. Results for QWB 
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calibrated by recombinant standards (QWB-std) were significantly higher compared to MS 
values for cathelicidin, cystatin C and S100A9, but were within the same range for 
ceruloplasmin and myeloperoxidase. Conversely, values for QWB calibrated by M-DOSCAT-
S (QWB-DOSCAT) were significantly lower for the same three proteins, but values for 
ceruloplasmin were similar to those obtained by MS.  
The elevated concentrations measured by QWB-std could be due to inaccurate concentrations 
of recombinant standards. If the standard concentration was actually lower than thought, 
erroneously high values of analyte would be measured. To test for this, three of the 
recombinant proteins that were used in the QWB experiments were analysed on an SDS-
PAGE gel alongside BSA and affirmer standards, with samples prepared by adding sample 
buffer straight to aliquots to minimise losses (Figure 5.30).  Affimers are based on cystatin C 
structure and so were deemed more suitable to act as a standard for cystatin C. BSA was 
used as a standard for the other two proteins. The affimer aggregated despite prior incubation 
with DTT and heating with sample buffer; to account for this the fraction of monomer intensity 
out of the sum of the five main aggregation species was used to calculate monomer 
concentration from the total protein concentration. Concentration of protein standards were 
calculated to be much lower than expected, compared to the amounts that were thought to be 
loaded onto the gel. Using these data, correction factors were calculated for each recombinant 
protein and applied to the QWB-std results (Figure 5.31). The corrected values agree much 
better with the SRM-MS and Hi3 results, suggesting that the abnormal QWB-std results were 
due to incorrect standard concentrations.  
These results do not account for QWB-DOSCAT results; incorrect standard concentration is 
not a likely explanation as differences in measured concentration are not uniform across all 
proteins. Standard curves generated in QWB-DOSCAT and QWB-std (using corrected 
concentrations) were compared, revealing a discrepancy between the two (Figure 5.32). The 
differences in slopes (i.e. much higher signal for DOSCAT for the same amount of protein in 
cathelicidin and cystatin C) match the relative difference in measured analyte concentration 
between QWB-DOSCAT and QWB-std. It should be noted that data presented here are from 
recombinant proteins not treated with DTT/IAM, although the conclusions as still valid as such 
treatment would only reduce rather than increase signal.  
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Figure 5.29 Comparison of quantification by different datasets. Protein level quantification 
values as calculated by Hi3 methodology using a label-free MSE dataset, QWB calibrated by both 
recombinant protein standards (QWB-standards) and M-DOSCAT-S (QWB-DOS), and SRM-MS 
calibrated by M-DOSCAT-S. Data presented are mean values from SPP samples only ± standard 
error (n = 15).  
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Figure 5.30 Quantification of recombinant standards. Recombinant Cystatin C, cathelicidin and 
ceruloplasmin alongside albumin and affimer standards were analysed on a 12% SDS-PAGE gel. 
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Figure 5.31 Comparison of quantification from different datasets with correct protein standard 
abundances. Protein level quantification values as calculated by Hi3 methodology using a label-free 
MSE dataset, QWB calibrated by both M-DOSCAT-S and recombinant protein standards with 
corrected concentrations, and SRM-MS calibrated by M-DOSCAT-S. Data presented are mean 
values from SPP samples only ± standard error (n = 15). 
 
 
 
 
Figure 5.32 Standard curves in QWB from M-DOSCAT-S and recombinant standards. Standard 
curves resultant from dilution series of recombinant protein standards and M-DOSCAT-S analysed 
by cathelicidin, ceruloplasmin and cystatin C antibodies in automated capillary WB, processed using 
Compass software.  
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Until this point DOSCAT technology had been used to quantify a set of well characterised 
target proteins in a relatively small sample size. This work both demonstrates the effectiveness 
and highlights the issues of DOSCAT technology to calibrate a different set of six potentially 
clinically relevant proteins in human samples over an expanded sample size. In contrast to 
the NF-κB work, SRM-MS proved more effective in detecting and quantifying target proteins. 
This was due to good peptide selection and under-performing antibodies that either did not 
detect proteins with required sensitivity or had poorly characterised epitopes so that M-
DOSCAT-S was not detected. Protein fold changes measured in both assays were consistent 
between one another and with previous measurement by quantitative proteomics and western 
blotting (Gómez-Baena et al., 2017), adding confidence to the DOSCAT methodology and 
further validity to the biomarker panel as a diagnostic test. There is still further work required 
to validate the biomarker panel for use as a diagnostic test, however. Future validation studies 
will have to be carefully designed and used with an increased sample size so that the study is 
of sufficient statistical power for results to be deemed clinically relevant (Alonzo et al., 2002; 
Skates et al., 2013).  
In addition to further demonstrating the utility of DOSCAT technology in a clinically relevant 
area, this work also compares absolute values derived by DOSCAT calibration to values 
generated by Hi3 quantification and QWB calibrated by recombinant standards from datasets 
produced in a previous complementary study (Gómez-Baena et al., 2017). This aids in 
improving accuracy and evaluating the true concentration of the target analytes in CSF. The 
comparison highlights a substantial difference in absolute quantification values derived from 
QWB calibrated by M-DOSCAT-S and the three other independent measurements. Why this 
is the case is difficult to understand. If an inaccurate amount of M-DOSCAT-S was loaded in 
QWB experiments so in actuality there was more standard loaded than thought, quantification 
of the analyte would be artificially low, as was observed in the results. This is unlikely, though, 
as inaccurate standard concentration would lead to a systematic error in analyte quantification 
that would be consistent across each protein, which was not reflected in the data (Figure 5.26). 
Moreover, M-DOSCAT-S concentration was carefully determined against a Glu-Fib peptide 
standard and workflows were designed to minimise losses of standard. 
The same amount of M-DOSCAT-S or recombinant protein effects a very different signal in 
capillary WB when the same antibodies are used (Figure 5.32). The presence of extra 
unexpected antibody binding sites in the M-DOSCAT-S sequence or antibodies binding to the 
epitope in M-DOSCAT-S with greater affinity than the recombinant standard (perhaps due to 
interference from nearby residues) would explain the different signals. However, both 
cathelicidin and cystatin C antibodies are monoclonal, therefore would not be expected to 
contain populations of non-specific antibodies that may bind to other regions in the DOSCAT 
like a polyclonal antibody might. Incidentally, the ceruloplasmin antibody was polyclonal, yet 
the same differences in signal were not observed. Additionally, the full sequence for Cystatin 
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C was included in the M-DOSCAT-S sequence so the epitope sequence context was the same 
between standard and analyte.  
Another explanation, based on previous observation based on automated capillary WB of 
DOSCAT proteolytic fragments, is that epitopes in smaller proteins could be compromised by 
UV cross linking of residues to the capillary surface. If a greater proportion of the epitope in 
endogenous analyte has been compromised by this chemical modification, then the resultant 
signal would be lower, accounting for the observed results. Both cystatin C (15.8 kDa) and 
cathelicidin (19.3 kDa) are much smaller than M-DOSCAT-S (65.0 kDa), whereas 
ceruloplasmin (122.2 kDa), for which M-DOSCAT-S signal was lower than recombinant 
protein, is larger, adding further credence to this hypothesis. Whilst this is far from conclusive 
evidence, it does warrant further investigation. Classic western blot analysis of the same molar 
amounts of standard and M-DOSCAT-S will allow for the comparison of signal when there is 
no possibility of epitopes being affected by modifications.   
By comparisons with other datasets, it might be concluded that QWB-DOS data are not 
accurate, however, values obtained by the other three methodologies agree well. Although 
the remaining three approaches all offer slightly different quantitative values, they are in 
general agreement. SRM-MS calibrated by M-DOSCAT-S is arguably the most robust data 
set and so can be the considered the most accurate. This is because quantification is based 
on two or three peptides, each measured by multiple transitions and against a well 
characterised stable isotope labelled standard.  
The overall agreement of Hi3 quantification with the other datasets is consistent with previous 
findings comparing Hi3 with quantification using QconCATs and immunoassays (Smith et al. 
2016; Kramer et al. 2015; Carroll et al. 2011). Hi3 quantification is consistently lower, though, 
and the difference is more pronounced in smaller protein such as S100A8 and S100A9. 
Underestimation of protein levels using Hi3, especially in smaller proteins, has previously been 
reported (Carroll et al. 2011; Kramer et al. 2015; Ahrné et al. 2013), and can result from 
miscleaves or poor ionisation efficiencies in the most intense three peptides selected. Smaller 
proteins would have fewer potential peptides to choose from, so these effects would be 
amplified leading to less accurate quantification. It has also been shown that different 
bioinformatic pipelines can affect accuracy of the data (Ahrné et al., 2013; Rami et al., 2017), 
so it is possible that reprocessing of the data may yield a different result. 
Although performing poorly when calibrated by M-DOSCAT-S, QWB values calibrated by 
recombinant standards agreed fairly well with both MS methodologies, validating the use of 
automated capillary WB for quantitative assays. This was only true, though, after protein 
standard concentrations were corrected from the inaccurate information given by the 
manufacturers, demonstrating the need to perform in-house validation of protein 
concentration. It would be anticipated that the values for S100A9 would decrease if calibrant 
Chapter 5: DOSCAT technology to quantify of putative pneumococcal meningitis biomarkers  
 
167 
 
concentration was also adjusted; this was not possible here as stocks of the standard had 
been exhausted. 
5.3. Conclusions 
The work presented in this chapter is another example of how DOSCATs can be used as 
multiplexed standards to facilitate the quantification of target proteins. Building on previous 
work that has demonstrated the proof of principle and initial success of the approach, a 
DOSCAT has now been used to quantify a putative biomarker panel in complex human CSF 
samples. This is significant given the trend towards using panels of biomarkers rather than 
single proteins; it is easy to see the benefits a multiplexed standard would have over individual 
protein or peptide standards in the routine quantification of such panels. Having said this, the 
difference in quantification values obtained by SRM-MS and automated QWB is a result that 
requires resolution to ensure future confidence in using DOSCATs for calibration. Forthcoming 
studies should seek to determine whether this difference in results between analytical 
platforms is due to inadequacies in the DOSCAT principle and/or design, or if it is an artefact 
of using the automated capillary WB system, Wes. If it is the former, a re-think on epitope 
selection, experimental design and workflows will be required and if it is the latter the use of 
classic WB over automated capillary WB must be considered, unless a workaround can be 
found. 
Despite the WB results requiring further clarification, SRM-MS data agreed very well with 
label-free MS and QWB datasets from a previous study. This gives general confidence in 
automated capillary WB as a platform for quantification, even if data presented in this chapter 
exposes some unresolved issues. For some proteins, SRM-MS and Hi3 data agree so well 
that one could question the purpose of performing time-consuming targeted assays using 
expensive stable isotope labelled reagents when fast, seemingly accurate quantification is 
possible by label-free proteomic approaches. Indeed, studies evaluating the merits of label-
free quantification have found it performs favourably in terms of accuracy and reproducibility, 
although not to the same level as SRM-MS (Distler et al., 2016; L et al., 2013; Lawless et al., 
2016).  However, clinical validation of biomarkers, to date almost exclusively performed by 
ELISAs (Drabovich et al., 2015), requires a level of accuracy and reproducibility that label-free 
workflows cannot provide. Therefore, despite how well label-free workflows can perform, 
targeted MS and immunoassay approaches alongside highly quality and well characterised 
reference standards such as DOSCATs are still required and will continue to be in the future. 
Throughout the optimisation work described in this chapter more unforeseen challenges in the 
deployment of DOSCATs have been recorded, namely the formation of higher order 
aggregates post-purification. A viable strategy has been devised to overcome this issue, using 
DTT and IAM to reduce and alkylate thiol groups in cysteine residues so that they cannot form 
disulphide bonds, which is postulated to cause the aggregation. The knowledge that 
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aggregation is a potential problem, though, can aid the design process in future DOSCAT 
builds in an attempt to minimise the possibility of aggregation occurring in the first place.  
Some of the aims of the chapter were not realised, namely the generation of an anti-DOSCAT 
antibody and a satisfactory conclusion to the restricted proteolysis work. The failure of the 
immunogen protein to express prevented the development of the antibody from ever being 
attempted. As some of the commercial antibodies failed to detect DOSCAT, it would have 
been interesting to see if an anti-DOSCAT antibody could have fared better. It would be 
certainly worth attempting expression of the immunogen again in future work, using the 
sequence reshuffle or cell-free expression strategies described earlier. Optimising conditions 
for successful restricted proteolysis should also be a goal for work in the near future. As well 
as realising the aims of giving improved flexibility and multiplexing capabilities, WB of 
proteolytic fragment, with the same epitope but smaller size of intact DOSCAT protein, could 
resolve the issue of whether signal is reduced in smaller protein when analysed by capillary 
WB. This could have big implication for further use of automated capillary western blotting in 
the DOSCAT workflow.  
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Chapter 6: Commercialisation of DOSCAT technology 
6.1. Introduction 
6.1.1. Trends in technology transfer 
It has long been acknowledged that the commercialisation of publicly funded, university based 
research delivers considerable economic and social benefits in terms of industrial growth, job 
creation, increased funding opportunities for universities the creation of products and services 
that improve public health (Caulfield et al., 2015; Salter et al., 1999). Commercialisation of 
academic research is most often achieved through licensing of intellectual property (IP) to 
existing companies or setting up new spin-out companies. There are now numerous examples 
of products arising from basic scientific research including recombinant protein expression 
technology (Ratzkin, 1977; Vapnek et al., 1977), the ‘super material’ graphene (Novoselov et 
al., 2004) and CRISPR-CAS9 gene editing (Jinek et al., 2012).   
The positive effects of commercialising research have not gone unnoticed by world 
governments; indeed there has been a concerted effort at a statutory and institutional level to 
encourage the transfer and commercialisation of public research in order to drive economic 
growth (Mowery et al., 2006). A fundamental instrument for the commercialisation of a 
technology by universities and researchers is the patenting of IP linked to an invention. Prior 
to the 1980s, patents derived from public research were owned by the government, who 
licensed out the technology on a non-exclusive basis. This resulted in a low take up of product 
commercialisation (due to non-exclusivity), with only 5% of patents owned by the USA 
government being used by industry (Schacht, 2012).  The legislative groundwork to overcome 
this was contained in the Bayh-Dole Act, passed in the USA in 1980 (Public Law 1980). The 
Act permitted universities or small companies to have ownership of an invention derived from 
public funding rather than the government. This enabled institutions to form exclusive licensing 
agreements with industry, incentivising them to commercialise technology to generate 
revenue streams. Moreover, the private sector had a greater incentive to develop inventions 
as they have the exclusive rights to market them, and governments benefit from increased tax 
revenue generated from a stronger private sector. 
Since the passing of the Bayh-Dole Act the number of patents of issued to universities 
increased exponentially (Berkeley, 2004) and the legislation has now been replicated in most 
countries across the world (Meyer et al., 2007; OECD, 2013). Since then governments have 
introduced additional regulation to create a clear legal framework for IP ownership and extra 
policies to incentivise universities to file patents. For example, some government have 
introduced a legal ‘grace period’ where disclosure of an invention in a journal or conference is 
permitted 6-12 months prior to applying for a patent (Edmondson, 2013). Although this is a 
growing trend it is not yet embraced by all countries, so great care should still be taken prior 
to disclosure depending on location.   
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As well as IP legislation, governments have also been proactive in forming bridging 
organisations to facilitate the transfer of technology and knowledge between academia and 
industrial partners. The formation of technology transfer offices (TTO) has taken place in 
nearly all research institutions and they have been credited with the increase in IP ownership 
and entrepreneurial activity in institutions (Grimaldi et al., 2011; Siegel et al., 2007). At a basic 
level, TTOs act to identify commercialisation opportunities arising from academic research 
and assist in the transfer of this knowledge to the private sector, where it can be translated 
into products and services. This is commonly achieved by performing administrative tasks 
such as patent filing and IP portfolio management, however some TTOs have expanded their 
activities to providing seed funding for start-up companies and proof of concept studies 
(OECD, 2013). 
As well as government policy encouraging commercialisation, there has also been a push at 
the institutional level to change the culture within the academic community to encourage 
researchers to be more entrepreneurial, disclose inventions and begin the commercialisation 
process. Disclosure refers to a confidential document describing the invention in detail that 
can be used by the university or a patent attorney to determine whether patent protection can 
and should be sought. Researchers may not disclose their inventions due to lack of 
commercial-mindedness (i.e. not realising the commercial value of their research) or though 
concerns about delays to publications or personal perception by academic peers (Wright et 
al., 2012). One obvious way to encourage researchers to disclose is to offer a financial 
incentive. Most often a rate of revenue generated from IP will be offered, although other 
incentives such as a lump-sum payment, promise of additional funding or career progression 
have also been used (Lach et al., 2008; Zuniga, 2011). Another tack institutions have taken is 
to foster an entrepreneurial culture among staff and students.  Workshops, mentoring, 
seminars and business plan competitions, such as Biotech YES in the UK (BBSRC, 2017), 
have all been used to educate and create skills for entrepreneurship (A. Nelson et al., 2010).  
6.1.2. Intellectual property rights 
Intellectual property refers to an idea or creation of the mind, and is assigned to an individual 
by law. In the process of scientific research it is inevitable that IP will be created, which for the 
purpose of commercialisation needs to be properly protected and managed from an early 
stage, much before any products come to market. Therefore, IP strategy, which simply refers 
to a plan to acquire and extract maximum value from IP, is a vital consideration during the 
commercialisation process. There are several types of intellectual property rights (IPRs) 
(summarised in Table 6.1) that can be granted to the creators of IP, affording protection and 
exclusivity when bringing the idea to market. Usually more than one type of IPR is employed 
in an IP strategy.  
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Table 6.1 Most common types of intellectual property rights (based on UK law). 
IPR type Protection offered Cost Length of 
protection 
Patent Exclusive right to 
inventions and products 
Filing, legal and 
ongoing renewal fees 
can total £000s 
20 years from 
filing date 
Copyright Original works e.g. 
literacy creations, 
video/sound recordings, 
art, software 
Free Life of the creator 
+ 70 years 
Trademark Product names, brands or 
company logos 
UK registration is 
approximately £200, 
but with international 
registration and 
ongoing legal fees 
can be £1000s 
Must be renewed 
every 10 years 
Registered 
designs 
How a product appears 
e.g. specific packaging 
including colours, 
patterns etc.  
Up to £150 Must be renewed 
every 5 years up 
to 25 years 
Unregistered 
design rights 
Shape or orientation of an 
original design  
Free 10 years after 
product was first 
sold or 15 years 
after it was 
created 
Trade 
secrets 
A formula, process, 
design etc. that is not 
readably identifiable 
without confidential 
‘know-how’ 
Free  As long as a 
company can 
guard its secret 
 
 
Patent protection offers a monopoly in the market for a fixed period of time, and so gaining 
one is usually (although not exclusively) a key strategic step in the successful 
commercialisation of an idea. A patent acts as a contract between state and inventor, granting 
exclusive rights to manufacture and sell an invention. In return for this, a full and detailed 
disclosure of the invention must be made available in the public domain. There are, however, 
criteria that must be met for a patent to be granted. Firstly, the invention must be novel, which 
is ascertained by assessing it against the “State of the Art”. This means everything that it is 
the public domain in any way (e.g. written, oral, in use) before the date the patent is filed. This 
can include the invention itself, so if it is disclosed to the public domain (e.g. via publication, 
conference talk or poster etc.) a patent cannot be filed. Secondly, the invention must contain 
Chapter 6: Commercialisation of DOSCAT technology 
172 
 
an inventive step. This means that it must not be obvious to a skilled person trained in the art 
who has knowledge of the current state of the art. Inventiveness can be hard to assess and is 
to an extent subjective, so the counsel of a Patent Attorney is often sought. Finally, an 
invention must have an industrial application and be in a tangible, physical form. It cannot be, 
for example, a mathematical theorem, a computer program or an artistic piece of work.  
If an invention is deemed suitable a patent application can be filed and the process can begin. 
The application process is long and costly, taking several years between filing and granting of 
the patent (Figure 6.1). During the application process a detailed description of the invention 
with claims and technical drawings is submitted to the Patent Office, usually with the 
assistance of a Patent Attorney. Initial searches against the prior art are carried out to establish 
novelty and inventiveness, and if no infringements are found the application is taken forwards. 
If the invention is to be patented in international territories, this must be done within 12 months 
of the original application. Further, more detailed, examination of the application then takes 
place before publication and eventual granting of the patent can occur. Once the patent is 
granted ongoing costs are incurred through renewal fees for each territory in which the patent 
is filed and any legal challenges that may have to mounted because of third party infringement. 
Owing to the time and financial implications businesses (particularly small ones) must consider 
very carefully whether it is worth pursuing patent protection. A lot of money can be invested 
without the outcome of the patent being granted and, if granted, enforcement may not be 
possible due to the substantial legal costs involved. It is therefore worth examining whether 
other forms of IPR can be used to protect the idea.  
Copyright and unregistered design rights are automatically assigned to a creation; however, 
they only offer protection for written/artistic works and original product shapes respectively. 
Trademarks and registered design rights can, for a relatively small fee, act to protect a strong 
brand identity for a product in terms of product names and logos and how the product 
packaging appears. These IPRs can be very valuable in certain industries (e.g. music, as 
songs cannot be patented), or if a product has an extremely strong brand that elicits a high 
level of consumer trust and confidence (which may confer an advantage over any ‘copycat’ 
competitors). However, these rights will not prevent a competitor using the fundamental idea 
of an invention in a different form. A patent may not be necessary if an invention relies on a 
formulation or process that is not obvious or relies on a large amount of research and 
development. In these cases, keeping this a trade secret will prevent competitors from copying 
the idea. However, this may be difficult in a publicly funded academic setting as there is 
pressure to publish all research outcomes in journals. 
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6.1.3. Aims  
DOSCATs have the potential to be commercialised into a valuable product within the life 
science and biotechnology industry. The technology has been developed in collaboration with 
an industrial partner, Badrilla, a life sciences company that specialises in producing high 
quality affinity reagents.  
This chapter aims to look at some of the key considerations to make when devising a strategy 
to exploit DOSCATs for commercial gain. The process for protecting DOSCATs though 
intellectual property rights will be explored, as will the procedure and challenges in bringing 
DOSCAT technology to market.  
 
 
 
 
Figure 6.1 Timeline from patent filing to granting in the UK. Figure replicated from Albright 
IP (2017). 
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6.2. DOSCAT IP strategy 
For DOSCAT technology there are multiple types of IPRs with which it can be associated. 
Patent protection would be the most valuable in that it would prevent competitors from copying 
the idea, thus maximising the commercial opportunity. This section describes a series of work 
carried out to investigate whether DOSCAT was a patentable invention, and what form the IP 
strategy for the product should take. 
As previously described, an invention is patentable only if it is novel and there is no prior art 
relating to it. Before embarking on a costly patent application process, it is vital to perform 
searches to ascertain the state of the IP landscape and evaluate if there are any existing 
disclosures in the scientific literature or patent library that would prevent a patent being 
granted, or restrict the freedom to operate; that is the right to market a technology without 
infringing on another’s IP. 
The first step taken in embarking on the prior art search was to define the core technology of 
the invention and list all possible uses. From this, relevant search terms can be easily 
identified. For the case of DOSCATs, the core technology was defined as a calibration 
standard material that comprises calibrators for assays conducted on different analytical 
platforms. This does not necessarily limit the invention to SRM and western blotting, so every 
possible use for DOSCATs were thought of. Multiple variants of immunoassays and targeted 
mass spectrometry were identified, which were included in searches and could be 
encompassed in the wording of a future patent (Table 6.2).  
As described extensively in this thesis DOSCAT can be used in western blotting with a variety 
of detection methods and platforms, as well as with targeted SRM-MS assays. Additionally, 
although not yet tested, it is anticipated DOSCAT could also be used in other targeted MS 
assays such as PRM. ELISAs are an often-used quantitative immunoassay technique and 
DOSCATs in their current configuration would be compatible with a direct ELISA experiment. 
Many ELISA assays use the sandwich format, in which two antibodies are used; one to capture 
the antigen and another to detect it. This will require two separate epitopes or domains to be 
incorporated into the DOSCAT standard. The epitopes in the standard must be available to 
bind the antibodies simultaneously and in an equivalent manner compared to the endogenous 
protein.  For this, strategies to fold DOSCAT so that it is equivalent to the endogenous protein 
must be developed and evaluated.  
Additionally, DOSCATs could be used in planar and suspension multiplex ELISA assays 
described in detail in Chapter 1. The same principle applies that DOSCAT would need to 
contain epitopes for capture and detection antibody recognition. Moreover, it is likely that 
multiple DOSCAT proteins will be required if many analytes are to be measured in multiplex.  
Guided by the definition of the core technology and the list of uses for DOSCAT, search terms 
were derived and the literature was searched. This returned numerous results for each term 
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(Table 6.3); for some there were too many results to analyse so only top 50 results were 
analysed when results were ordered by ‘relevance’.  Each paper was analysed to assess 
whether it was pertinent to DOSCAT technology and if so whether it was likely to constitute 
prior art that could negatively affect patent granting. Papers were considered pertinent if they 
combined immunoassays and mass spectrometry in a single workflow to improve data quality 
or if they described a single calibration material in a multiplexed assay. Contained in the results 
were multiple descriptions of immuno-MS workflows (described in Chapter 1), in which protein 
or peptide antibodies are used to enrich for specific proteins prior to targeted SRM analysis 
using SIL peptide or protein standard. Although these bring the concept of MS and 
immunoassay together there is no quantitative measurement by immunoassay and no novel 
calibration material is used and so do not anticipate the DOSCAT concept. There were 
numerous examples of both immunoassay and MS data being compared to assess the 
accuracy of the data, but these data were always acquired independently and there was no 
mention of combining the two workflows in a single experiment. No novel calibration material 
to allow for quantification by MS and immunoassay could be identified in any of the results. 
 
 
Table 6.2 Technologies to which DOSCAT could be applied. 
Application Comments 
Western blot Describes all variations of western blots e.g. different 
transfer (wet, semi-dry), detection (ECL, fluorescent) 
and imaging (film, CCD camera) methodologies. Also 
includes newer automated capillary based Simple 
Western technology. 
ELISA 
DOSCAT protein will require additional engineering Planar multiplex assay 
Suspension multiplex assay 
Targeted mass spectrometry Stable isotope labelled DOSCAT digested and 
analysed at a peptide level; applicable in a range of 
MS methods such a SRM, PRM or SWATH 
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Table 6.3 DOSCAT prior art search. Search terms and number of results for literature search using 
Web of Science, using the Core Collection database with all Citation Indexes from 1900 to 2017, 
accurate as of September 2017. 
Web of Science search term Results 
TOPIC: (absolute quant*) AND TOPIC: (mass spec*) 4,936 
TOPIC: (multiplex* immunoassay) 2,533 
TOPIC: (selected reaction monitoring) AND TOPIC:(mass 
spec*) AND TOPIC: (quant*) 
2,505 
TOPIC: (multiplex* immunoassay) AND TOPIC: (quant*) 824 
TOPIC: (targeted mass spec*) AND TOPIC: (selected reaction 
monitoring) 
800 
TOPIC: (orthogonal calibration standard) 349 
TOPIC: (absolute quant* western blot*) 315 
TOPIC: (multiplex* immunoassay luminex) 216 
TOPIC: (protein standard concat*) 130 
TITLE: (quant* western blot*) 130 
TOPIC: (quant* multiplex standard calibration) 78 
TOPIC: (QconCat) 76 
TOPIC: (multiplex* immunoassay luminex) AND TOPIC: (quant*) 70 
TOPIC: (western blot calibration) 63 
TOPIC: (absolute quant*) AND TOPIC: (immunoblot) 40 
TOPIC: (multiplex* protein calibration standard) 36 
TOPIC: (multiplex* immunoassay) AND TOPIC: (absolute quant*) 28 
TOPIC: (western blot calibration curve) OR TOPIC: (immunoblot 
calibration curve) 
27 
TOPIC: (multiplex* immunoassay calibration standard)  22 
TOPIC: (epitope concat*) 21 
TOPIC: (dual calibration standard) AND TOPIC: (protein quant*) 17 
TOPIC: (orthogonal calibrat* standard quant* assay)  16 
TOPIC: (orthogonal multiplex calibration standard) 14 
 TOPIC: (protein quant* calibration standard) AND TOPIC: (orthogonal) 12 
TOPIC: (parallel multiplex calibration standard) 11 
TOPIC: (multiplex* immunoassay luminex) AND TOPIC: (absolute 
quant*) 
3 
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Patent searches were carried out using the same search terms as the literature search. The 
results of the patent search unveiled 8 key patents that could be judged as prior art and so 
necessitated further evaluation (Table 6.4). 
Two of the patents were anticipated to appear in the search. The first (EP 1904517) relates to 
QconCAT technology, which has been described and discussed at length in previous 
chapters. The patent protects the idea of an artificial protein comprising a sequence of 
quantotypic peptides separated by an enzymatic or chemical cleavage sequence.  The other 
patent, held by Badrilla (EP 1711835), describes a scaffold material containing multiple sites 
or domains to which a target moiety is covalently attached. The moiety could be a protein, 
peptide, antibody epitope, or a sequence of nucleic acids, and is designed to mirror a target 
moiety present in the sample. Therefore, the entire structure can be used as a multiplexed 
calibrator for numerous different assays. 
Patent US 20140322732 describes an assay or kit for the diagnosis, therapy, prognosis or 
patient stratification of prostate cancer based a biomarker panel of four proteins contained in 
human serum, blood or plasma samples. It was deemed relevant as it describes a biomarker 
discovery workflow using label-free discovery proteomics followed by a validation step in 
which targeted MS or an immunochemical assay could be used. In the patent text SRM, 
western blotting and ELISAs are all specifically mentioned. This patent comes close to 
anticipating the DOSCAT concept as it proposes linking MS and immunoblotting as orthogonal 
techniques for biomarker validation, despite each technique being employed independently 
from another. Calibration standards are mentioned for each technique but there is no 
reference of unifying them to combine the assays. 
Two patents in the list are focussed on immuno-MS; that is the selection of proteins or peptides 
by antibodies (or other affinity reagents) prior to MS analysis. US 20120171782 describes the 
advantages of immuno-MS in that it offers an extra dimension of selectivity compared to one 
assay alone. It also depicts how the assay could be quantitative if an internal reference species 
is combined with the sample. The patent offers protection for the immuno-MS workflow, where 
proteins are captured, eluted, and analysed by MS at the protein or peptide level. US 
20100267069 builds on this, but specifically protects MSIA (mass spectrometric 
immunoassay) tip technology. Affinity reagents are covalently bound to porous solid supports 
that are contained within pipette tips through which sample can be passed and subsequently 
eluted for MS analysis. This increases the throughput and allows for automation of immuno-
MS assays. In both these inventions the concept of immunoassays and mass spectrometry 
have been combined, however, analytical measurements are only ever made by MS. Although 
the addition of reference standards for quantification is discussed, there are no claims in the 
patents for a reference standard that can act across the two techniques. It is therefore a 
tandem use of the two techniques rather than an orthogonal use, and so these patents were 
not considered to anticipate the DOSCAT concept.   
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The other inventions are a step beyond immuno-MS as they use both immunoassay and MS 
as an analytical technique to detect and quantify proteins. US 20080003599 describes a 
biological microchip for the multiplexed analysis of compounds. The microchip comprises an 
array of three-dimensional hydrogel elements, each containing an immobilised affinity ligand 
for immunoassay analysis. Compounds can be captured on the microchip in parallel and 
subsequently analysed in situ by sequential techniques such as immunoassay, MALDI-TOF 
MS and PCR.  
The invention contained in US 2007009292 constitutes a method for the detection and 
quantification of a specific protein isoform in a complex sample. A proteolytic peptide unique 
to the isoform is selected, the sample is them digested and the peptide detected by MS and/or 
immunoassay (ELISA, western blot, dot-blot are all specifically mentioned in the text) using 
anti-peptide affinity reagents.  For quantification, synthetic isoform-specific peptides would be 
used to build calibration curves for whichever assay was employed. 
US20110287446 discloses a novel device that contains an immunoanalytical section and a 
mass spectrometry section and is designed to eliminate the problem of cross-reactivity in 
immunoassay. The immunoanalytical section uses antibodies to capture target molecules and 
quantify them in the form of an ELISA. Quantification is achieved through recombinant 
standards that are contained within the device. Captured molecules are then released and 
subsequently analysed by mass spectrometry. This comprises identification of the target 
molecule plus any non-specific molecule that was captured by the antibody. If non-specific 
species are found by MS, the quantitative value derived by ELISA can be adjusted based on 
the ratio of specific analyte to non-specific contaminant.   
These three inventions are particularly pertinent with regards to DOSCAT technology as they 
explicitly advocate using both MS and immunoassay as analytical techniques to improve the 
identification and quantification of target analytes. In particular, the invention by Kanda et al 
illustrates an invention designed to improve the accuracy of an immunoassay by using an 
orthogonal technique. Calibration standards referred to in the patents comprise different 
material for each assay type e.g. recombinant protein for immunoassay and stable isotope 
labelled peptide or protein for MS analysis.  
In conclusion, the prior art search has revealed that combining immunoassay and MS analysis 
to improve performance is a known concept and practice. It must be assumed that a person 
skilled in the art would have knowledge of this. When this is taken in tandem with the 
description of multiplexed calibration standards for MS (Pratt et al) and immunoassay (Colyer), 
it could be reasonably argued that a skilled person motivated to find a more accurate method 
of assay calibration would combine the described teachings and arrive at a product akin to 
DOSCATs. Therefore, although novel, there cannot said to be a significant inventive step in 
the creation of DOSCAT technology, thus rendering the invention not patentable.  
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This decision gives clear guidance to the IP strategy for DOSCAT. Rather than pursuing patent 
protection for DOSCAT, protection could come from the Badrilla and Polyquant patents. Of 
course, collaboration and discussion between the two companies must take place so that 
Badrilla has the freedom to operate, and not risk litigation from infringement of another 
company’s patent. Additional IPR could come in the form of trademarking the DOSCAT names 
and any design rights that associated with the logo, brand and product design.   
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Table 6.4 Patents relevant to DOSCAT technology. 
 
 
  
Patent 
code/reference 
Title Inventors Reference 
US 
20140322732 
A1 
Method for biomarker and 
drug-target discovery for 
prostate cancer diagnosis 
and treatment as well as 
biomarker assays determined 
therewith 
Wilhelm Krek, Igor 
Cima, Rudolf 
Aebersold, Ralph 
Schiess, Thomas 
Cerny, Silke 
Gillessen 
(Thomas 
Cerny, 
2009) 
US 
20120171782 
A1 
Mass spectrometric 
immunoassay  
 
Randall W. Nelson, 
Peter Williams, 
Jennifer Reeve Krone 
(R. W. 
Nelson et 
al., 2011) 
US 
20100267069 
A1 
Analysis of proteins from 
biological fluids using mass 
spectrometric immunoassay  
Urban A. Kiernan, 
Eric E. Niederkofler, 
Kemmons A. Tubbs, 
Dobrin Nedelkov, 
Randall W. Nelson 
(Kiernan et 
al., 2003) 
US 
20080003599 
A1 
Biological Microchip for 
Multiple Parallel 
Immunoassay of Compounds 
and Immunoassay Methods 
Using Said Microchip  
Ekaterina Dary, 
Ekaterina 
Dementieva, 
Veronika 
Butvilovskaya, 
Alexandr 
Zasedatelev, Alla 
Rubina, Andrei 
Stomakhin, Elena 
Savvateeva 
(Angenedt 
et al., 
2002) 
EP1904517 Artificial protein for absolute 
quantification of protein and 
uses thereof  
Julie Pratt, Robert 
Beynon, Simon 
Gaskell 
(J M Pratt 
et al., 
2009) 
US 
20110287446 
A1 
Immunoanalytical method 
and system using mass 
spectrometry technology  
 
Katsuhiro Kanda, 
Makoto Nogami, 
Izumi Waki 
(Kanda et 
al., 2011) 
US 
20070092926 
A1 
Analysis of protein isoforms 
using unique tryptic peptides 
by mass spectrometry and 
immunochemistry 
Michail Alterman, 
Boris Kornilayev 
(Alterman 
et al., 
2006) 
EP 1711835 B1 Agents for and method of 
quantifying binding  
 
John Colyer (Colyer, 
2011) 
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6.3. Bringing DOSCAT technology to market 
Bringing a new technology to any market is a difficult task as potential customers must be 
convinced to change their existing practices and start using a new product. To maximise 
chances for success, target customers must be identified and their requirements understood. 
This purpose of this section is to critically interrogate the invention to define where the 
commercial value within it lies, and to discuss the work required to develop the technology 
into a marketable product that fulfils the target consumers’ needs.  
To fully exploit an ideas potential, careful though must be given to an invention’s applications, 
the fundamental uses or unique selling points (USPs) and all the conceivable ways the 
invention can be applied. Overlap between these areas delivers the benefit to the consumer 
that can be marketed and sold (Figure 6.2). As part of the prior art search strategy the 
applications for DOSCAT have already been listed (Table 6.2) and are summarised again in 
Figure 6.2. The USPs of DOSCAT are, that compared to currently available techniques and 
products, it confers improved data quality in terms of quantitative accuracy and precision, and 
that it increases the success of obtaining quantitative data (i.e. one platform can provide data 
if the other one fails). Also, using one standard to quantify multiple proteins is more financially 
economical for the end user. DOSCATs could be used in numerous different applications and 
industries. DOSCATs could be at the basic research level to, for example, quantify entire 
signalling pathways or protein subunits for complex stoichiometry analysis. They could also 
be used in quality controls processes to quantify protein contaminates in industrially produced 
samples or allergens in food products, for instance. Within the diagnostics field DOSCATs 
could be designed to quantify several proteins in a panel of biomarkers, thus creating a dual 
diagnostic assay with one standard. It may even be possible to create a point of care 
diagnostic kit with DOSCAT as the calibration standard for multiple analytes.  
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This exercise clearly defines a market, a consumer base and the motivation for a consumer 
to use the product. This must then be placed in the context of the market and the competition. 
The laboratory diagnostics market alone was worth $72 billion in 2012, with 5-10% annual 
growth (Wild et al., 2013). Although the market for calibration standards will make up a small 
percentage of this market, it is still a sizable area to tap in to if the consumer can be persuaded 
to use DOSCAT technology rather than competing techniques. Within the market the 
competition consists of reference standards that are identical or very close to the analyte (i.e. 
recombinant proteins), and of a known identity, concentration and purity. These standards can 
be grouped into one of three categories (Validation, 1998): 
1) Certified reference standards that adhere to the highest regulatory standard (primary 
standards) 
2) Commercially available standards from reputable companies (secondary standards) 
3) Custom made standards from non-commercial analytical laboratories 
Currently, DOSCATs would fall into group (3). Despite the advantages that DOSCATs can 
deliver, it is unlikely a consumer would switch from using current practices without clear 
evidence assays calibrated by DOSCATs can perform as well as what is currently on the 
market. Therefore, work would be required to validate the DOSCAT standard itself and the 
quantitative assays that DOSCAT is built for. 
A calibration standard must be well-characterised with respect to its identity, molecular weight 
and purity (Lee et al., 2009). This can be achieved with analytical methods such as HPLC and 
mass spectrometry. The standard must also be producible in sufficient amounts, with high 
consistency of production (i.e. low lot-to-lot variability). Stability of the standard should be well 
understood in terms of freeze-thaw cycles, short term exposure to room temperature and long 
term stability at storage conditions.  
Once characterised, the standard should be validated in the assay in which it will be used (in 
the case of DOSCAT, automated western blotting and SRM-MS). For diagnostic grade 
assays, there are key parameters that need to be assessed and determined: selectivity, 
sensitivity, accuracy and precision (Plant et al., 2014; Valentin et al., 2011; Wild et al., 2013). 
Each parameter must be individually tested and the results documented. 
Sensitivity  
Sensitivity is the level at which quantification is not possible due to noise in the system. It is 
defined by the lower limit of quantification (LLOQ), which is the lowest analyte concentration 
that can be measured above the system noise. This is determined by measuring serial 
dilutions of standard spiked into a suitable background matrix until the signal to noise ratio 
reaches a specific level. 
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Selectivity 
This is the ability to differentiate and quantify an analyte within a sample in the presence of 
other compounds. Selectivity can be evaluated by measuring at least six biological matrices 
both blank and with spiked in reference material at different concentrations. The blank matrix 
sample should not contain interferences and the reference material should be present at the 
LLOQ.  
Accuracy 
Accuracy describes the closeness of the measured value of a target analyte to its true value 
within a sample. It is determined by the analysis of samples containing known amounts of the 
analyte at a range of levels, with at least five repeat measurements at each concentration. At 
each concentration, the mean value should be within 15% of the actual value except for the 
LLOQ where it must not exceed 20%.  
Precision 
Precision encompasses both repeatability, that is variation when measurements are made 
one after the other with the same experimental conditions, and reproducibility, which describes 
variance when experiments are repeated by different analysts at another time and place. 
Precision should be determined by the repeated measurement of analytes in a biological 
matrix across the working range of the assay, using at least five measurements per 
concentrations. Acceptable precision at each concentration is 15% except for the LLOQ where 
it must not exceed 20%.  
For DOSCATs to be used in diagnostic grade assays, there would have to be stringent 
validation per the above criteria for each analyte and analytical platform. This would create a 
considerable amount of development work, but result in a product that is superior to its 
competitors. Alternatively, DOSCAT could be used at research grade, which requires less 
stringent validation of assays. This would limit the market, but perhaps allow for DOSCATs to 
a wider range of targets to be created.  
6.4. Summary and conclusions 
The transfer of technology from bench to a commercial product is important for social and 
economic reason, and has been encouraged by governments and universities by numerous 
laws and policies. DOSCAT is a prime example of a technology emerging from a university 
that can be commercialised and brought to market. Whilst the DOSCAT idea itself is not 
patentable due to insufficient inventiveness, it is protected by previous patents owned by 
Badrilla and Polyquant as well as various other types of IPR. From the identification of the 
target market and consumer base that DOSCAT will be marketed to, it is clear that there is 
further work required at a commercial level to demonstrate the stability and robustness of the 
assays that DOSCAT is built for. 
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7.1. General conclusions 
The primary aim of the work presented in this thesis was to demonstrate that DOSCATs could 
be designed, expressed and used to calibrate both quantitative western blotting and mass 
spectrometry assays, uniting the two orthogonal techniques into a single workflow. This has 
largely been achieved through two deployments of DOSCATs, first targeting the quantification 
of NF-κB proteins in SK-N-AS cell lysate and secondly, host proteins associated with 
pneumococcal meningitis in human CSF samples. This has required the development of three 
DOSCAT proteins, with each iteration further refining design principles in terms of epitope and 
Q-peptide selection and inclusion of restricted specificity proteolytic sites, as well as solidifying 
procedures for the successful expression and purification of the DOSCAT protein. As such, it 
should now be possible for a person skilled in the art to use the design principles laid out in 
this thesis to design, express and utilise their own DOSCAT to any set of target proteins.   
As with any new technology, the development of DOSCATs has not been problem-free, with 
several challenges emerging that required resolution. Some issues related to the behaviour 
of the DOSCAT protein itself, such as adsorption to surfaces and irreversible aggregation. 
DOSCATs are artificial proteins and so will not necessarily behave like proteins that have 
evolved within the constraints of their local environment. Similar issues have been extensively 
observed and documented with QconCAT technology (Brownridge et al. 2011; Simpson and 
Beynon 2012). Both adsorption and aggregation result in a discrepancy between the 
measured concentration of the standard and the amount of standard that is present in an 
assay so that there is less standard present than thought, resulting in an overestimation of 
analyte abundance. These issues were overcome by relatively trivial modifications to the 
DOSCAT production workflow; addition of Rapigest SF to buffer solutions to prevent excessive 
protein adsorption and the reduction and alkylation of DOSCAT immediately after purification 
to prevent the formation of disulphide bonds that enhance aggregation.  
Reliable selection of antibodies is another challenge when it comes to deploying DOSCAT 
technology. Across the three DOSCATs made in this thesis, 14 different antibodies were 
selected, of which 12 recognised endogenous protein and 10 recognised the DOSCAT protein 
in western blots. This is perhaps reflective of an industry-wide issue of antibody reliability, with 
many antibodies not meeting requirements in terms of selectivity. The main criteria for 
selecting antibodies to use with a DOSCAT are that they must a) specifically bind the target 
analyte with high affinity, and b) bind the linear peptide epitope contained in the DOSCAT 
sequence. Fulfilling criterion a) is perhaps the easier of the two, as there have now emerged 
several tools and initiatives to improve validation of commercial antibodies and highlight highly 
cited or well-validated antibodies. Finding such an antibody that is also accompanied by 
published data relating to its epitope further diminishes the number of possible antibodies, and 
even then, as demonstrated in this thesis, it is not always the case that the given epitope data 
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is accurate. The design and expression of a DOSCAT is a substantial commitment in terms of 
time and money, and so to discover that it is not recognised by one or more target antibodies 
represents a considerable waste of resources. Therefore, more work is needed to mitigate 
against the risk of this occurring. It is perhaps understandable that antibody manufacturers do 
not want to share epitope data as substantial work can go into finding a suitable and well 
performing immunogen, making such information commercially sensitive, although this 
practice does not meet the principles of open and reproducible science (Munafò et al., 2017). 
Closer collaboration with antibody manufacturers could overcome this hurdle, perhaps leading 
to DOSCATs being built that compliment well characterised, highly validated and widely used 
antibodies. Another approach would be to produce antibodies (or alternative protein binders) 
in-house, although this is costly, requires a high level of expertise and does not automatically 
resonate with 3R’s (reduction, replacement and refinement) initiatives (Törnqvist et al., 2014).  
The inclusion of restricted proteolytic sites to shift electrophoretic mobility has had mixed 
results, with numerous proteases not cleaving DOSCAT specifically and proteolytic fragments 
not having the same chemiluminescent signal as intact DOSCAT in capillary WBs. The 
inclusion of proteolytic sites is a supplementary benefit rather than a core component of 
DOSCAT function, and whether they should be included in the design of future DOSCATs is 
for debate. Whilst certainly having the potential to add to the multiplexing capability, further 
work is required to understand the performance of the proteolytic fragments in western 
blotting. This could be performed using the existing NFκB-DOSCAT-2 rather than creating 
new DOSCATs. Once this is known, a more informed judgement can be made as to whether 
they add enough value to warrant inclusion in further DOSCAT designs. 
As well as overcoming the technical challenges associated with creating and implementing 
DOSCATs, another stated aim of this thesis was to compare data generated by QWB and 
SRM, which has been facilitated by the success of the DOSCAT approach. Using the NFκB-
DOSCAT-2, it has been demonstrated that QWB using automated capillary WB 
instrumentation can produce quantitative data with comparable reproducibility and accuracy 
comparable to the gold standard MS-based technique. Moreover, DOSCATs have been used 
to compare SRM to ‘classic’ western blotting, which although did not quite meet the same 
analytical standards of automated WB, produced quantitative data that was highly agreeable 
with SRM approaches. However, the second deployment of DOSCATs to quantify meningitis 
proteins resulted in a wide discrepancy between QWB and SRM quantification values that 
remains unexplained. Further experimentation is required to explain this result and determine 
whether it is a technical issue that can be resolved or a fundamental problem with the 
DOSCAT approach. This is clearly a vital task and will be discussed further in the future work 
section.  
Now that experience has been accumulated with the use of DOSCATs, an assessment can 
be made with regards to whether the technology is mature enough to be regularly used by the 
research community. Each deployment of DOSCAT as described in this thesis has presented 
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technical challenges that, whilst being ultimately resolved, have taken time and resources that 
would not be tolerated if DOSCATs were a commercial product. One would assume that as 
more DOSCATs are made, the frequency of these issues would decrease, but currently it 
cannot be assured that all possible issues can be anticipated. There also needs to be a 
resolution as to why WB and MS data generated using M-DOSCAT-S differ and do not give 
complete confidence in the accuracy of the DOSCAT approach. For these reasons, it can be 
concluded that whilst DOSCATs offer great potential more work is required to fully understand 
all possible issues surrounding their manufacture so that they can be produced and deployed 
with regularity and consistency.  
Assuming these technical challenges can be met, there remains the question of how 
DOSCATs might be applied in research. Some of the results presented in this thesis challenge 
the previously postulated notion that western blotting is a vastly inferior technique to SRM, 
and thus cannot be a truly orthogonal technique for data comparison (Aebersold et al., 2013). 
With careful experimental design and, importantly, a well characterised calibration standard, 
western blotting can be used with confidence to verify MS data or even replace MS entirely, if 
the assay can be well validated. The addition of DOSCATs into workflows would be beneficial 
for studies that require highly accurate and robust quantitative data, for example molecular 
systems biology studies or experiments elucidating protein complex subunit stoichiometry. It 
is easy to anticipate the motivation to include DOSCATs in the workflows of such studies to 
facilitate the orthogonal quantification of targeted MS data by immunoblotting, a common 
request from reviewers upon publication.  
It is also worth considering how DOSCATs might be used in biomarker development workflows 
and the routine analysis of biomarkers in the clinic. Such workflows follow a well-documented 
path of discovery, verification and validation stages with a decreasing set of target proteins 
and an expanding sample size as the pipeline progresses (Parker et al., 2014). Discovery 
methods, based on shotgun (DDA) MS or more recently DIA methods such as SWATH, are 
tensioned against targeted assays for the process of verification and validation. These assays 
can take the form of SRMs for the verification for up to 10-20 markers, but for clinical validation 
where only 1-5 biomarkers will be studied, immunoassays are still preferred by the clinical 
community and regulatory bodies. DOSCATs could be used to ease this transition from MS to 
antibody based assays as the use of a consistent, highly characterised standard between two 
assays would lessen the immunoassay development time as a well improve confidence in 
resultant data as generated by the two platforms. There are some issues that would preclude 
the use of DOSCATs in biomarker discovery pipelines, however. Between the verification and 
validation stages numerous proteins are dropped from the analysis, so there would be many 
epitopes built into DOSCATs that would be redundant for the immunoassay stage. Moreover, 
ELISAs rather than western blots are commonly used for clinical validation studies due to their 
robustness and high throughput capacity. Therefore, DOSCATs would have to be re-
engineered to work in the sandwich immunoassay format that is commonly used in clinical 
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ELISAs. Having said this, automated high-throughput western blot technologies such as the 
Wes platform used throughout the work presented in this thesis offer an attractive alternative 
to ELISA and may be well-placed to eventually replace ELISAs for validation and routine 
testing of clinical biomarkers. It is clear from this work that the Wes system can be relied upon 
for quantification and a single system can realistically be used to analyse up to 72 samples 
daily by a single operator in an unsupervised manner. Although not as high-throughput as 
ELISAs, protein separation by electrophoresis reduces issues of cross-reactivity that can 
dramatically affect ELISA accuracy. Some Wes-based assays for clinical applications have 
already been developed (J.-Q. Chen et al., 2015) and it remains to be seen if they are 
incorporated into clinical laboratories for routine use.  
For much of the research community, MS based techniques for targeted quantification are not 
considered due to inaccessibility; the high-cost and expertise required to design and execute 
an SRM assay means that it is only practised by a limited number of research laboratories 
and core facilities. For many research groups, western blotting remains the primary method 
for generating quantitative data and MS approaches are not used, so the introduction of 
DOSCATs would not be necessary or beneficial. DOSCATs could, however, be used to 
improve the quality of western blot assays so that confidence in quantitative values is on par 
with those generated by gold-standard MS-based techniques. A DOSCAT could be used to 
demonstrate that a western blot carried out using specific reagents and a defined SOP could 
perform equally, in terms of quantitative accuracy and precision, to an SRM assay. Such assay 
validation and reporting of reagents and operating protocols in a detailed manner is likely to 
contribute to an increase in reproducibility (Helsby et al., 2013). Validation could be performed 
commercially and details of these ‘DOSCAT-validated’ WB made available alongside the 
reagents (e.g. specific mAbs) and SOPs they were validated alongside. To improve such 
assays further, a version of DOSCAT containing only epitopes could be supplied to enable 
absolute quantification and so cross-comparison of outputs with other laboratories.  
In a similar vein, DOSCATs could also be employed in the process of antibody validation. 
Antibody-independent validation has recently been proposed by The International Working 
Group for Antibody Validation as a method to validate antibody specificity (Uhlen et al., 2016). 
They propose using targeted proteomics with internal standards to quantify target protein 
expression across a set of samples with variable expression of the target protein. Western 
blots can then be performed using the same samples and if relative protein abundances 
correlate with the targeted proteomics data, specificity of the antibody is confirmed. DOSCATs 
could be used to improve the robustness of this process by facilitating the absolute 
quantification of target proteins in both assays and so allowing cross-comparison of data 
generated by different users in different laboratories.  
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7.2. Future work 
The immediate next stages of work must concentrate on the resolution of different quantitative 
values for QWB and SRM using M-DOSCAT-S. As explained in Chapter 5, the working 
hypothesis is that for Wes analysis, epitopes in smaller proteins are compromised by UV cross 
linking to the capillary surface in a way that does not occur in the larger DOSCAT standard. 
This can easily be assessed by classic western blotting of an equimolar mixture of 
recombinant protein and DOSCAT. If this experiment results in equal signal between DOSCAT 
and analyte rather than a larger signal for DOSCAT as observed in Wes results, this would 
demonstrate that the DOSCAT principle still stands and that there are technical issues with 
using capillary WB that need to be addressed. An understanding of the crosslinking chemistry, 
which is currently proprietary, would be required to see if there was a way to circumvent the 
problem, perhaps by engineering the DOSCAT so it would bind to the capillary wall in the 
same manner as the analyte. If this is not possible other methods of classic western blotting 
or technologies such as µWesterns would have to be explored for use with DOSCATs. 
Alternately, experiments might show that capillary WB technology is not an issue and the 
antibodies have a different affinity for M-DOSCAT-S compared to analyte proteins. This would 
present a more serious issue as it would undermine the principle that DOSCATs are based 
on. Further experiments to pinpoint the flaw in the design and see if it applies to other 
DOSCATs would then have to be carried out.  
If these technical difficulties can be overcome the next stage of work would focus on ensuring 
DOSCATs can be designed and manufactured consistently and maintain stability during an 
extended storage period. As discussed, a better understanding of antibody selection is 
required to increase the reliability that DOSCATs that will be detected by immunoassay. 
Further work will also focus on improving the solubility and stability of DOSCAT, which is 
especially important if DOSCATs are to be made into a commercial product. Different buffer 
solutions, solubility tags or vaccine preservation approaches could all be employed towards 
this goal. 
All the work presented in this thesis has been towards developing DOSCATs for use with 
western blotting, but there are many different immunoassays for which multiplexed calibration 
standards could be used with, as discussed in Chapter 6.2. ELISAs are a well-known 
immunoassay and are extensively used in clinical laboratories, so there is clear motivation for 
developing ELISA-compatible DOSCATs. Significant re-engineering of DOSCATs would be 
required to include epitopes for capture and detection antibodies and, perhaps most 
challengingly, present these epitopes in their native state as ELISAs are not performed under 
denaturing conditions. A possible approach might be to use an inflexible scaffold region, with 
capture and detection epitopes presented at either side, with Q-peptides contained within the 
scaffold and released upon proteolysis. 
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APPENDIX 
Nucleotide sequences of DOSCATs  
Nucleotide sequences are stored electronically and can be obtained by contacting 
the Centre for Proteome Research at the University of Liverpool. 
Protein sequences of DOSCATs  
NFκB-DOSCAT 
> NFκB-DOSCAT 
MGTREGVNDNEEGFFSARDHDSYGVDKKRKRGMPDVLGELNSSDPHGIESKRRKKKPAILDHRLVPRG
SEGRSAGSILGESSTEASKTLPMLRSGPASGPSVPTGRAMPQVAIVFRTPPYADPSLQAPVRVSMQLR
RPSDRELSEPMEFQYLPDTDDRHRIEEKLEVLFQGPEGRSAGSIPGERSTDSQRIQTNNNPFQVPIEE
QRGDYDLNAVRLCFDCRDGFYEAELCPDRCIHMFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDS
MKDEEYEQMVKELQEIRIEGRTLLRDAGADLDKPEPTCGRSPLHLAVEAQAADVLELLLRAGAEEKAL
TMEVIRQVKVPRGSEPWKQQLEGRSAGSIPGEHSTDNNRTYPLLRVGADPALLDRHGDGHTALHLACR
VGAHACARALLQPRPRRPREAPDTYLAQGPDRTPDTNHTPVALYPDSDLEKENLYFQGQDRHGDTALH
VACQRQHLSGKTALHLAVETQERGLVLQRLTDGVCSEPLPFTYLPRDHDTPRSGNTNPLSSFSTRTLP
LYKLLEIPDPDNWAPVKKTTSQAHSLPLSPASTRELVNMRNDLYQTPLHLAVITKQEDNARLFGLAQR
SARSLPESTSAPASGPSDGSPQPCTHPPGPVKEPQEKEDADGERADSTYGSSLTYTLSLLGGPEAEDP
APRAGAGAAGHHHHHH 
 
NFκB-DOSCAT-2 
 
> NFκB-DOSCAT-2 
MGTREGVNDNEEGFFSARDHDSYGVDKKRKRGMPDVLGELNSSDPHGIESKRRKKKPAILDHRTVRFQ
SEGRSAGSILGESSTEASKTLPMLRSGPASGPSVPTGRAMVFRLNQGIPVAPHTTEPMLMEYPEAITR
LVTGAQRPPDPAPAPLRLEVLFQGPEGRSAGSIPGERSTDSQRIQTNNNPFQVPIEEQRGDYDLNAVR
LCFDCRDGFYEAELCPDRCIHMFQAAERPQEWAMEGPRDGLKKERLLDDRHDSGLDSMKDEEYEQMVK
ELQEIRDDDDKDAGADLDKPEPTCGRSPLHLAVEAQAADVLELLLRAGAEEKALTMEVIRQVKVPRGS
EPWKQQLEGRSAGSIPGEHSTDNNRTYPLLRVGADPALLDREKSGPCSSSSDSDSGDEGDEYDDIVVH
SSRSQTRLPPTPASKPLPDDPRPVKENLYFQGQDRHGDTALHVACQRQHLSGKTALHLAVETQERGLV
LQRLTDGVCSEPLPFTYLPRDHDTPRSGNTNPLSSFSTRTLPLYKLLEIPDPDKNWAPVKTTSQAHSL
PLSPASTRELVNMRNDLYQTPLHLAVITKQEDNARLFGLAQRSARASGPSDGSPQPCTHPPGPVKEPQ
EKEDADGERADSTYGSSSLTYTLSLLGGPEAEDPAPRLPLPHSRQYDSGIESLRSLRSLRAGAGAAGH
HHHHH 
 
M-DOSCAT-S 
 
>M-DOSCAT-S 
MGTREGVNDNEEGFFSAREQKLISEEDLDSVDPRIANVFTNAFRYGHTLIKDIFTGLIGPMKICKKGS
LHANGRQKDVDKEQISLPRIICDNTGITTVSKNNIFMSRVPLSRVFFASWRVVLEGGVAAHKKSHEES
HKEDKDNKRFALLGDFFRKSKEKIKEAVLRAIDGINQRSSDANLENLYFQGMKTQRDGHSLGRWSLVL
LIDIFTKENLTAPGSDSAVFFEQGTTRIGGSYGVTCPEQDKYRTITGSPGKPPRLVGGPMDASVEEEG
VRRALDFAVGEYNKASNDMYHSRALQVVRARKQIVAGVNYFLDVELGRTTCTKTQPNLDNCPFHDQPH
LKRKAFCSFQIYAVPWQGTMTLSKSTCQDALEVLFQGPGRGRLYKKALYLQYTDETFRTTIEKPGITY
YKEHEGAIYPDNTTDFQRADDKVYIGKEFKRIVQRIKDFLRNLVPRTESKELVRKDLQNFLKKENKNE
TVRFQSLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLMTCKMSQLERNIETIINTFHQYSVKL
GHPDTAGAGAGAKAGAGAAGHHHHHH 
 
M-DOSCAT-i 
 
>M-DOSCAT-i 
MAGRGVTCPEQDKYRTITGKDIFTGLIGPMKICKKGSLHANGRQKDVDKEIGKEFKRIVQ 
RIKDFLRNLVPRTESVAAHKKSHEESHKEAAGLEHHHHHH   
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